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ABSTRACT 
Chemotherapy, employing single-molecule or multidrug concoctions inspired by the 
diverse repository of plant chemicals, has been the mainstay of cancer treatment for years. 
However, isolating single molecules has proven to be expensive along with limited therapeutic 
window and toxicity. On the other hand, whole foods, while preserving the natural complex 
balance between their constituent phytochemicals and being non-toxic, have proven to impart 
better disease-fighting efficacies, thus leading to an increased focus on dietary interventions to 
both treat and prevent cancer. Owing to the complex interactions between their constituent 
phytochemicals, several dietary agents have been investigated for their therapeutic and 
preventive efficacies. However, due to lack of emphasis on confounding factors like 
bioavailability, absorption, metabolism, and excretion, essentially driven by phytocomplexity, 
incorporation of whole foods in therapeutic regimen has not been successful. This thesis 
exemplifies the need to investigate factors associated with the limitations in the current approach 
with respect to dietary agents. Bioactivity-guided fractionation of sweet potato greens extract 
(SPGE) led to the identification of ~100-fold more potent fraction in vitro. However, this 
efficacy could not be translated in vivo. We also studied whole ginger extract (GE) for its in vitro 
and in vivo prostate tumor growth-inhibitory and apoptosis-inducing effects. In addition, GE 
proved to be more efficacious as compared to its individual most-active constituents owing to the 
differences in their pharmacokinetic (PK) and bioavailability measurements. Hence, these studies 
emphasize the crucial role of synergistic/additive interactions among the constituents of whole 
foods in successful translation of their therapeutic benefits. Another factor that seeks further 
attention is the unique cellular mechanisms engaged by these phytochemicals to confer their 
remarkable effects. Phenolic compounds, the most-abundant of all phytochemicals, are well 
known for their antioxidant properties and act via reactive oxygen species (ROS)-mediated 
mechanisms. We however assert the underappreciated xenohormetic prooxidant role of 
phenolics, where cancer cell death is caused by induction of intolerable levels of ROS. We 
demonstrated that a Piper betel constituent, hydroxychavicol (HC), mediates cytotoxicity via 
ROS-induced DNA-damage. This thesis thus provides compelling grounds for future preclinical 
studies to validate their potential usefulness for cancer management. 
 
INDEX WORDS: Phytochemicals, Phytocomplexity, Sweet potato greens, Ginger, Betel leaves, 
Pharmacodynamic synergy, Pharmacokinetics, Enterohepatic recirculation, 
Xenohormesis, Reactive oxygen species, Pharmacokinetic synergy  
PHYTOCOMPLEXITY: IMPLICATIONS FOR DEVELOPMENT OF NOVEL 
ANTICANCER THERAPEUTICS USING DIETARY AGENTS 
 
 
 
 
by 
 
 
 
 
SUSHMA REDDY GUNDALA 
 
 
 
 
 
 
A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
in the College of Arts and Sciences 
Georgia State University 
2014 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Sushma Reddy Gundala 
2014  
PHYTOCOMPLEXITY: IMPLICATIONS FOR DEVELOPMENT OF NOVEL 
ANTICANCER THERAPEUTICS USING DIETARY AGENTS 
 
 
by 
 
 
SUSHMA REDDY GUNDALA 
 
 
Committee Chair:  Ritu Aneja 
 
Committee: Jenny J. Yang 
Zhi-ren Liu 
Shailesh Singh 
 
 
Electronic Version Approved: 
 
Office of Graduate Studies 
College of Arts and Sciences 
Georgia State University 
August 2014  
iv 
 
DEDICATION 
This thesis in its entirety is dedicated to Sravan, my best half and soulmate, who has 
showered relentless love and given me all the strength and support I needed. Without his 
cooperation, patience, and advisement, I could not even endeavor this task. He has inspired me in 
several ways and I am blessed to have him in my life.   
This thesis is also dedicated to my parents, Sanjeeva Reddy and Ramulamma, my twin, 
Sudhir Reddy and my parents-in-law, Krishna Reddy and Hamsavenu, my brother-in-law, 
Vikramaditya. Their patience and understanding inspired me every step of the way. I owe you all 
a special word of thanks.  
My parents – my roots, they not only gave me life but also a much cherished childhood 
that every kid would dream of. They also taught me to love and respect while instilling the 
values that I live by today. Their enormous support, encouragement and emphasis on education 
are the drivers that made me successfully complete this journey and will steer me towards my 
future accomplishments. Thank you Amma and Nanna for everything.  
Sudhir – my twin, my beginning, and ofcourse the better one. He is my support, my 
strength and my love. He encouraged me to explore my fullest potential and inspires me to 
believe in myself even in the most desperate circumstances. You are more than a sibling and 
friend. You are a part of my soul. I would like to express my sincere gratitude to my dearest 
brother Sudhir, his wife Vinatha and my darling nephew Sriyansh for their constant love and 
support.  
Last but not the least I thank each and every member of my family since a great family is 
the best concrete basis for a great life. 
v 
 
 
ACKNOWLEDGEMENTS 
As I walk towards the dawn of a new beginning, earning my doctorate degree, I 
remember the numerous people who have helped me all along my journey to get this far. I would 
like to firstly thank my advisor Dr. Ritu Aneja for her incessant support, guidance and believing 
in me throughout the course of my research. She has indeed been a great source of inspiration 
making me strive hard for the best each time. She has steered me into the right direction with all 
her wisdom and knowledge. I would also like to thank the members of my committee Drs. Jenny 
Yang, Zhi-ren Liu and Shailesh Singh for their advice, extraordinary support and time. All the 
past and present members of the Aneja lab, and especially Dr. Chunhua Yang are thanked for 
their support. Dr. Chunhua Yang and MVS are especially thanked for extending immense help in 
performing all the pharmacokinetic and analytical experiments.  
Vaishali Pannu – my colleague and a wise friend has been a great support, encouraging 
me to believe in myself both during the tough and happy times. 
 Ravi Chakra Turaga – a fellow graduate student, a dear friend, a selfless, intelligent, kind 
and gentle soul. He has been a constant support since day one, helping me in all walks of this 
tremendous journey.  
This dissertation is not just a compilation of my research in Dr. Ritu Aneja’s lab, but is 
the fruit of countless blessings and kind wishes from my closest family and friends. 
vi 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS .......................................................................................... v	  
LIST OF FIGURES .................................................................................................... xiii	  
1     INTRODUCTION ................................................................................................... 1	  
1.1	   Dietary Phytochemicals and Cancer ................................................................... 2	  
1.2	   Whole food extracts vs single agents – significance of phytocomplexity ......... 4	  
1.3	   Synergy: Complex interactions among constituent phytochemicals in whole 
food extracts ................................................................................................................... 7	  
1.4	   Untapped arena: Pharmacokinetic analysis of whole food extracts .............. 10	  
1.5	   Xenohormesis: Potential pro-oxidative and/or anti-oxidant cancer-fighting 
properties of dietary phytochemicals ......................................................................... 11	  
1.6	   Summary .............................................................................................................. 15	  
2	  WHOLE FOOD EXTRACTS PRESENT SUPERLATIVE EFFICACY 
COMPARED TO THEIR PURIFIED COUNTERPARTS ..................................... 17	  
2.1	   Abstract ................................................................................................................ 17	  
2.2	   Introduction ......................................................................................................... 19	  
2.3	   Materials and Methods ....................................................................................... 23	  
2.3.1	   Cell culture, antibodies and reagents ...................................................... 23	  
2.3.2	   Preparation of SPGE and estimation of polyphenolics .......................... 23	  
2.3.3	   In vitro proliferation assay ...................................................................... 25	  
2.3.4	   Colony survival assay .............................................................................. 25	  
vii 
2.3.5	   Cell cycle analysis, immunofluorescence microscopy and immunoblot 
analysis ................................................................................................................. 25	  
2.3.6	   Determination of mitochondrial transmembrane potential and caspase-
3/7 activity and TUNEL assay ............................................................................. 26	  
2.3.7	   In vivo tumor growth, SPGE and F5 treatment and bioluminescent 
imaging ................................................................................................................. 27	  
2.3.8	   Histopathologic and immunohistochemical analyses ............................ 27	  
2.3.9	   Immunoblot analysis and immunofluorescent microscopy ................... 28	  
2.3.10	   High performance liquid chromatography with UV and mass 
spectrometric detection ........................................................................................ 28	  
2.3.11	   Sub-fractionation of F5 using analytical HPLC-UV chromatography29	  
2.3.12	   Experimental design for the combination studies and determination of 
synergy 29	  
2.3.13	   Statistical analysis .................................................................................. 30	  
2.4	   Results .................................................................................................................. 30	  
2.4.1	   SPGE inhibits proliferation, perturbs cell cycle progression, and induces 
mitochondrially-mediated intrinsic apoptosis in human prostate cancer cells . 30	  
2.4.2	   Oral SPGE feeding significantly inhibits PC-3 tumor growth, induction 
of apoptosis and is non-toxic ............................................................................... 37	  
2.4.3	   Identification of constituent bioactive phytochemicals via fractionation 
of SPGE ................................................................................................................ 41	  
viii 
2.4.4	   A moderately polar fraction, F5, enriched of major SPGE phenolics 
exhibits remarkable antiproliferative activity in prostate cancer cells .............. 42	  
2.4.5	   Subfractionation of F5 results in loss of bioactivity indicating synergism 
among F5 phytochemicals ................................................................................... 49	  
2.4.6	   Oral feeding of F5 inhibits prostate tumor growth in vivo and is non-
toxic 52	  
2.5	   Discussion ............................................................................................................. 57	  
3	  IMPORTANCE OF SYNERGISTIC INTERACTIONS AMONG 
CONSTITUENT PHYTOCHEMICALS OF WHOLE FOOD EXTRACTS ........ 67	  
3.1	   Abstract ................................................................................................................ 67	  
3.2	   Introduction ......................................................................................................... 69	  
3.3	   Materials and Methods ....................................................................................... 75	  
3.3.1	   Cell lines, media, antibody and reagents ................................................ 75	  
3.3.2	   Preparation of GE stocks and isolation of ginger phenolics ................. 76	  
3.3.3	   In vitro proliferation and colony survival assay ..................................... 77	  
3.3.4	   Cell-cycle progression studies by flow cytometry ................................... 78	  
3.3.5	   Immunoblot analysis ............................................................................... 78	  
3.3.6	   Mitochondrial and cytosolic fractionation ............................................. 78	  
3.3.7	   Immunofluorescence microscopy ........................................................... 79	  
3.3.8	   JC-1 staining for mitochondrial transmembrane potential ................... 79	  
3.3.9	   Caspase-3/7 activity assay ........................................................................ 79	  
ix 
3.3.10	   Experimental design of the binary combination studies ...................... 80	  
3.3.11	   Determination of CI and DRI ............................................................... 80	  
3.3.12	   High-Performance Liquid Chromatography and Mass-Spectrometric 
Detection ............................................................................................................... 81	  
3.3.13	   Formulation recipe of GE, Mix and GE-Mix for in vivo PK studies .. 82	  
3.3.14	   Choice of in vivo dose for efficacy and pharmacokinetic studies ........ 82	  
3.3.15	   In vivo tumor growth and treatment ..................................................... 83	  
3.3.16	   Histopathological and immunohistochemical staining ........................ 84	  
3.3.17	   Pharmacokinetic studies of GE versus Mix .......................................... 84	  
3.3.18	   Enzymatic hydrolysis of gingerol conjugates ....................................... 85	  
3.3.19	   Plasma Protein Binding Assay .............................................................. 85	  
3.3.20	   Bioanalysis ............................................................................................. 85	  
3.3.21	   Pharmacokinetic analysis ...................................................................... 87	  
3.3.22	   Statistical analysis .................................................................................. 87	  
3.4	   Results .................................................................................................................. 88	  
3.4.1	   Ginger extract displays selective antiproliferative activity, arrests cell-
cycle progression, and induces apoptosis in prostate cancer cells ..................... 88	  
3.4.2	   Oral ginger extract feeding achieves inhibition of PC-3 tumors in nude 
mice and in vivo mechanisms of ginger extract-mediated inhibition of tumor 
growth 98	  
x 
3.4.3	   HPLC-UV Quantification of Ginger Phytochemicals in GE and 
determination of synergy among GE phytochemicals ...................................... 103	  
3.4.4	   GE is superior to the quasi “Mix” of active GE constituents in inhibiting 
prostate tumor growth ........................................................................................ 109	  
3.4.5	   GE biophenolics exhibit potential enterohepatic recirculation in vivo, 
while other less abundant GE phenolics collaborate with main GE constituents 
to enable delivery of optimal in vivo benefits .................................................... 112	  
3.5	   Discussion ........................................................................................................... 119	  
4	  “XENOHORMETIC” PROOXIDANT/ANTIOXIDANT POTENTIAL OF 
DIETARY PHYTOCHEMICALS ........................................................................... 132	  
4.1	   Abstract .............................................................................................................. 132	  
4.2	   Introduction ....................................................................................................... 133	  
4.3	   Materials and Methods ..................................................................................... 138	  
4.3.1	   Cell culture, chemicals and reagents .................................................... 138	  
4.3.2	   Preparation of methanolic betel leaf extract and Isolation of HC from 
betel leaves .......................................................................................................... 139	  
4.3.3	   Fractionation of BLE and identification of constituents using 
chromatography techniques .............................................................................. 140	  
4.3.4	   Nuclear magnetic resonance (NMR), High-performance liquid 
chromatography (HPLC) with UV and mass-spectrometric detection ............ 142	  
4.3.5	   Antiproliferative MTT assay .................................................................. 143	  
xi 
4.3.6	   Trypan blue and colony survival assay ................................................. 143	  
4.3.7	   Measurement of ROS ............................................................................ 144	  
4.3.8	   Cell-cycle studies .................................................................................... 144	  
4.3.9	   Immunofluorescence Microscopy ......................................................... 144	  
4.3.10	   Immunoblotting ................................................................................... 145	  
4.3.11	   Detection and Quantification of Acidic Vesicular Organelles (AVOs)
 145	  
4.3.12	   Electron Microscopy ............................................................................ 145	  
4.3.13	   In vivo tumor growth and bioluminescent imaging ........................... 146	  
4.3.14	   Immunofluorescence and immunohistochemical staining ................ 147	  
4.3.15	   Determination of half-maximal lethal dose (LD50) and acute in vivo 
toxicity 147	  
4.3.16	   Statistical analysis ................................................................................ 147	  
4.4	   Results ................................................................................................................ 148	  
4.4.1	   BLE induces apoptosis and inhibits proliferation of tumor growth in 
vivo 148	  
4.4.2	   Identification and quantitation of bioactive constituents of BLE using 
column chromatography .................................................................................... 151	  
4.4.3	   Subfractionation of F2 and nuclear magnetic resonance and mass 
spectrometric characterization of F2 subfractions ........................................... 156	  
xii 
4.4.4	   Determining the contribution of HC to BLE’s antiproliferative activity
 160	  
4.4.5	   HC inhibits proliferation and perturbs the cell cycle progression of 
human prostate cancer cells .............................................................................. 161	  
4.4.6	   HC induces ROS-dependent mitochondrially-mediated intrinsic  
apoptosis, DNA damage and autophagy ........................................................... 164	  
4.4.7	   Oral HC feeding significantly inhibits PC-3 tumor-growth ................ 173	  
4.5	   Discussion ........................................................................................................... 175	  
5	  CONCLUSIONS ..................................................................................................... 184	  
6	  OVERALL SIGNIFICANCE ................................................................................ 188	  
REFERENCES ........................................................................................................... 193	  
  
xiii 
LIST OF FIGURES 
Figure 1.1 Representation of the fate of cancer cells under varying ROS levels ............. 13	  
Figure 1.2 Xenohormetic response ................................................................................... 15	  
Figure 2.1 SPGE inhibits growth and reproductive capacity of prostate cancer cells. ..... 31	  
Figure 2.2 SPGE perturbs cell cycle progression. ............................................................ 33	  
Figure 2.3 SPGE activates the intrinsic apoptotic pathway. ............................................. 35	  
Figure 2.4 Dietary feeding of SPGE inhibits human prostate tumor xenograft growth in 
nude mice. ......................................................................................................................... 38	  
Figure 2.5 Tumor tissue lysates express high apoptotic and low proliferation markers. .. 40	  
Figure 2.6 Fractionation of SPGE using column chromatography. .................................. 43	  
Figure 2.7 Fractionation and evaluation of bioactivity of various SPGE fractions. ......... 44	  
Figure 2.8 F5 exhibited the presence of major phenols of SPGE. .................................... 47	  
Figure 2.9 Subfractionation of F5. .................................................................................... 50	  
Figure 2.10 Dietary feeding of F5 showed enhanced inhibition of human prostate tumor 
xenograft growth in nude mice compared with SPGE. ..................................................... 53	  
Figure 2.11 F5 induces apoptosis. ..................................................................................... 55	  
Figure 2.12 F5 is non-toxic. .............................................................................................. 56	  
Figure 3.1 GE has potent antiproliferative activity ........................................................... 89	  
Figure 3.2 GE and ginger phytochemicals inhibit proiferation of prostate cancer cells. .. 91	  
Figure 3.3 GE effects cell cycle progression kinetics by causing S and G2/M arrest 
followed by an increase in sub-G1 cell population ........................................................... 94	  
Figure 3.4 GE induces mitochondrially mediated intrinsic apoptosis .............................. 97	  
Figure 3.5 GE caused in vivo inhibition of tumor growth ................................................ 99	  
xiv 
Figure 3.6 GE induced in vivo apoptosis ........................................................................ 102	  
Figure 3.7 Quantitation of gignerols in GE. ................................................................... 104	  
Figure 3.8 Ginger phytochemicals act in concert to confer antiproliferative activity. ... 106	  
Figure 3.9 Line plots of combination index (CI) versus fraction of cell affected (Fa). .. 108	  
Figure 3.10 Oral administration of GE exhibited enhanced inhibition of human prostate 
tumor xenograft growth in nude mice compared to Mix. ............................................... 111	  
Figure 3.11 GE feeding results in enterohepatic recirculation causing multiple peaking 
phenomenon. ................................................................................................................... 113	  
Figure 3.12 Pharmacokinetic parameters of GE versus Mix. ......................................... 114	  
Figure 3.13 Proof of enterohepatic recirculation of active ginger constituents. ............. 116	  
Figure 3.14 Oral administration of GE-Mix also exhibited inhibition of human prostate 
tumor xenograft growth in nude mice. ............................................................................ 118	  
Figure 3.15 GE is more efficacious than the Mixture of its active constituents. ............ 128	  
Figure 4.1 Dietary feeding of BLE showed inhibition of human prostate tumor xenograft 
growth in nude mice. ....................................................................................................... 149	  
Figure 4.2 Organ-associated toxicity was not observed in BLE-fed group. ................... 150	  
Figure 4.3 BLE induces apoptosis .................................................................................. 151	  
Figure 4.4 Antiproliferative assay of BLE in normal prostate epithelial cells. .............. 152	  
Figure 4.5 Fractionation of BLE using column chromatography. .................................. 153	  
Figure 4.6 Qualitative analysis of HC and EU. .............................................................. 155	  
Figure 4.7 Antiproliferative efficacy and subfractionation of F2. .................................. 157	  
Figure 4.8 Comparison between F2 and combined fractions F4-F10. ............................ 160	  
xv 
Figure 4.9 HC inhibits proliferation and perturbs the cell cycle progression of human 
prostate cancer cells. ....................................................................................................... 163	  
Figure 4.10 HC induces reactive oxygen species in prostate cancer cells. ..................... 165	  
Figure 4.11 HC induced apoptosis is ROS dependent. ................................................... 168	  
Figure 4.12 HC induces ROS-dependent DNA damage. ................................................ 170	  
Figure 4.13 HC induces autophagy in prostate cancer cells. .......................................... 172	  
Figure 4.14 Dietary feeding of HC showed inhibition of human prostate tumor xenograft 
growth in nude mice. ....................................................................................................... 174	  
 
1 
1     INTRODUCTION  
Background and Significance1 
At least since the 4th century BC, cancer has maliciously loomed in mankind. It has been 
the leading cause of death over the past two decades affecting various populations worldwide at 
alarming rates (Parkin et al., 2005). Despite the continuing attempts in search of a cure for cancer 
to alleviate its appalling outcomes, the war against this deadly neoplasm is growing stronger day 
by day. Surgery, radiation, chemotherapy, immunotherapy, laser therapy, etc., modalities of the 
current day have met with limited success. Chemotherapy, employing single-molecule or 
multidrug concoctions aiming at various targets, is the most sought after treatment for cancer 
today. It involves pharmaceutical compositions of various purified compounds identified from 
the endless repository of plant chemicals.  However, this approach of isolating the active 
ingredients from plant resources so far has had a restricted control over this aggressive 
malignancy. On the other hand, whole foods, which preserve the natural balance between their 
constituent phytochemicals as bestowed by Mother Nature, have proven to impart better disease-
fighting efficacies, thus leading to an increased focus on dietary interventions to both treat and 
prevent cancer. This thesis focuses on engaging the benefits of phytocomplexity in our 
persevering pursuit of the war against cancer. 
 
                                                
1 Parts of this chapter have been published verbatim in Carcinogenesis 2014 as 
Enterohepatic re-circulation of bioactive ginger phytochemicals is associated with enhanced 
tumor growth-inhibitory activity of ginger extract  and Cancer Prev. Res. (Phila). 2014 as Piper 
betel leaf: A reservoir of potential xenohormetic nutraceuticals with cancer-fighting properties.  
 
2 
1.1 Dietary Phytochemicals and Cancer 
Cancer develops in various phases starting from initiation, as triggered by environmental 
carcinogens, radiation etc., and progressing to develop into a malignant state via the promotion 
and progression phases, which are relatively protracted processes (Mann et al., 2005). Thus 
cancer proliferates uncontrollably and ultimately invades the surrounding tissues, spreading to 
distant organs resulting in metastases. Modulation of this disease progression by interfering with 
various drugs and chemicals has been the focus of current-day chemotherapy. Although this kind 
of intervention is often associated with toxic side effects, it has been the most sought-after 
approach. Furthermore, the concept of chemoprevention emerged in the 20th century, which 
targets at thwarting the developmental process of cancer using relatively non-toxic chemicals 
(Sporn, 1976; Sporn and Suh, 2000; Surh, 2003). Since its inception, researchers worldwide have 
been focusing on developing agents that can obstruct each step of carcinogenesis, which also can 
be used to treat fully developed cancers. Several such agents including the current-day 
chemotherapeutics are obtained or inspired from Nature (Houghton, 1995). Most of these 
anticancer agents are widely present in our regular diet including fruits and vegetables.  
 
On the other hand, one-third of the estimated cancer cases in the United States have been 
attributed to improper diet, nutrition, obesity and lack of physical activity. These cues linking 
nutritional aspects leading to cancer are important to design and develop novel strategies and 
therapeutics as our arsenal against cancer (Hanahan and Weinberg, 2000, 2011). Substantial 
evidence has revealed that a wholesome diet constituting of fruits, vegetables, whole grains, 
cereals, dietary fibers etc., has not only protective and preventive effects against various cancers 
but also a lower risk of developing the malignancy (Quideau et al., 2011; Surh, 2003). The vital 
3 
components of these natural dietary sources are phenolic compounds, anthocyanins, terpenoids, 
aromatic acids, alkaloids, glucusonilates etc., collectively known as phytochemicals. Several 
researchers have extensively worked on determining the health benefits of these dietary 
phytochemicals. Major focus has been aimed at identifying the blocking agents that obstruct the 
initiation phase and suppressing agents that retard the promotion and progression phases of the 
carcinogenesis process. Some of these dietary phytochemcials include catechins from green tea, 
resveratrol from grapes, proanthocyanidins from grape seed extracts, isothiocyanates from 
cruciferous vegetables, curcuminoids from turmeric, flavonoids and phenolic compounds from 
fruits and vegetables and many others. Most importantly these phytochemicals have been shown 
to possess potent tumor growth inhibiting properties while remaining non-toxic towards the 
normal cells and tissues. For example, curcumin, a beta diketone purified from turmeric, has 
been long known to act as an effective anti-inflammatory agent along with anticancer properties 
(Sharma, 1976). It was shown to inhibit the tumor initiation process developed due to BaP and 
DMBA (dimethylbenz[α]anthracene), while also inhibiting tumor promotion induced by 12-O-
tetradecanoylphorbol-13-acetate (TPA) (Singletary and MacDonald, 2000). Sulforaphane (SFN), 
a component of cruciferous vegetables, was shown to inhibit gastro-intestinal adenoma 
formations in APC 112 Min/+ mice and DNA adduct formation due to polycyclic aromatic 
hydrocarbon - benzo[a]pyrene (BaP) and 1, 6-dinitropyrene (Hu et al., 2006). On the other hand, 
another cruciferous component, phenylethylisothiocyanate (PEITC), in combination with 
curcumin was found to significantly inhibit tumor formation in athymic nude mice implanted 
with human prostate xenografts. EGCG (epigallocatechin gallate), the active constituent of green 
tea, was also proven to promote apoptosis in human bladder cancer cells while modulating the 
PI3K/Akt signaling pathway (Johnson et al., 2010; Raza and John, 2005). 
4 
 
All these anticancer dietary phytochemicals were found to have one aspect in common: 
non-toxicity towards normal tissues/cells. This differential outcome was observed to be due to 
the ability of these phytochemcials to induce apoptosis selectively in the abnormally proliferating 
cancer cells by exploiting their higher metabolic activity and inducing detoxifying enzymes, 
which in turn makes them non-toxic towards the normal cell population. Extensive research on 
chemopreventive mechanisms rendered by active phytochemicals presented us with some crucial 
cues.  For example, upregulation of phase I and II detoxifying enzymes, quinone reductase (QR), 
UDP-glucuronyltransferase (UGT) and glutathione-s-transferase (GST) in particular, by the plant 
chemicals like SFN, curcumin, PEITC, EGCG etc., was associated with enhanced elimination of 
toxic molecules and carcinogens from the system (Surh, 2003). Hence, prudent modulation of 
physiological cascades within the cancer cells by employing dietary phytochemicals presents a 
safer route to fight against this malicious disease.   
1.2 Whole food extracts vs single agents – significance of phytocomplexity 
Extensive research conducted on determining the disease-fighting properties of individual 
phytochemicals has also revealed that they must be consumed in large quantities to achieve 
physiologically relevant doses in order to exert the respective health benefits. For example, the in 
vitro IC50 concentration of 6-gingerol (6G), an active constituent of ginger extract, was found to 
be ~88-177 µg/ml in various cell lines (Brahmbhatt et al., 2013; Wang et al., 2003). On the other 
hand, an in vivo oral dose of 100 mg/kg bw of 6G yielded blood plasma levels of ~ 2µg/ml 6G 
(Zick et al., 2008; Zick et al., 2010). Thus, it requires ~6g/kg bw of 6G to be consumed in order 
to achieve equivalent active concentrations of 6G in the blood plasma. Such high doses of 
bioactive phytochemicals often result in cellular and organ toxicity. Similar is the case with the 
5 
current chemotherapeutic drugs, which despite their lower effective doses, exert undesirable side 
effects, thus categorizing them as toxic drugs.  
 
With the accession of organic chemistry since early 19th century, several drugs, including 
morphine, taxol, cocaine, vincristine, vinblastine, codeine, quinine, noscapine, digitoxin etc., 
have been purified and extracted from medicinal plants and herbs (Ji et al., 2009). This idea of 
purifying a single agent from a complex natural material has misled us to assume that only one 
or few components of a plant are responsible for the efficacy. Ever since, the researchers and 
drug industries have invested in designing and producing purified drugs directed towards specific 
ligands acting on disease targets. There have been such several successful anticancer agents with 
remarkable efficacy. However, in the past few decades, the number of innovative drugs 
introduced into the market has declined and a majority of these failed during the final phases of 
clinical trials and some even after introduction into the market. The reason behind these debacles 
is mainly due to the fact that cancer has a multi-factorial pathogenesis. Targeting a single 
molecular player in a specific pathway is no longer suitable to destroy the tumors, as metastasis 
and relapse are highly likely outcomes of such therapies. Furthermore, such highly selective 
targeted therapies may even have certain unexpected biochemical effects, resulting in toxicity. 
Thus, to address these failures, in the recent years, scientists have focused on multi-targeted 
therapies employing combination chemotherapy, where two or more chemotherapeutic drugs are 
given in a concoction (Azuine and Bhide, 1992; Chou, 2010; Clark et al., 2006; Lansky et al., 
2005; Wagner, 2011; Xiao and Yang, 2008). Still, toxicity issues persist, likely due to the need 
for administering varying doses of the each drug in the cocktail such that their respective potent 
doses can be achieved in vivo to have an effect against the malignancy.  
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However, Mother Nature has a solution concerning this matter, particularly in the form of 
whole foods that have been overlooked for ages. The idea of isolating the “active constituent” 
from plant extracts does not take into account the possibility of natural phytochemical cocktails 
that may interact among themselves to deliver combined superior health benefits. Several lines of 
evidence also indicate that a single constituent isolated from a complex phytochemical mixture 
present in whole foods or their extracts may even lose its bioactivity or cause undesirable cancer-
promoting effects, as in the case of β-carotene (Omenn et al., 1996). It is also likely that isolating 
a single compound from complex foods may not be effective even at high, relatively toxic doses, 
whereas combinations of lower, less-toxic doses of each compound may be effective. The natural 
balance among various constituent phytochemicals in whole foods or extracts not only presents 
lower doses of predefined formulations to impart health benefits, but also the additive and 
synergistic interactions among these phytochemicals support multiple roles from preventing 
DNA mutations, impeding cell cycle, inhibiting cell proliferation, inducing apoptosis to even 
modifying the immune responses compared to their comprising individual components. This 
advantage of whole foods could perhaps be because of the natural preservation of a complex 
phytochemical mixture in whole foods that can act on multiple targets due to their physiological 
consequences, i.e., particularly increasing solubility and absorption of these active ingredients. 
This natural setting in whole foods thus delivers desired beneficial effects while eliminating the 
possible harmful effects of the individual components. However, the outcomes of these complex 
interactions between various constituents of plant-based foods are dictated by several 
mechanistic factors such as bioavailability, cellular transport mechanisms, pro-drug activation 
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and deactivation of active drug entities and, most importantly, the action of synergistic allies at 
multiple target sites.  
 
As defined by Nature, every fruit and vegetable contains a defined ratio of 
phytochemicals within them, which are pre-designed to target several sites in the body upon 
ingestion. Poor quality of plant material processing, incompetent fractionation processes, 
degradation of active constituents and lack of appropriate biological models for testing are some 
of the several explanations for the unsuccessful isolations of active constituents from whole 
extracts. It is thus important to maintain the balance of phytochemicals and keep their intricate 
network intact by employing whole foods instead of single active entities. Furthermore, despite 
the innumerable advantages acquired by consuming whole food extracts, they have not gained 
much attention to be employed as chemotherapeutic or chemopreventive agents. This could 
possibly be due to the lack of understanding of the interactions between plant constituents, in 
vivo physiological interactions, and the prospects of these phytochemicals at the target sites. 
Hence, a detailed evaluation of the in vivo mechanisms of action and the fate of the constituent 
phytochemicals upon consumption of whole foods is required in order to employ whole foods as 
therapeutic and preventive agents.  
1.3 Synergy: Complex interactions among constituent phytochemicals in whole food 
extracts (Gundala et al., 2014) 
Disease pathogenesis is a continuous developmental process, which often renders the 
disease-inducing pathogens or cells in case of cancer to develop resistance against the effective 
drugs or individual phytochemicals. However, whole food extracts have an advantage against 
this predicament due to the co-existence of several phytochemicals within them that interact with 
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the organism or cells and among each other to ward off the disease. For example, in case of 
cancer, the malignant cells are metabolically highly active and these processes involve a variety 
of enzymes and receptors containing specific sites that can accommodate the phytochemicals and 
drug molecules. However, several constituent plant chemicals of whole foods compete with each 
other or interact among themselves to attack these specific sites to impart better efficacy (Liu, 
2003, 2004). Further, there might be several mechanisms by which these phytochemicals act in 
parallel at the target sites. Furthermore, the complexity of phytochemicals in their natural forms 
in plant-based foods precludes a definitive conclusion regarding their mechanisms of action. 
However, the existence of synergistic interactions have been long known and linked to the 
activity of whole foods.  
Epidemiological studies suggest that a high intake of fruits and vegetables is linked to a 
reduced cancer risk. Phytochemicals present in fruits and vegetables (e.g., carotenoids, 
polyphenolics, anthocyanins, terpenes, alkaloids) are functionally pleiotropic; they possess 
multiple intracellular targets, simultaneously affecting different signaling cascades usually 
altered in cancer cells with limited toxicity to normal cells, thereby reducing overall cancer risk. 
Several reports suggest that the anticancer benefits of fruits and vegetables are due to an additive 
or synergistic interplay of the complex mixture of phytochemicals present in them. This 
emerging notion further lends support to the premise of concomitantly targeting multiple 
pathways. Whole foods have been so far studied to deliver “pharmacodynamic synergy” 
(Danielsson et al., 2011), where the constituent phytochemicals act at different target sites to 
enhance the overall therapeutic index.  
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Such kind of synergy or potentiation is where the effect of the combination of 
phytochemicals is greater than the additive sum of effects of individual phytochemicals. For 
example, studies of green tea polyphenols have demonstrated that EGCG and at least four other 
catechins are necessary for maximum in vivo efficacy, suggesting that synergistic inter-reactivity 
or dependency on other components of the whole food is required for optimal activity (Azam et 
al., 2004; Johnson et al., 2010; Kinjo et al., 2002; Raza and John, 2005). Similarly, the highest 
antioxidant activity was realized with the combination of polyphenols in pomegranate juice as 
opposed to the constituent polyphenols alone. In a comparable investigation of cranberry extract, 
enhanced antiproliferative activity was attributed to the synergistic and additive interactions of 
its main components, including anthocyanins, proanthocyanidins, and flavanol glycosides 
(Ferguson et al., 2004; Kandil et al., 2002; Seeram et al., 2004). Recent findings from our 
laboratory also underscore the importance of synergistic interactions among ginger biophenolics 
present in GE (Gundala et al., 2014), which may tremendously lower the concentration of the 
effective doses while maintaining efficacy. The natural abundance, low cost, and non-toxicity of 
this very common spice are strong attributes that favor ginger as a chemopreventive as well as a 
potential chemotherapeutic alternative in the treatment of prostate cancer. Such studies thus offer 
a plausible explanation as to why clinical trials with pure, single phytochemicals, such as α-
tocopherol, β-carotene, and vitamin C, have met with limited success (1994; Greenberg et al., 
1994; Liu, 2003; Omenn et al., 1996). It is thus likely that disrupting the natural balance of 
phytochemicals as it exists in fruits and vegetables by extracting individual phytochemicals from 
the “food matrix” may result in sub-optimal health benefits.  
Apart from the pharmacodynamic synergy, phytocomplexity further offers additional 
significant in vivo benefits in terms of “pharmacokinetic synergy” (Yang et al., 2014), where the 
10 
constituent phytochemicals of whole foods with less or no activity aid the most-active 
constituent phytochemicals to reach the sites of action either by improving bioavailability or by 
decreasing metabolism and excretion. Our laboratory is the first to demonstrate that ginger 
biophenolics upon oral administration of whole ginger extract exhibit such pharmacokinetic 
synergy to enhance the bioavailability of 6-gingerol (6G), 8-gingerol (8G), 10-gingerol (10G) 
and 6-shogaol (6S) (Gundala et al., 2014). While improving the bioavailability, pharmacokinetic 
synergy might also result in resistance-reversal mechanisms and induction of other 
complementary mechanisms including immunomodulation.  
1.4 Untapped arena: Pharmacokinetic analysis of whole food extracts 
Researchers have been investigating the in vivo fate of drug molecules or single active 
constituents of plant origins, while evaluating the kinetics and extent of absorption by measuring 
the plasma, urine and/or feces concentrations of drugs and phytochemicals after administration. 
Bioavailability, including maximum plasma concentration (Cmax), time taken to reach Cmax 
(Tmax), area under the plasma concentration-time curve (AUC), elimination half-life etc., 
parameters are evaluated in order to determine the right dosage to achieve maximum anticancer 
benefits. Though the efficacy of several whole food extracts has been determined, such kind of 
detailed pharmacokinetic evaluation is limited. The paucity of the pharmacodynamic and 
pharmacokinetic data involving whole foods needs to be addressed in order to exploit their health 
benefits imparted due to phytocomplexity. This data will further be useful to design and interpret 
the intervention studies employing fruits and vegetables. 
Bioavailability, metabolism and elimination of active phytochemicals in whole foods can 
be greatly affected by other constituent partners. The non-active phytochemicals can enhance the 
permeability of the active ones, inhibit efflux pumps required for elimination of drugs in order to 
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increase the latter’s mean residence time, modify the ADME (absorption, distribution, 
metabolism and excretion) characteristics and even modulate the phase I and II metabolizing 
enzymes favoring the metabolism of the active constituents. Recent findings from our laboratory 
support the idea of pharmacokinetic synergy, as the bioavailability of active ginger biophenolics 
was improved upon administering whole ginger extract, where it is likely that other constituent 
partners of GE helped in better absorption of 6G, 8G, 10G and 6S either by competing to get 
glucuronidated for elimination or via regulating the phase I and II metabolizing enzymes.  
Further studies to determine the nature of interactions and mechanisms by which these 
“silent” partners help the active associates to deliver maximum efficacy are crucial in developing 
new therapeutic and preventive strategies. This information will further acknowledge the idea of 
pharmacokinetic synergy imparted via phytocomplexity in the case of whole foods.  Also, this 
will open new avenues in the fields of chemotherapy and chemoprevention, where phytotherapy, 
the alternate school of thought, will be further appreciated for its safe yet complex mode of 
action and cost-effectiveness. 
1.5 Xenohormesis: Potential pro-oxidative and/or anti-oxidant cancer-fighting properties 
of dietary phytochemicals (Gundala and Aneja, 2014) 
Health-promoting phytochemicals, mainly the phenolic compounds merit a special 
mention, as they are the most-abundant and primary defense molecules of plants and have 
protected them during evolution. In addition, these phenolics have “chemically” contributed to 
maintain an ecological equilibrium between plants and other living organisms feeding on them, 
including us humans. The magnanimous nature of these compounds can be attributed to the 
inherent physicochemical properties packaged within the phenol functional group, which 
bestows unto them a versatile phenolic function of acting as an antioxidant as well as a 
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prooxidant. Plant foods consisting of such nutraceuticals also offer both chemotherapeutic 
(cancer cells) and chemopreventive benefits (pre-malignant cells), albeit through different 
mechanisms. Furthermore, an interesting novel paradigm called “xenohormesis”, involving 
polyphenols is gaining momentum, which hypothesizes that polyphenols were synthesized by 
common ancestors of plants and animals (Howitz and Sinclair, 2008). Despite the evolutionary 
divergence of the respective kingdoms, it is intriguing that many crucial mammalian enzymes 
and receptors have been conserved which can be regulated and modulated by plant-produced 
phytochemicals.  
 
Paramount interest centers on the belief that adverse environmental conditions or stress 
induces the synthesis of phytochemicals including polyphenols in plants. Interestingly, when 
ingested by humans, these phytochemicals upregulate pathways that provide stress-resistance in 
animals. Conceivably, this suggests that humans that consume phytochemicals via plant-based 
foods have sensing mechanisms (enzymes/receptors) to perceive these chemical cues and elicit 
beneficial responses that enhance the well-being of humans thus imparting overall health 
benefits. This phenomenon has been brilliantly termed as “xenohormesis” by Howitz and 
Sinclair fairly recently in 2008, wherein xenos, is the Greek word for stranger, and hormesis, the 
term for health benefits (Hooper et al., 2010; Howitz and Sinclair, 2008; Lamming et al., 2004; 
Surh, 2011). In simplistic terms, it is health benefits conferred by a stranger! In a nutshell, 
ingestion of phytochemicals causes the body to be tricked into believing that it is under some 
kind of stress, which triggers a system-wide response to combat stress.  
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While normally, the presence of a handful of initiated or pre-malignant cells would not be 
able to trigger a sufficiently strong signal for the body to perceive and respond to, 
phytochemicals may place the system on “high-alert” and stimulate a heightened stress-response 
that could effectively eliminate the initiated or pre-malignant cells thus emphasizing the 
workings of plant phytochemicals in the chemopreventive context. Once the pre-neoplastic cells 
undergo malignant transformation into cancer cells, they can perhaps only be eliminated through 
chemotherapeutic strategies, as upon becoming cancerous, as these cells have surpassed their 
amenability to chemopreventive measures.  
 
Figure 1.1 Representation of the fate of cancer cells under varying ROS levels 
Cancer cells having moderate levels of ROS tend to adapt to the stress conditions and show 
enhanced expression of pro-survival molecules. For example, when whole food constituents like 
betel leaf nutraceuticals interfere with this situation, causing the moderate ROS levels to increase 
over the threshold, the cancer cells can no longer withstand the oxidative stress and thus are 
killed via various possible mechanisms (Atsumi et al., 2005; Bhide et al., 1991a; Bhide et al., 
1979; Bhide et al., 1991b; Chang et al., 2007; Chang et al., 2002; Chen et al., 2000; Gibellini, 
2010; Kumar, 2010; Lee-Chen et al., 1996; Ma et al., 2013; Nagabhushan et al., 1989; Sakihama 
et al., 2002; Trachootham et al., 2009; Verma et al., 2010). 
 
Unlike normal cells, cancer cells owing to their enhanced metabolic activity have 
constitutively higher levels of reactive oxygen species (ROS), which spawns a persistent 
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prooxidative environment (Schumacker, 2006; Szatrowski and Nathan, 1991; Trachootham et al., 
2009). Nonetheless, cancer cells despite high ROS concentrations, survive by adapting to the 
increased oxidative stress by upregulating pro-survival mechanisms and altering their antioxidant 
systems (Figure 1.1). Normal cells, however, operate within an “optimal window” to maintain a 
redox balance between generation and elimination of free radicals, but also possess a robust 
capacity to tolerate a sizeable fluctuation in ROS levels. In contrast, the high basal ROS levels in 
cancer cells provide a much narrower window to endure elevations in ROS levels, thus making it 
their “Achilles heel”. This “vulnerability” or susceptibility of cancer cells can be exploited by 
whole foods containing phenolic entities to selectively kill cancer cells by augmenting ROS 
levels beyond the toxic threshold that cancer cells can withstand and thus induce apoptosis 
(Figure 1.2). Nevertheless, a “similar-scaled” prooxidant deviation from redox homeostasis is 
well tolerated by normal cells (Figure 1.2). This partly explains why plant-based foods with a 
concoction of free radical scavenging and generating agents are well-tolerated and non-toxic. 
The width of the “therapeutic window” may be evaluated by the redox differences between 
normal and tumor cells and may be specific to the nature of the components present in the plant-
based food. 
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Figure 1.2 Xenohormetic response 
The bioactive phenolics of betel leaves may facilitate elimination of initiated cells, thus ensuring 
that they do not develop into cancer. By ‘signaling’ that there is some “stress” in the 
environment, ingested phytochemicals like betel nutraceuticals are thought to potentiate a 
systemic stress-combating response in normal cells, which in turn triggers the up regulation of 
endogenous antioxidant enzymes by modulating the nuclear transcription factor erythroid 2p45 
(NF-E2)–related factor 2 (Nrf2) expression or the endogenous thiol (GSH) levels. Due to the 
systemic activation of this defense system, the initiated cells can be effectively scavenged and 
eliminated, presumably by the immune system, which is placed on “high-alert”. On the other 
hand in the cancer cells, an opposite effect of further stress induction is observed due to which 
apoptosis is induced and/or the endogenous Nrf2 and thiol levels are depleted (Lee-Hilz et al., 
2006; Surh, 2011).  
The xenohormetic process thus fills the gaps in knowledge on the cancer preventative 
benefits of plant-based phytochemicals in addition to their roles to kill transformed cancer cells. 
The xenohormesis phenomenon aids to comprehend the basis of the chemopreventive potential 
of phytochemicals or whole foods that prevent carcinogenesis and intervene early on in the 
malignant transformation process. 
1.6 Summary 
The primary focus of my research emphasizes understanding the health benefits imparted 
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by dietary phytochemicals. For this we chose to work with in vitro and in vivo prostate cancer 
models. Prostate cancer is the second leading cause of death among American men, next to lung 
cancer. Though it is a slow-growing cancer, it can be aggressive and even fatal. Given its 
hormone-dependency, many prostate cancer patients often respond to hormone ablation therapy. 
Yet in most cases, it becomes hormone refractory, which cannot be treated effectively thus 
resulting in death. Furthermore, due to its high prevalence in American men, its treatment-
associated morbidity, long latency period, and defined molecular pathogenesis, prostate cancer 
serves as a potential target to develop novel chemotherapeutic and chemopreventive strategies. 
 
Dietary interventions seem to be cost-effective and safer options in treating cancer as the 
constituent phytochemicals, polyphenols in particular, of dietary agents can deliver maximum 
therapeutic benefits via pharmacodynamic and pharmacokinetic synergies. Furthermore, plant 
extracts constituting xenohormetic phytochemicals are the new age drugs to be employed and 
engaged in the war against cancer. This dissertation compiles the results from investigations 
performed in our laboratory involving a variety of plant-based foods with exceptional anticancer 
potential, which are as follows: 1) Polyphenol-rich sweet potato greens extract inhibits 
proliferation and induces apoptosis in both in vitro and in vivo prostate cancer models. Its 
constituent polar phenolic acids synergize to inhibit prostate cancer cell proliferation and in vivo 
tumor growth. 2) Benefits of whole ginger extract in prostate cancer, where ginger 
phytochemicals exhibit robust synergy to inhibit prostate cancer cell proliferation. They also 
undergo enterohepatic re-circulation, which is associated with enhanced tumor growth-inhibitory 
activity of ginger extract. 3) The anticancer benefits and bio-guided fractionation of Piper betel 
leaf extract, a reservoir of potential xenohormetic nutraceuticals with cancer-fighting properties, 
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to identify active constituents for prostate cancer management. Hydroxychavicol, a betel leaf 
component, inhibits prostate cancer through an interplay of ROS-driven autophagy and 
apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
2     WHOLE FOOD EXTRACTS PRESENT SUPERLATIVE EFFICACY 
COMPARED TO THEIR PURIFIED COUNTERPARTS2  
2.1 Abstract 
Polyphenolic phytochemicals present in fruits and vegetables indisputably confer 
anticancer benefits upon regular consumption. Sweet potato (Ipomoea batatas) leaves or greens, 
extensively consumed as a vegetable in Africa and Asia, are an excellent source of dietary 
polyphenols such as anthocyanins and phenolic acids. Here, we demonstrated that sweet potato 
                                                
2 This chapter has been published verbatim in Carcinogenesis 2011 as Polyphenol-rich 
sweet potato greens extract inhibits proliferation and induces apoptosis in prostate cancer cells 
in vitro and in vivo and Carcinogenesis 2013 as Polar phenolic acid constituents in sweet potato 
greens extract synergize to inhibit prostate cancer cell proliferation and in vivo tumor growth. 
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greens extract (SPGE) has the maximum polyphenol content compared with several commercial 
vegetables including spinach. Further, we demonstrated the growth-inhibitory and apoptosis-
inducing properties of polyphenol-rich sweet potato greens extract (SPGE) in cell culture and in 
vivo prostate cancer xenograft models. Oral administration of 400 mg/kg SPGE remarkably 
inhibited growth and progression of prostate tumor xenografts by 69% in nude mice, as shown 
by tumor volume measurements and non-invasive real-time bioluminescent imaging. We also 
report a bioactivity-guided fractionation of SPGE based upon differential solvent polarity using 
chromatographic techniques that led to the identification of a remarkably active polyphenol-
enriched fraction, F5, which was ~100-fold more potent than the parent extract as shown by IC50 
measurements in human prostate cancer cells. HPLC-UV and mass-spectrometric analyses of the 
seven SPGE fractions suggested varying abundance of the major phenols, quinic acid (QA), 
caffeic acid (CA) its ester, chlorogenic (ChA) acid, and isochlorogenic acids, 4,5-di-CQA, 3,5-
di-CQA and 3,4-di-CQA, with a distinct composition of the most-active fraction, F5. Sub-
fractionation of F5 resulted in loss of bioactivity, suggesting synergistic interactions among the 
constituent phytochemicals. Quantitative analyses revealed a ~2.6 and ~3.6 fold enrichment of 
QA and ChA respectively, in F5 and a definitive ratiometric relationship between the 
isochlorogenic acids. Daily oral administration of 400 mg/kg bw of F5 inhibited growth and 
progression of prostate tumor xenografts by ~75% in nude mice, as evidenced by tumor volume 
measurements and non-invasive real-time bioluminescence imaging. These data generate 
compelling grounds to further examine the chemopreventive efficacy of the most-active fraction 
of sweet potato greens extract, and suggests its potential usefulness as a dietary supplement for 
prostate cancer management.  
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2.2 Introduction 
Nearly one-third of all cancer deaths in the USA can be prevented through appropriate 
dietary modification (Anand et al., 2008; Khan et al., 2008; Kolonel et al., 2004). Regular 
consumption of fruits and vegetables (five servings per day) (Williams, 1995) is highly 
recommended today in the American and European diet, mainly because the constituent 
phytochemicals, in particular, polyphenols, they contain are known to play important roles in 
long-term health protection, notably by reducing the risk of chronic and degenerative diseases 
including cancer (Crozier et al., 2009; Treutter, 2005). Prostate cancer is particularly amenable to 
dietary chemopreventive strategies since it presents a significantly large-window of latency (20–
30 years) and its mean age of diagnosis is ~68 years (Cooke et al., 2005; Kaur et al., 2009; 
Veluri et al., 2006; Yang et al., 2001). About 35 plant-based foods identified by the NCI display 
effective anticancer properties including garlic, turmeric, cruciferous vegetables (e.g. broccoli, 
brussels sprouts, cabbage) and grape seed extracts (Colli and Amling, 2009; Kaur et al., 2009; 
Steinkellner et al., 2001; Surh, 2003; Traka et al., 2008). Many fruit and vegetable whole extracts 
have also been tested for their efficacy in inhibiting prostate cancer growth (Cooke et al., 2005; 
Kaur et al., 2009; Ray et al., 2010; Surh, 2003; Yang et al., 2001). Plant polyphenols, a class of 
naturally occurring water-soluble phenolic compounds, are crucial for optimal human health 
benefits and are being increasingly recognized owing to their abundance in fruits, vegetables and 
derived foodstuffs (Quideau et al., 2011). The conformational flexibility of polyphenols 
facilitates complex oligo/polymeric assemblies that enable plants to take advantage of the 
remarkably diverse range of biophysicochemical properties exhibited by the phenol functional 
group thus making plant polyphenolics as unique and intriguing natural products (Quideau et al., 
2011). No wonder polyphenols have sparked a new appraisal of diverse plant-derived foods and 
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beverages such as tea, red wine, coffee, cider, chocolate as well as many other food commodities 
derived from fruits, including berries. The ability of phenolics to homolytically release a 
hydrogen atom is one of the fundamental processes that underlie the acclaimed health-benefiting 
antioxidative property of polyphenolics to act as scavengers of free radicals and reactive 
oxidative species that may drive malignant transformation and carcinogenesis (Quideau et al., 
2011). 
Nutrition research has long favored a reductionist approach emphasizing single 
phytochemical-based health benefits. However, the idea of synergy among constituent 
phytochemicals present in whole foods is gaining momentum. Several reports underscore the 
benefits of a multi-targeted approach offered by a synergistic mixture of phytochemicals present 
in whole foods (Craig, 1999; Dragsted et al., 1993; Liu, 2003; Surh, 2003; Ulbricht and Chao, 
2010; Waladkhani and Clemens, 1998). It is becoming recognizable that a whole or partially 
purified extract of a plant offers significant advantages over a single isolated ingredient. This can 
be most appropriately described as the “herbal shotgun” approach, as opposed to the “silver 
bullet” method of conventional medicine (James A. Duke, 2008) and may partially explain the 
limited success of clinical trials involving individual phytochemicals such as Vitamin E and 
beta-carotene for cancer chemoprevention (Greenberg et al., 1994; Liu, 2004; Tsao et al., 2004). 
Nonetheless, these data solidify the notion that health benefits from fruits and vegetables may 
not be solely because of the isolated single compounds, but are mainly due to additive and/or 
synergistic interactions among components that “partner” together in the concoction at their 
relative concentrations. For example, studies with skin-bearing apples have demonstrated strong 
antiproliferative activity in human colon and hepatic cancer cells, compared to apples without 
skin or its most studied constituent, vitamin C (Wolfe et al., 2003).  
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Well-known for their abundance in fruits and vegetables, polyphenols are versatile 
molecules containing several hydroxyl groups with multiple aromatic rings. The amphiphilic 
phenolic moiety of polyphenols blends the hydrophobic character of its planar aromatic core 
with the hydrophilic nature of its polar hydroxy substituent (Quideau et al., 2011). The inherent 
bio-physicochemical properties of the phenolic group display a wide repertoire of functional 
roles, including plant resistance against microbial pathogens, and protection against solar 
radiation. Epidemiological studies suggest an inverse relationship between consumption of 
polyphenol-rich foods like cocoa, red wine, tea, fruits, vegetables, etc. and the incidence of 
chronic diseases including cancer (Cooke et al., 2005; Kaur et al., 2009; Yang et al., 2001). 
Although it is easy to evaluate the protective effect of a single phytochemical, for example, a 
single polyphenolic compound, the health benefits of dietary polyphenols are difficult to discern 
when numerous phytochemicals including polyphenolics, flavonoids, lignans and tannins are 
active and work synergistically. The complexity of polyphenols in foods limits the identification 
of definitive compositions of partially purified extracts that display superior efficacy compared 
to single-agents or whole foods. Nevertheless, it is likely that a reductionist approach involving 
fractionation of a whole extract may result in the increased concentration of bioactive 
constituents in a particular sub-fraction, thus enhancing efficacy. 
Sweet potato greens (SPG), Ipomoea batatas, a significant source of dietary polyphenols, 
are widely consumed as a fresh vegetable in West Africa and Asia, in particular, Taiwan and 
China (Mosha and Gaga, 1999). Rich in vitamin B, β-carotene, iron, calcium and zinc, sweet 
potato greens (SPG) are highly nutritive and contain as many vitamins, minerals and other 
nutrients as spinach (Islam, 2006). SPG are an excellent source of antioxidative polyphenolics, 
namely anthocyanins and phenolic acids such as caffeic, monocaffeoylquinic (chlorogenic), 
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dicaffeoylquinic and tricaffeoylquinic acids (Huang et al., 2007; Kurata et al., 2007). 
Particularly, anthocyanins in SPG have been described to be cyanidin-type rather than peonidin-
type (Islam et al., 2002a). SPG have been shown radical-scavenging, antimutagenic, antidiabetic, 
antibacterial, anti-inflammatory, and anticancer activities (Huang et al., 2007; Islam, 2006). The 
chemopreventive action of SPG is suggested by a case–control study in Taiwan reporting that 
higher SPG consumption is associated with reduced lung cancer risk (Jin et al., 2007). Although 
sporadic studies have reported identification of bioactive polyphenolics and anthocyanin 
constituents of SPG (Islam et al., 2002b), there has, heretofore, not been a study that offers a 
detailed evaluation of the anticancer potential of sweet potato greens extract (SPGE). To the best 
of our knowledge, we are the first to investigate the anticancer attributes of SPGE in vitro and in 
vivo and to develop it as a mechanism-based anticancer agent for prostate cancer. 
In this chapter, we examine the anticancer effects of SPGE in a panel of prostate cancer 
cells by evaluating its effects on cellular proliferation, cell cycle progression and apoptosis. Our 
results demonstrate that SPGE causes growth inhibition by inducing a G1 phase arrest followed 
by a mitochondrially mediated caspase-dependent intrinsic apoptosis in prostate cancer, PC-3 
cells. In vivo studies show that SPGE remarkably inhibits tumor growth of subcutaneously 
implanted PC-3 human tumor xenografts in nude mice models without any detectable toxicity. 
Also a detailed bioactivity-guided fractionation of SPGE, emphasizing the importance of 
synergistic interactions among various bioactive components to confer remarkable in vitro and in 
vivo effects in prostate cancer models is reported here.   
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2.3 Materials and Methods 
2.3.1 Cell culture, antibodies and reagents 
Human prostate cancer cell lines (LNCaP, DU145, PC-3, C4-2, C4-2B) were cultured in 
RPMI medium (Mediatech, Manassas, VA) with 10% fetal bovine serum. Luciferase-expressing 
PC-3 cells (PC3-luc) were from Perkin Elmer (Hopkinton, MA) and were maintained in 
modified Eagle’s medium with 10% fetal bovine serum. Antibodies to cyclin D1, cyclin A, 
cytochrome c, Bcl2, phospho-Bcl2, cleaved caspase-3 and cleaved poly (adenosine diphosphate-
ribose) polymerase (PARP) were from Cell Signaling (Beverly, MA). BAX, p21, cyclin E, p53 
and β-actin were from Santa Cruz Biotechnology (Santa Cruz, CA). Chlorogenic acid (ChA) and 
caffeic acid (CA) were from Sigma (St Louis, MO). MTT dye (Thiazolyl blue tetrazolium 
bromide, 98% TLC) and dimethyl sulfoxide (DMSO) were from Sigma-Aldrich (St. Louis, MO). 
Quinic acid (QA), chlorogenic acid (ChA), caffeic acid (CA), and Folin-Ciocalteau (FC) reagent, 
ACS grade methanol, ethyl acetate, hexanes and high-performance liquid chromatography 
(HPLC) grade solvents were from Sigma-Aldrich (St. Louis, MO).  
2.3.2 Preparation of SPGE and estimation of polyphenolics  
Forty-five-day-old sweet potato (I.batatas) greens [Whatley/Loretan, (TU-155) variety] 
were obtained from Tuskegee University Agriculture Department. Extracts were prepared by 
soaking shade-dried leaves in methanol overnight for three consecutive days. The supernatant 
was collected daily and finally concentrated in vacuo (Buchi-Rotavap) followed by freeze drying 
to powder using a lyophilizer. SPGE stock solution was prepared by dissolving 200 mg SPGE in 
1 ml dimethyl sulfoxide and various concentrations were obtained by appropriate dilutions.  
Batch-to-batch variation was evaluated by analysis of total polyphenolic  (~6.5/100 g) 
(Truong et al., 2007; Yoshimoto et al., 2002) and anthocyanin (~10.8 Color value/g powder) 
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(Islam et al., 2002a) contents, which was observed to be consistent across batches of similar age. 
Total phenolic content was determined by Folin–Ciocalteu (FC) method using chlorogenic acid 
as the standard. Chlorogenic acid (0.5 g) was dissolved in 10 ml ethanol and then diluted to 100 
ml with water to make a final concentration of 5 g/L. 50, 100, 250, and 500 mg/L concentrations 
of standards and 0.5, 1, 2, 3, 4 and 5 mg/ml concentrations of test extracts were prepared in 
distilled water. 20 µl sample of standard or test extract was dissolved in 1.58 ml water, followed 
by 100 µl FC reagent. This mixture was mixed thoroughly and incubated no longer than 8 min. 
300 µl sodium carbonate solution was added to the above mixture and was incubated for 2 h at 
room temperature. A final volume of 2 ml was measured for absorbance at 765 nm and the 
results were expressed as milligrams of chlorogenic acid equivalents (ChAE) per gram dry 
material (ChAE mg/g). The linear range of the calibration curve was 0.02 to 0.2 mg/ml. All 
samples were analyzed in triplicates. 
Classical column chromatographic separation was performed on SPGE (3 g) that was 
loaded on to a silica gel column, which was run down using hexane: ethyl acetate solvent system 
starting with 500 ml of 100% hexane. The fraction was collected in a conical flask and stored at 
4oC.  This was followed by elution using 500 ml of hexane:ethyl acetate solution (90:10). 
Subsequently, a gradient increase in the percentage of ethyl acetate (10% each time) was 
incurred in the mobile phase to elute various components of SPGE into different fractions. After 
the elution of 50:50 hexane:ethyl acetate fraction, hexane was replaced by 50% methanol to elute 
the highly polar components. With an increment of 10% methanol each time (starting from 50:50 
methanol:ethyl acetate) the column was finally eluted with 100% methanol to ensure complete 
elution of all components. A total of 17 fractions thus obtained were concentrated in vacuo 
(Buchi Rotavap) followed by separation on thin layer chromatography (TLC). Based on the 
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observed bands, fractions with similar TLC profiles (Rf values) were pooled to finally obtain 7 
fractions (F1-F7). All 7 fractions were freeze-dried using a lyophilizer and were stored at -80oC 
until tested.  
2.3.3 In vitro proliferation assay 
Briefly, 5 x 103 cells/well in a 96-well format were treated with gradient concentrations of 
SPGE and test fractions dissolved in DMSO (0.1%). The concentrations used were 1, 10, 25, 50, 
75, 100 and 250 µg/ml.  F5 was further tested at lower concentrations (0.075, 0.1, 0.5, 1, 5 and 
10 µg/ml). After 48 h incubation, cells were washed with PBS followed by addition of 5 mg/ml 
MTT solution. Cells were then incubated at 37°C in dark for 4 h. The formazan product was 
dissolved by adding 100 µl of 100% DMSO after removing the medium from each well. The 
absorbance was measured at 570 nm using a Spectra Max Plus multi-well plate reader 
(Molecular Devices, Sunnyvale, CA).  
2.3.4 Colony survival assay 
1000 PC-3 cells were seeded in a 6-well plate and were treated with 10 µg/ml F5 for 24 
and 36 h, then washed, and replaced with regular RPMI medium including the controls. After 7 
days, each well was washed twice with 1X PBS, and fixed and stained with the clonogenic 
reagent for 20 mins followed by rinsing with tap water. The stained colonies in the control and 
treated wells were then counted. A colony was arbitrarily defined to consist of at least 50 cells.  
2.3.5 Cell cycle analysis, immunofluorescence microscopy and immunoblot analysis 
PC-3 cells treated with 250 µg/ml SPGE for 6, 12, 24, 48, and 72 h, were lysed, 
centrifuged, washed with ice-cold PBS, fixed in 70% ethanol and stored at 4°C. Pellets were 
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collected, washed twice with PBS and stained with propidium iodide in the presence of RNaseA 
for 45 min in the dark. Cell cycle profile was analyzed by flow cytometry (Aneja et al., 2010).  
PC-3 cells grown on coverslips were treated with 250 µg/ml SPGE for 24 h, and were 
then fixed with ice-cold methanol for 10 min. This was followed by blocking with 2% bovine 
serum albumin/PBS at 37°C for 1 h. The coverslips were then incubated with Ki67, cleaved 
PARP, and cleaved caspase-3 (1:100 dilution) 37°C for 1 h, which were then washed with 2% 
bovine serum albumin/PBS for 10 min at room temperature and incubated with 1:500 dilution of 
Alexa 488- (Ex:Em::499:519) or 555- (Ex:Em::553:568) conjugated secondary antibodies. The 
coverslips were then mounted with Prolong Gold antifade reagent containing 4’,6-diamidino-2-
phenylindole (Invitrogen) (Karna et al., 2010).  
Protein lysates were collected from cells treated with or without 250 µg/ml SPGE and 
were resolved by SDS-PAGE, followed by a transfer onto polyvinylidene difluoride membrane 
that was incubated with a primary antibody of choice overnight at 4°C. Appropriate secondary 
antibody was used followed by visualization of the immune-reactive bands by 
chemiluminescence detection kit (Pierce). β-actin was loading control (Karna et al., 2010).  
2.3.6 Determination of mitochondrial transmembrane potential and caspase-3/7 activity and 
TUNEL assay 
Mitochondrial transmembrane potential was measured flow cytometrically using 
5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazol-carbocyanine iodide (JC) staining and 
caspase-3 activity was measured using a fluorescent substrate (Karna et al., 2010). Annexin-V 
and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay 
was performed where SPGE-treated cells were stained with Alexa-Fluor 488-conjugated 
Annexin-V using the Vybrant-Apoptosis Assay Kit from Invitrogen as per the manufacturer’s 
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protocol. Annexin-positive cells were visualized using confocal microscopy and quantitated flow 
cytometrically. DNA strand-breaks were quantified flow cytometrically using the TUNEL assay 
(Aneja et al., 2010). 
2.3.7 In vivo tumor growth, SPGE and F5 treatment and bioluminescent imaging 
Six-week old male nude mice were obtained from NCI (Frederick, MD) and/or Harlan 
laboratories (Indianapolis, IN) and 1 x 106 PC-3-luc cells in 100 µl phosphate-buffered saline 
were injected subcutaneously in the right flank. When tumors were palpable, mice were 
randomly divided into two groups of eight mice each. Control group received vehicle 
(phosphate-buffered saline with 0.05% Tween-80, pH 5 7.4) and the treatment group received 
400 mg/kg body wt SPGE and F5 daily by oral gavage. Tumor growth was monitored in real 
time by bioluminescent imaging of luciferase activity in live mice using the cryogenically cooled 
IVIS-imaging system (Perkin Elmer) with the live imaging software. Briefly, mice were 
anesthetized with isoflurane, intraperitoneally injected 25 mg/ml luciferin and imaged with a 
CCD camera. Integration of 20 s with four binnings of 100 pixels was used for image acquisition 
and signal intensity was quantitated as sum of all detected photon counts within the lesion. Mice 
from vehicle or SPGE-treated groups were imaged twice a week allowing temporal assessment 
of in vivo tumor growth. All animal experiments were performed in compliance with 
Institutional Animal Care and Use Committee guidelines.  
2.3.8 Histopathologic and immunohistochemical analyses 
After 6 weeks of SPGE, F5 or vehicle feeding, mice were euthanized by exposing to CO2 
for 2 min. Organs and tumors were either formalin fixed or frozen immediately. Tumor or organ 
sections were stained with hematoxylin and eosin, Cleaved caspase-3, cleaved PARP, Ki67 and 
TUNEL staining (Aneja et al., 2008; Aneja et al., 2006). Microscopic evaluation was performed 
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by a pathologist in a blinded manner. Blood was collected by cardiocentesis in accordance with 
our standard IACUC protocol.  
2.3.9 Immunoblot analysis and immunofluorescent microscopy 
Tumor lysates treated with vehicle and 400 mg/kg bw F5 were subjected to western blot 
analysis. Membranes were probed for cleaved caspase-3 and cleaved PARP along with β-actin, 
which was used as a loading control. Paraffin-embedded tumor sections from control and F5-
treated groups were processed and immunostained with apoptotic markers, cleaved caspase-3 
and cleaved PARP, and the proliferation marker, Ki67. Fluorescent images were captured using 
confocal microscopy. Human prostate cancer, PC-3 cells were treated with 10 µg/ml F5 and cell 
lysates were collected at 0, 6, 12, 24, and 48 h. Immunoblot analysis was performed on the F5-
treated and control samples by probing for cleaved PARP and β-actin to confirm the induction of 
apoptosis.  
2.3.10 High performance liquid chromatography with UV and mass spectrometric detection 
The high performance liquid chromatography (HPLC)-UV separations were achieved on 
an HP1100 series Instrument (Agilent Technologies, Wilmington, DE) equipped with a UV-
photodiode array detector using an Eclipse plus reversed phase C-18column (3.5 µm, 4.6 x 150 
mm). HPLC-UV separation of 7 fractions was achieved on a HP1100 series Instrument (Agilent 
Technologies, Wilmington, DE) equipped with a photodiode array detector, using an Agilent 
Zorbax reversed phase (SB-C18, 3.0 × 250 mm, 5.0 µm) column. The mobile phase system 
consisting of solvent A (0.1% formic acid in water) and solvent B (ACN) was employed to 
achieve the separations. The gradient elution was set as follows: starting at 10% B, achieving 
20% B at 20 min followed by 60% B over the next 20 min, which was held for an additional 10 
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min; reconditioning to 10% B at 51 min and ending the run at 60 min with a flow rate of 0.4 
ml/min. 10 µL of each fraction (1.0 mg/ml), dissolved and filtered in 25% ACN, was injected 
into the system and the resultant HPLC-UV peaks were detected at 326 nm. 
The HPLC-MS analyses were performed in tandem with HPLC-UV using the Agilent 
Zorbax reversed phase (SB-C18, 3.0 × 250 mm, 5.0 µm) column interfaced to an Agilent 6400 
series Triple quadrupole LC/MS equipped with an electrospray ionization source, operated in 
negative-ion mode. The nebulizer and collision gases were nitrogen and helium, respectively, 
with the former set at 40 psi. A drying gas temperature of 300oC, drying gas flow rate of 9 L/min 
and capillary voltage of -3000V were the spray chamber parameters. The presence of quinic 
(QA, m/z = 191, RT: 2.7min), chlorogenic (ChA, m/z = 353, RT: 11.6min) and caffeic (CA, m/z 
= 179, RT: 15.5min) acids in the fractions was confirmed using selected ion monitoring (SIM) 
and the HPLC retention time (RT) of the same in all the fractions against pure standards. 
2.3.11 Sub-fractionation of F5 using analytical HPLC-UV chromatography 
The most-active fraction, F5 was further fractionated into 2 sub-fractions based on the 
retention time, F5-A (0-25 min) and F5-B (25.1-50 min) using analytical high performance 
liquid chromatography. The sub-fractions thus collected were concentrated and lyophilized to 
determine the in vitro efficacy by MTT assay.  
2.3.12 Experimental design for the combination studies and determination of synergy 
The pure standards, QA, ChA and CA, were combined as a mixture to mimic their 
respective concentrations as quantitated in F5. This mixture was used at various increasing 
gradient concentrations to test its in vitro efficacy against PC-3 cells. Specifically, the 
concentrations used were, 0.075, 0.1, 0.5, 1, 5, and 10 µg/ml. The percentage of cell proliferation 
was measured by MTT assay.  
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2.3.13 Statistical analysis 
The mean and standard deviations were calculated for all quantitative experiments using 
Microsoft-Excel software. The Student’s t-test was used to determine the differences between 
groups with P-values of <0.05 considered as statistically significant. 
2.4 Results 
2.4.1 SPGE inhibits proliferation, perturbs cell cycle progression, and induces 
mitochondrially-mediated intrinsic apoptosis in human prostate cancer cells  
Given that prostate cancer has a long latency time and is ideal for chemopreventive 
intervention by non-toxic dietary extracts, we asked if SPGE inhibited growth of prostate cancer 
cells (LNCaP, DU145, PC-3, C4-2 and C4-2B) in a concentration gradient-dependent manner. 
SPGE significantly inhibited cellular proliferation of all prostate cancer cells with IC50 values in 
the range of 145–315 µg/ml (Figure 2.1A). The order of sensitivity was C4-
2<LNCaP<DU145<C4-2B<PC-3, with C4-2 being the most sensitive and PC-3 the least. 
Importantly, the IC50 of SPGE in normal prostate epithelial cells (PrEC and RWPE-1) was 
between 1000 and 1250 µg/ml (Figure 2.1B), which was ~5-fold higher than for cancer cells 
suggesting that SPGE specifically targets cancer cells while sparing normal cells. 
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Figure 2.1 SPGE inhibits growth and reproductive capacity of prostate cancer cells. 
(A) Bar graphical representation of IC50 values of SPGE for various prostate cancer cells and (B) 
normal prostate epithelial cells. (C) Bar-graph representation and photograph of crystal violet-
stained surviving colonies from control and SPGE-treated groups. (Di) Fluorescence 
micrographs of PC-3 cells stained for Ki67 or 4’, 6-diamidino-2-phenylindole. (Dii) Bar-graph 
quantitation of Ki67- positive or 4’,6-diamidino-2-phenylindole-stained cells treated with vehicle 
or 250 µg/ml SPGE. Values and error bars represent average and standard deviations, 
respectively, of three independent experiments (P <0.05). 
 
Next, we performed a clonogenic or colony formation assay that evaluates the capacity of 
a cell to proliferate indefinitely upon drug removal to form a colony or clone (Figure 2.1C). The 
most resistant cell line (i.e. highest IC50), PC-3, was selected for clonogenic assay and 
subsequent studies to delineate mechanisms of SPGE action. While controls produced several 
colonies, only a fraction of SPGE-treated cells retained the ability to form colonies. Figure 2.1C 
shows the effect of 250 µg/ml SPGE on the relative clonogenicity of control and SPGE-treated 
PC-3 cells. Representative micrographs of colonies in control and SPGE-treated cells shown at 
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the apex of bar graphs quantitated to a ~80% reduction in number and size of surviving colonies 
upon SPGE treatment (Figure 2.1C). We also examined nuclear Ki67 expression, which 
correlates well with growth fraction and found that Ki67 immunostaining was significantly more 
intense in control cells compared with 250 µg/ml SPGE-treated cells over 24 h (Figure 2.1Di). 
Bar graph quantitation of Ki67-positive cells scored in both control and SPGE-treated cells 
showed a ~82% decrease in treated cells (Figure 2.1Dii). Furthermore, 4’,6-diamidino-2-
phenylindole staining (Figure 2.1Di) indicated a ~5-fold increase in cells with nuclear 
fragmentation (Figure 2.1Dii) compared with controls, suggesting SPGE-induced apoptotic cell 
death. In addition, trypan blue data showed that SPGE-induced cell death over time (0, 12, 24, 48 
and 72 h) at 250 µg/ml in PC-3 cells. 
We next asked if SPGE-mediated growth suppression was due to its cell cycle 
intervention. To this end, we evaluated the effect of varying dose and time of SPGE exposure on 
the cell cycle progression of PC-3 cells. Figure 2.2Ai and 2.2Aii show dose and time courses of 
SPGE treatment in a three-dimensional format. SPGE caused cells to accumulate in the G1 phase 
at doses ~100 µg/ml over 24 h and at a dose of 250 µg/ml up to 12 h. This was followed by a 
dose- and time-dependent increase in sub-G1 population, representing cells with hypodiploid 
(~2N) fragmented DNA, a hallmark of apoptosis. The quantitation of sub-G1 population over 
varying dose levels and times is shown in Figure 2.2Aiii and 2.2Aiv, respectively. Since SPGE 
arrested cell cycle in the G1 phase at low doses and shorter time periods, we examined this acute 
effect of SPGE on G1 phase regulators. Immunoblot analysis revealed a decrease in protein 
levels of cyclin D1, cyclin A and cyclin E after 24 h of 250 µg/ml SPGE treatment (Figure 2.2B). 
An increase in Cip1/p21 levels was evident at 24 h, in agreement with the G1 arrest (Figure 
2.2B). 
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Figure 2.2 SPGE perturbs cell cycle progression. 
(A) SPGE perturbs cell cycle progression by causing a G1-arrest and increases sub-G1 cell 
population, indicative of apoptosis. (Ai) Cell cycle progression over dose (0–600 µg/ml) and 
(Aii) time (0–72 h) is shown in a three-dimensional format. (Aiii) Bar graphs depicting sub-G1 
population of PC-3 cells treated with SPGE over varying doses and (Aiv) time. (P<0.05 
compared with controls). (B) Immunoblots of cell lysates treated in absence or presence of 250 
µg/ml SPGE for cyclins D1, A, E and p21. The protein levels were determined by quantifying 
the pixel values of the protein bands using ImageJ on the immunoblots and normalized to the 
measured value at 0 h treatment. Uniform loading was confirmed by β-actin. (Ci) Confocal 
micrographs of Annexin-V-positive cells (staining at cellular rim) upon SPGE treatment for 48 h 
and (Cii) quantitation of Annexin-V- or TUNEL-positive cells for vehicle and SPGE treatment 
over time determined flow cytometrically. (P<0.05 compared with controls). 
 
Although an increase of sub-G1 population upon SPGE treatment indicated fragmented 
DNA suggesting apoptosis, we validated apoptosis both qualitatively and quantitatively by 
Annexin-V staining using confocal microscopy and flow cytometry methods. 
Immunofluorescence confocal micrographs showed that SPGE treatment for 48 h at 250 µg/ml 
externalized phosphatidylserine to the outer leaflet of the plasma membrane (observed as a rim) 
in PC-3 cells, a hallmark of early apoptosis (Figure 2.2Ci). Flow cytometric quantitation 
suggested a steady increase in Annexin-positive cells to ~37% at 72 h (Figure 2.2Cii). It is well 
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appreciated that altered cellular morphology, including membrane blebbing, formation of 
apoptotic bodies, disruption of cytoskeleton, hypercondensation and fragmentation of chromatin 
characterize termination of apoptosis. Thus, we next quantified the increase in concentration of 
3’-DNA ends due to DNA fragmentation using a flow cytometry-based TUNEL assay. We found 
that SPGE-treated cells showed ~42% TUNEL-positive cells (Figure 2.2Cii) at 72 h compared 
with controls, suggesting extensive DNA cleavage. 
Both extrinsic and intrinsic apoptotic pathways are well recognized as major mechanisms 
of cell death in most cellular systems (Fulda and Debatin, 2006). Having identified that SPGE 
induced robust apoptosis, we next evaluated whether the apoptosis was caspase driven. Our data 
showed that treatment of PC-3 cells with SPGE did not result in caspase-8 activation and 
cleavage (data not shown) indicating non-recruitment of the extrinsic apoptotic pathway. 
However, SPGE demonstrated a strong time-dependent cleavage of caspase-3 and PARP, as 
observed by immunofluorescence and immunoblotting methods (Figure 2.3Ai and 2.3Aii). 
Caspase involvement was further confirmed by measuring caspase-3/7 activity using a 
fluorescent substrate (Figure 2.3Aiii). Activation of caspase-3/7 without an effect on caspase-8 
suggested involvement of the intrinsic pathway. To establish that this was the major mechanism 
of SPGE-induced apoptotic death in PC-3 cells, we pretreated cells for 3 h with pan caspase 
inhibitor z-vad-fmk followed by a 48 h treatment with 250 µg/ml SPGE treatment. The extent of 
apoptosis was then determined by estimating the sub-G1 population flow cytometrically. We 
observed that z-vad-fmk pretreatment significantly inhibited SPGE-induced apoptosis by 65% 
(P<0.01), suggesting that cell death was primarily caspase mediated. 
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Figure 2.3 SPGE activates the intrinsic apoptotic pathway. 
(Ai) Immunofluoresence micrographs of vehicle-treated controls and 250 lg/ml SPGE-treated 
cells stained for cleaved caspase-3 and PARP. (Aii) Immunoblot analysis of cleaved caspase-3 
and cleaved PARP levels in cell lysates from vehicle-treated controls and SPGE treated PC-3 
cells. (Aiii) Caspase-3/7 activity assay over time. SPGE alters mitochondrial transmembrane 
potential. (P>0.05 compared with controls). (Bi) Histogram profiles and (Bii) quantitation of 
cytosolic monomeric JC-1 in unstained, control and SPGE-treated cells that were read flow 
cytometrically (P>0.05 compared with controls). SPGE-induced collapse of transmembrane 
potential was measured by increased green fluorescence indicated by a right shift in the 
fluorescence intensity curve. (Biii) Immunoblot analyses for p-Bcl2, total Bcl2, BAX and 
cytosolic cytochrome c. The protein levels were determined by quantifying the pixel values of 
the protein bands using ImageJ on the immunoblots and normalized to the measured value at 0 h 
treatment or controls. 
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We further confirmed intrinsic apoptosis by measuring the collapse of mitochondrial 
transmembrane potential (Ψm) and examining release of mitochondrial cytochrome c into the 
cytosol (Martinou et al., 2000). The effect of 24 h SPGE treatment on Ψm was observed by 
staining with 5,5’,6,6’-tetrachloro- 1,1’,3,3’-tetraethylbenzimidazol-carbocyanine iodide (JC-1), 
a cationic dye, which exhibits potential-dependent mitochondrial accumulation (Reers et al., 
1991). An increase in JC-1 monomeric form indicative of Ψm collapse was quantitatively 
determined using flow cytometry. As seen in Figure 2.3Bi, 250 µg/ml SPGE-treated cells at 24 h 
showed a right shift in the mean-fluorescence intensity of green JC-1 monomers compared with 
controls. There was a ~90% increase in the mean-fluorescence intensity of SPGE-treated JC-1-
stained cells compared with controls (Figure 2.3Bii). Most often, disruption of Ψm accompanies 
alterations in expression level of Bcl2 members, in particular, the ratio of antiapoptotic Bcl2 to 
proapoptotic BAX. We found that a 24 h 250 µg/ml SPGE treatment increased the levels of 
phosphorylated Bcl2 indicating its inactivation, whereas total Bcl2 levels remained unchanged 
(Figure 2.3Biii). A significant increase in BAX levels was observed at 24 h of SPGE treatment 
(Figure 2.3Biii). In addition, cytosolic cytochrome c was elevated upon a 24 h SPGE exposure 
(Figure 2.3Biii). Thus, these data strongly indicated a mitochondrially driven apoptosis upon 
SPGE treatment. We further confirmed the extent of contribution of the mitochondrial pathway 
toward SPGE-induced apoptosis using cyclosporin A, a mitochondrial permeability transition 
pore inhibitor. Our results show that pretreatment of cells with cyclosporin A for 3 h before 
SPGE treatment for 24 h resulted in ~38% sub-G1 population compared with ~62% upon SPGE 
treatment alone. Our experiments to study the drop in Ψm correlated with our flow cytometry 
data, in that we observed a diminution of the number of cells with depolarized mitochondria 
when cyclosporin A was added 3 h before SPGE treatment compared with when SPGE was 
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administered alone. This is clearly indicative of the protective effect of cyclosporin A. These 
results suggest that there is a significant mitochondrial component to the total apoptotic response 
of SPGE. 
2.4.2 Oral SPGE feeding significantly inhibits PC-3 tumor growth, induction of apoptosis 
and is non-toxic 
Having identified significant in vitro antiproliferative and proapoptotic activity of SPGE, 
we were curious to examine the in vivo efficacy of SPGE to inhibit human prostate tumor 
xenografts subcutaneously implanted in athymic nude mice. We employed a PC-3 cell line 
stablyexpressing luciferase (PC-3-luc) that allowed real-time visualization and monitoring of 
prostate cancer growth non-invasively. Animals in the treatment group were fed daily with 400 
mg/kg body wt SPGE by oral gavage for 6 weeks and treatment responses were followed by 
bioluminescent imaging in longitudinal studies using the same cohorts of mice (Figure 2.4Ai). In 
vehicle-treated control animals, tumors showed unrestricted progression (Figure 2.4Ai and Aii). 
In contrast, SPGE feeding showed a time-dependent inhibition of tumor growth over .6 weeks 
(Figure 2.4Ai and Aii), though significant retardation was evident as early as 2–3 weeks post 
treatment (Figure 2.4Aii). Quantification of relative photon counts revealed a 69%reduction in 
tumor volume with a confidence level of P<0.05 (n=8, Figure 2.4Aii) at week 6 compared with 
vehicle-treated controls. To assess overall general health and well being of animals during 
treatment, body weights were recorded twice a week. SPGE treatment was well tolerated and 
mice maintained normal weight gain (Karna et al., 2011b) with no signs of discomfort during the 
treatment regimen. To corroborate our bioluminescent imaging data, we also measured tumor 
volumes using a vernier caliper. As shown in Figure 2.4Bi, tumor volume measurements 
demonstrated that oral SPGE treatment for 6 weeks (42 days) reduced tumor volume by ~75%. 
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All animals in the control group were euthanized by day 42 postinoculation due to tumor 
overburden, in compliance with Institutional Animal Care and Use Committee guidelines. At the 
end point of animal experiments (week 6), the excised tumors (Figure 2.4Bii) were weighed and 
a ~65% reduction in tumor weight was observed in SPGE-treated group compared with controls. 
We next determined the longevity of surviving mice by monitoring them for general health and 
well being for 10 weeks. Kaplan–Meier analysis revealed a significantly increased survival time 
with 87.5% animals treated with SPGE surviving until 10 weeks (P<0.05; Figure 2.4C). This was 
a significant prolongation of survival compared with controls where median survival time was 
only 6 weeks.  
 
Figure 2.4 Dietary feeding of SPGE inhibits human prostate tumor xenograft growth in 
nude mice. 
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Male nude mice were subcutaneously injected with 106 PC-3-luc cells. (Ai) Bioluminescent 
images indicating inhibition of tumor growth over a period of time. (Aii) Graphical 
representation of the quantitative photon count from control and SPGE-treated mice for 6 weeks. 
(Bi) Tumor growth monitored (by vernier calipers) and presented as tumor volume in cubic 
millimeters, over a period of 42 days. (Bii) Photographic images of excised tumors and graphical 
representation of tumor weight. (C) Kaplan–Meier survival graphs of SPGE treatment over 10 
weeks. (P<0.05, Aii, Bi). 
 
To evaluate the in vivo effect of SPGE feeding on the antiproliferative response 
associated with tumor growth inhibition, tumor tissue lysates were analyzed for cyclins 
(including cyclins D1, A, E) and cyclindependent kinase inhibitor, p21, using immunoblotting 
methods (Figure 2.5A). SPGE treatment caused a decrease in cyclin D1, A and E, which 
correlated with our in vitro findings in PC-3 cells (Figure 2.5A). In addition, p21 upregulation 
was evident as a potential mechanism of cell cycle inhibition of tumor cells (Figure 2.5A), which 
was in accordance with the G1 phase cell cycle arrest observed in vitro. In vivo apoptotic 
response of SPGE feeding in PC-3-luc tumor xenografts was evaluated by caspase 3/7-activity 
assay and immunoblotting of tumor lysates for cleaved caspase-3 expression. As expected, 
cleaved caspase-3 expression (Figure 2.5A) as well as caspase-3/7 activity (Figure 2.5B) was 
higher in SPGE-treated tumors compared with controls. We further asked if SPGE caused 
regression of xenografted tumors by inhibiting proliferation and triggering apoptosis.  
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Figure 2.5 Tumor tissue lysates express high apoptotic and low proliferation markers. 
(A) Western blot analysis, (B) Caspase-3/7 activity (P<0.05), (Ci) hematoxylin and eosin, (Cii) 
Ki67, (D) cleaved caspase-3 and PARP from control and 400 mg/kg body wt SPGE-treated mice 
tumors. 
 
Hematoxylin and eosin-stained tumor sections from SPGE-treated animals revealed large 
areas of tumor cell death seen as tumor necrosis adjacent to normal looking healthy cells. 
Significant loss of tumorigenic cells in SPGE-treated animals (Figure 2.5Ci, right, arrow) was 
consistent with the therapeutic effect of SPGE. However, some viable tumor cells were observed 
at the periphery of cell death zones. In contrast, microsections from control tumor tissues 
revealed sheets of tumor cells with high-grade pleomorphic nuclei and angiolymphatic invasion 
(Figure 2.5Ci, left). Furthermore, Ki67-stained tumor sections from SPGE-fed animals showed 
weak immunoreactivity (Figure 2.5Cii) compared with vehicle-fed animals. Tumor sections from 
SPGE-treated groups also showed a marked increase in cleaved caspase-3 and PARP staining 
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(Figure 2.5D) compared with vehicle-fed controls, suggesting induction of robust apoptosis in 
tumors from SPGE-treated mice. 
Toxicity, particularly in tissues with actively proliferating cells, remains a major concern 
in prostate cancer patients treated either radiotherapeutically or by chemotherapeutic drug 
regimes. We found that there were no detectable differences in the histological appearance of 
tissues including the gut, liver, spleen, lung, brain, heart, testes and bone marrow from vehicle 
and SPGE-treated tumor-bearing mice (Karna et al., 2011b). In addition, colonic crypts from 
both mice groups showed comparable nuclear Ki67 staining, suggesting that SPGE did not affect 
normal tissues with rapidly proliferating cells. Furthermore, complete blood count (e.g. red blood 
cells, white blood cells, lymphocytes, hemoglobin), serum biochemical-profile markers [alanine 
transaminase, aspartate transaminase, alkaline phosphatase for hepatic function and creatinine, 
blood urea nitrogen and electrolytes including potassium, magnesium, sodium, calcium and 
chlorides for renal function] were within the normal range and similar between the control and 
SPGE-treated groups (Karna et al., 2011b). 
2.4.3 Identification of constituent bioactive phytochemicals via fractionation of SPGE 
Given the significant activity of SPGE, we next attempted to examine and identify its 
bioactive constituents. To this end, we first performed a simultaneous on-line HPLC–UV and 
HPLC–mass spectrometry (MS) comparative detection in both positive and negative ion modes 
for SPGE using acetonitrile (ACN):water (H2O) solvent system. The HPLC–UV chromatograms 
show the appearance of 11 peaks (Gundala et al., 2013). However, when SPGE passed through 
the MS detector after eluting from UV detector, new peaks appeared in both positive and 
negative ion modes, which were lacking UV chromophores. Two bioconstituents, ChA and 
caffeic acid (CA) with m/z values of 353.0 and 179.0, respectively, have been successfully 
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identified in SPGE using tandem-mass spectrometry (MS–MS) technique. The multiple reaction 
monitoring comparison for the respective product ions, 191 for ChA and 135 for CA, between 
SPGE and a mixture of pure standards confirmed the presence of both caffeic and ChAs in 
SPGE. However, two additional peaks were observed to be having the same m/z values as the 
product ion of ChA (which was not seen in case of pure standards), thus raising a possibility of 
the presence of ChA derivatives, which follow similar fragmentation pattern (353/191).  
2.4.4 A moderately polar fraction, F5, enriched of major SPGE phenolics exhibits 
remarkable antiproliferative activity in prostate cancer cells  
To gain insights into the nature of compounds present in the whole extract, we employed 
a “top-down logic” wherein we fractionated the whole extract using classical column 
chromatography (Figure 2.6). This led to the sequential separation of sub-fractions from the 
complex whole extract based upon their physicochemical characteristics such as polarity and 
solubility. To achieve optimal fractionation of SPGE, we employed a mobile phase system that 
ranged from the non-polar hexanes to highly polar methanol. The methanolic extract of SPGE 
was loaded onto the column and binary solvent combinations were used as the mobile phase. 
Finally, passing 100% methanol through the column ensured complete elution of all compounds.  
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Figure 2.6 Fractionation of SPGE using column chromatography. 
17 fractions were obtained by separating the sweet potato leaf extract with various solvent ratios 
using column chromatography as mentioned in the scheme (top-panel).  
 
The 17 fractions thus obtained were subjected to TLC and fractions with comparable Rf 
values were pooled together to finally yield 7 fractions (Figure 2.7A). Our next step was to 
perform a comparative quantitation of total polyphenolic content of all 7 SPGE fractions. Using 
Folin-Ciocalteu method, different fractions showed varying total polyphenolic content (Figure 
2.7B).  The quantitative comparison revealed that F5 contains ~2-fold higher phenolic content as 
compared to SPGE (Figure 2.7B).  Given that polyphenolic content has been correlated with 
bioactivity, these data prompted us to examine the in vitro efficacy of the various SPGE 
fractions.  
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Figure 2.7 Fractionation and evaluation of bioactivity of various SPGE fractions. 
(A) TLC of 17 SPGE fractions using an ethyl acetate:hexane (2:1) system for fractions 1–8; 
dichloromethane:methanol (3:1) for fractions 9–11 and 2:1 dichloromethane:methanol for 
fractions 12–17. Fractions with similar Rf profiles were pooled together to finally obtain seven 
fractions. Quantitation of total polyphenol content in all SPGE fractions. (B) Quantitation of total 
phenolic content of all the SPGE fractions quantified via FC method. SPGE and its fractions 
inhibit proliferation of PC-3 prostate cancer cells. (C) Plot of cell survival versus concentrations 
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of fractions tested for PC-3 cells. The IC50 values are indicated in the legend of line plot. Cells 
were treated for 48 h with increasing gradient concentrations of the seven fractions (F1–F7) and 
the parent SPGE. The percentage of cell proliferation was measured by MTT assay. (D) 
Determination of IC50 of F5. PC-3 cells were treated with the most active fraction, F5, from four 
different batches at increasing concentrations (0.075–10 µg/ml) for 48 h. The percentage cell 
proliferation was measured by MTT assay. (E) F5 shows enhanced inhibition of proliferation in 
various prostate cancer cells. Bar graphical representation of IC50 values (mentioned above) of 
SPGE and F5 tested in DU145, 22Rv1, LNCaP and C4-2 cells. Cells were treated for 48 h with 
increasing gradient concentrations of SPGE and F5. The percentage of cell proliferation was 
measured by MTT assay. (F) F5 inhibits the clonogenic capacity of prostate cancer cells. Bar 
graphical representation and photograph of crystal violet-stained surviving colonies from control 
and F5-treated groups. Results shown are means from three independent experiments (*, P<0.05 
compared with controls). 
 
Hence, we next determined the half-maximal concentration of growth inhibition (IC50) 
for the 7 SPGE fractions in PC-3 cells using the MTT assay. The IC50 values of F1-F7 were in 
the range of ~1-200 µg/ml (Figure 2.7C). Indeed the differential total phenolic content and 
polarity of various components that define a fraction might underlie the range of antiproliferative 
activity displayed by these fractions. Intriguingly, among the 7 fractions, fraction 5 (F5) was the 
most active and its IC50 value was initially calculated to be approximately 1 µg/ml (Figure 2.7C). 
To precisely determine the IC50 value of F5, we then tested still lower concentrations (0.075, 0.1, 
0.5, 1, 5 and 10 µg/ml) of F5 sub-fraction obtained from 4 different batches (F51, F52, F53 and 
F54) in PC-3 cells (Figure 2.7D). The IC50 of F5 was found to be within a range of 0.794-1.5 
µg/ml (Figure 2.7D), which was ~100 fold more potent compared to the whole SPGE extract 
(IC50=100 µg/ml). In addition, F5 exhibited better efficacy in other prostate cancer cell lines 
(LNCaP, 22Rv1, DU145 and C4-2) (Figure 2.7E) compared to SPGE suggesting the generality 
of the effect of F5 on a variety of prostate cancer cells.  
We next performed a clonogenic or colony formation assay to evaluate the capacity of a 
cell to proliferate to form a colony upon removal of the drug.  F5’s antiproliferative activity was 
demonstrated when several PC-3 colonies were observed in case of control, while the F5-treated 
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cells were found to only partially retain their colony forming ability (Figure 2.7F). The relative 
clonogenicity of control versus F5-treated PC-3 cells can be visually observed in the 
representative micrographs shown above the bar graphical quantitation of the colonies in Figure 
2.7F.  
Having identified the differential bioactivity of SPGE fractions, our next step was to 
perform a comparative quantitation of the phenolics present in all the 7 SPGE fractions by LC-
UV/MS analysis. Three major phenolics, quinic acid (QA, m/z=191), caffeic (CA, m/z=179) and 
chlorogenic (ChA, m/z=353) acids were identified to be present in SPGE, along with other 
isochlorogenic acids like 4,5-di-caffeoylquinic acid (4,5-di-CQA, m/z=515), 3.5-di-
caffeoylquinic acid (3,5-di-CQA, m/z=515) and 3,4-di-caffeoylquinic acid (3,4-di-CQA, 
m/z=515) (Figure 2.8Aii,B-Bi). Further analysis of F1 through F7 compared to SPGE 
demonstrated the differential relative abundance of the major phenols, QA, CA and ChA and the 
3 isochlorogenic acids (Figure 2.8A, Ai-Aii). For example, F1 and F2, the fractions of lower 
polarity, showed an absence of QA, CA and 4,5-di-CQA (Figure 2.8A, 2.8Ai-Aii). The CA 
content was found to be high in F3 and F4 as opposed to the ChA amounts (Figure 2.8Ai). 
However, the most-active fraction, F5 exhibited the highest amounts of QA and ChA (Figure 
2.8A, 2.8Ai-Aii). The enrichment of 4,5-di-CQA, 3,4-di-CQA and 3,4-di-CQA was observed 
from F3 onwards (Figure 2.8A,Aii). However, there was a decrease in their quantities in F6 and 
F7 as compared to F4 and F5 (Figure 2.8Aii). F4 was found to be enriched in all the 3 
isochlorogenic acids with 3,5-di-CQA being the most abundant, whereas the content of 3,4-di-
CQA is enhanced in F5 (Figure 2.8A,Aii). Fractions 6 and 7 exhibited a decrease in the 
composition of isochlorogenic acids.   
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Figure 2.8 F5 exhibited the presence of major phenols of SPGE. 
(A) LC-UV/MS comparison of constituents present in F1–F7 with respect to SPGE. Quantitation 
of the identified phenols, that is, QA, CA and ChA in F1–F7 and SPGE was obtained by 
performing a standard curve analysis using pure standards. Three other compounds, 4,5-di-CQA, 
3,5-di-CQA and 3,4-di-CQA, were quantitated relative to each other using the area under the 
curves. (Ai) Varying concentrations of QA, CA and ChA in all SPGE fractions. (Aii) Varying 
concentrations of 4,5-di-CQA, 3,5-di-CQA and 3,4-di-CQA in all SPGE fractions. (Bi) Different 
amounts of bioactive constituents such as neochlorogenic acid (nChA, m/z = 353), 
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cryptochlorogenic acid (cChA, m/z = 353), quercetin-glucoside (QnG, m/z = 463) and its isomer 
(QnG isomer, m/z = 463), quercetin (Qn, m/z = 447) and astragalin (m/z = 447) in SPGE versus 
F5 were identified using HPLC–UV/MS and tandem mass spectrometry (LC-MS/MS) analyses. 
(B) Tandem-mass spectrometry identification of 12 constituents (QA, nChA, cChA, ChA, CA, 
QnG, QnG isomer, 4,5-di-CQA, astragalin, Qn, 3,5-di CQA and 3,4-di-CQA) and 10 other 
unknown m/z values (u1–u10) in F5 and SPGE. Values and error bars represent average and 
standard deviations, respectively, of three independent experiments. 
 
The remarkable efficacy of F5 prompted us to examine the composition of this potent 
fraction. LC-UV/MS analysis of both SPGE and F5 confirmed the differential abundance of 
several phenolic compounds (Figure 2.8B-Bi), which were found to be enriched in F5. The 
hydroxycinnamic acids, ChA and CA along with QA in SPGE and F5 were quantitated using the 
respective pure standards. Tandem-mass spectrometric analysis affirmed the presence of QA, 
ChA and CA in SPGE and F5 (Figure 2.8B-Bi). The selected ion monitoring (SIM) of QA (191), 
ChA (353) and CA (179) confirmed their elution in both F5 and SPGE exactly at the same 
retention times (Figure 2.8A,Bi). Notably, the ratio between QA, ChA and CA differed between 
F5 and SPGE. The ratio of QA:ChA:CA in F5 has been (as observed in Figure 2.8Ai) calculated 
to be 6:1:0.005, whereas these same compounds existed in a 9:1:0.6 ratio in SPGE (Figure 
2.8Ai). On the other hand, the isochlorogenic acids were found to be in a ratio of 1:3:4.6 in F5 as 
compared to the 1:3:1.4 seen in SPGE (Figure 2.8Aii). Furthermore, the chemical fingerprints of 
F5 and SPGE as seen in Figure 2.8B-Bi, establish an obvious difference between their 
compositions. For example, the compound u4 with m/z value of 385 could not be observed in 
SPGE, whereas it was present at quantifiable levels in F5. QnG including 4 other unknown 
compounds, u5-u8, were absent in F5.  Among the major phenolics, there was an approximately 
2.6 (QA), 3.6 (ChA), and 3 (3,4-di-CQA) fold increase in F5 compared to SPGE. It is thus 
reasonable to speculate that these differences might be responsible for the higher bioactivity of 
F5 compared to SPGE in prostate cancer cells.  
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2.4.5 Subfractionation of F5 results in loss of bioactivity indicating synergism among F5 
phytochemicals 
Our next question was to examine if sub-fractionation of F5 into its constituent 
components employing analytical liquid chromatography resulted in identification of single-
agents that were much more active compared to the whole fractions. Repeated injections of 10µl 
of F5 were made into the HPLC system and the eluate from 0-25 min was collected as sub-
fraction, F5-A (Figure 2.9Ai) and the remaining part from 25.1-50 min as F5-B (Figure 2.9Aii). 
As seen in Figure 2.9Ai-Aiii, F5-A is a combination of QA, ChA and CA, whereas F5-B 
constituted the 3 isochlorogenic acids. These sub-fractions thus obtained were concentrated and 
lyophilized. Next, we again employed a bioactivity-guided approach to determine the efficacy of 
F5 sub-fractions. Both the sub-fractions were reconstituted in DMSO to yield 1 mg/ml stock 
solutions which were then used to dose PC-3 cells at gradient concentrations for 48 h. An MTT 
assay performed post-incubation showed that neither of the individual sub-fractions was as active 
as F5. Intriguingly, F5-A and F5-B did not show 50% inhibition of cell growth even at the 
highest test concentration (250 µg/ml) and hence, their IC50 values could not be determined 
(Figure 2.9B). This clearly indicated that F5-A needs F5-B and vice versa to mimic F5’s activity, 
hence suggesting a synergistic interplay among F5’s constituents. Additionally, the clear 
differences between the compositions of each sub-fraction compelled us to investigate if the loss 
of activity in the sub-fractions was related to their respective compositions. 
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Figure 2.9 Subfractionation of F5. 
(Ai) The chromatographic profile of F5 in MS scan mode. F5 was collected as two parts, F5-A 
(0–25 min) and F5-B (25.1–50 min) by injecting F5 for 17 times in the analytical HPLC system. 
MS scan mode chromatograms confirm the presence of (Aii) QA, ChA and CA in F5-A, (Aiii) 
4,5-di-CQA, 3,5-di-CQA and 3,4-di-CQA in F5-B. (B) Line plot of percentage cell survival 
versus concentration of F5 sub-fractions, F5-A and F5-B, tested against PC-3 cells. Cells were 
treated for 48 h with increasing gradient concentrations of the two sub-fractions of F5 and F5. 
The percentage of cell proliferation was measured by MTT assay. (C) Line plot of percentage 
cell survival versus concentration of a combination of QA, ChA and CA in increasing gradient 
concentrations treated for 48 h in PC-3 cells. The percentage of cell proliferation was measured 
by MTT assay. The test mixture of the three pure standards was constituted based upon their 
individual concentrations as in F5. Results shown are means from three independent 
experiments. 
 
To corroborate this observation, we next tested commercially-available QA, ChA and CA 
in combination at varying concentrations against PC-3 cells (Figure 2.9C). Quantitative data 
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points out that 1 mg of F5 contains 115 µg of QA, 16 µg of ChA and 0.1 µg of CA. Given the 
IC50 value of F5 is approximately 1 µg/ml (based on the range of 0.794-1.5 µg/ml, Figure 2.7D), 
F5 (1 µg) actually consists of 115 ng QA, 16 ng ChA and 0.1 ng CA. Assuming that these three 
compounds are the major players that contribute to F5-A’s activity, we tested the bioactivity of 
the mixture of the three pure standards by measuring the percentage of cell proliferation using 
the MTT assay. PC-3 cells were treated with this mixture in an increasing gradient concentration 
(0.075, 0.1, 0.5, 1, 5 and 10 µg/ml) ensuring that the relative quantities of the three compounds 
(QA+ChA+CA, the major constituents of F5-A), at each test concentration bore the same 
ratiometric relationship as was observed between them in F5. This mixture formulation thus 
mimicked the composition of F5-A (as it exists in F5). Evaluation of the in vitro efficacy of this 
subfraction might also enable exclusion of the possible antagonism of other yet unknown 
phytochemicals in F5-A. Our data suggested that even at the highest concentration tested (10 
µg/ml), the formulated mixture of pure standards did not show 50% inhibition in cell growth. As 
the pure standard mixture of three compounds could not reproduce equivalent efficacy as of F5, 
we speculate that the other unknown components in F5-A perhaps did not exert an antagonistic 
influence (Figure 2.9C). Thus our results from in vitro experiments testing various combinations 
of pure standards (QA, ChA and CA) suggested that higher efficacy of F5 could not only be 
ascribed to enhanced total polyphenolic content but also to possible synergistic interactions 
associated with definitive ratiometric composition of these phenolics.  
The other sub-fraction, F5-B also tested to be non-active (Figure 2.9B). Hence, the loss of 
bioactivity in both sub-fractions F5-A and F5-B individually suggested existence of synergism 
among the characterized and the yet unknown F5 components. It is perhaps likely that other 
identified compounds such as Qn, nChA, cChA, QnG, AGN contribute to uphold the superior 
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activity of F5. These data also emphasize the importance of the occurrence of QA, ChA, CA, 
4,5-diCQA, 3,5-di-CQA and 3,4-di-CQA in a distinct ratio, as found in F5 to display remarkable 
activity. To further substantiate our in vitro data, we tested the efficacy of F5 in an in vivo 
prostate xenograft model as discussed in the next section.   
2.4.6 Oral feeding of F5 inhibits prostate tumor growth in vivo and is non-toxic 
Given the significant difference in the in vitro anti-proliferative activity of F5 compared 
to SPGE, we next evaluated its in vivo efficacy to inhibit human prostate tumor xenografts 
subcutaneously implanted in athymic nude mice. We employed a PC-3 cell-line stably-
expressing luciferase (PC-3-luc), which enables real-time visualization and longitudinal 
monitoring of prostate cancer growth non-invasively in mice. We have previously shown that 
SPGE inhibits the in vivo tumor growth by 69% (Karna et al., 2011b). We found that the 
treatment group fed with 400 mg/kg bw F5 daily by oral-gavage for six weeks (Figure 2.10Ai) 
showed a time-dependent inhibition of tumor growth (Figure 2.10Ai-ii, B), compared to the 
vehicle-treated control animals. A relative total flux quantitation revealed a ~75% inhibition in 
tumor-volume with a confidence level of p<0.05 (n=8, Figure 2.10Aii) as measured at week 6 for 
the F5-fed group compared to vehicle-treated controls. All animals in the control group were 
euthanized due to tumor overburden, in compliance with institutional IACUC guidelines. At the 
end of week 6, the excised tumors (Figure 2.10Ci-ii) were weighed post-euthanasia and a ~74% 
reduction in tumor weight was observed in F5-treated groups respectively, compared to controls. 
Body weights were recorded twice a week to evaluate the general-health and well-being of 
animals during treatment. Mice in the F5 treatment group exhibited normal weight gain with no 
signs of discomfort during the treatment regimen (Figure 2.10D).  
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Figure 2.10 Dietary feeding of F5 showed enhanced inhibition of human prostate tumor 
xenograft growth in nude mice compared with SPGE. 
Male nude mice were subcutaneously injected with 106 PC-3-luc cells. (Ai) Representative 
bioluminescent images of one animal per group, indicating progression of tumor growth over 6 
weeks. (Aii) Graphical representation of quantitative radiance measured as the number of 
photons leaving a square centimeter of tissue and radiating into a solid angle of 1 steradian 
(photons/s/cm2/sr) from vehicle- and F5-treated mice for 6 weeks. (B) Tumor growth monitored 
(by vernier calipers) and presented as tumor volume in cubic millimeter over a period of 6 
weeks. (Ci) Graphical representation of tumor weight. (Cii) Photographic images of excised 
tumors. (D) Graphical representation of body weight of vehicle- and F5-treated mice [*, P < 0.05 
(two-way analysis of variance), Aii, B and C]. 
 
To evaluate in vivo inhibition of tumor growth upon oral feeding of F5, we 
immunostained for Ki67 (MIB-1), a well-known marker of cell proliferation. Essentially, the 
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Ki67 antigen is a non-histone protein expressed in all phases of the cell cycle except G0. We 
found that Ki67-stained tumor sections from F5-fed animals showed decreased immunoreactivity 
(Figure 2.11A) compared with vehicle-fed animals. Tumor sections from F5-treated groups also 
showed an increase in cleaved caspase-3 and PARP staining (Figure 2.11Ci and Cii) compared 
with vehicle-fed controls, suggesting induction of robust apoptosis in tumors from SPGE-treated 
mice. Furthermore, the tumor tissue lysates were immunoblotted for cyclin D1 and the apoptotic 
markers, cleaved caspase-3 and cleaved PARP (Figure 2.11B). Cyclin D1 plays a central role in 
the regulation of proliferation, linking extracellular signaling environment to cell cycle 
progression. There was a decrease in cyclin D1 expression in F5-fed tumor lysates suggesting a 
cessation of cell-cycle progression. Further, as expected, the cleaved caspase-3 and PARP 
expression (Figure 2.11B) were higher in F5-treated tumors compared with controls. Similar 
trend was observed in PC-cell lysates, where F5 treatment showed increased cleaved PARP 
expression compared with controls. 
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Figure 2.11 F5 induces apoptosis. 
Histochemical micrographs of tumor tissue sections from control and 400 mg/kg F5-fed groups 
stained for (Ai) hematoxylin and eosin and (Aii) Ki67. (B) Western blot analysis of tumor tissue 
lysates probed for cleaved caspase-3, cleaved PARP and cyclin D1. β-Actin was used as a 
loading control. Immunofluorescence micrographs of tumor sections from control and 400 mg/kg 
body wt F5-treated mice stained for (Ci) cleaved caspase-3 and (Cii) cleaved PARP. All images 
and blots shown are representative of three independent experiments. 
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Toxicity is overly concerning and is often observed in prostate cancer patients 
undergoing either radio or chemotherapy. The histopathological evaluation of the tissues of 
intestine, spleen, liver, lung, brain, heart, adrenal gland, and testes from both vehicle- and F5-fed 
mice (Figure 2.12A), revealed no detectable differences in architecture. Furthermore, analysis of 
biochemical markers in the sera (alanine transaminase, aspartate transaminase, alkaline 
phosphate, lactic acid dehydrogenase, creatinine kinase, and urea nitrogen) collected from both 
vehicle- and F5-fed mice was observed to be within the normal range (Figure 2.12Bi-iii). 
 
Figure 2.12 F5 is non-toxic. 
(A) The panels represented above are paraffin embedded; 5 µm thick tissue sections of intestine, 
liver, spleen, lung, brain, heart, testes and adrenal glands stained with hematoxylin and eosin and 
observed using a Å~20 objective. No visible differences were observed between the vehicle- and 
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F5-fed groups. (B) Organ-associated toxicity was not observed in F5-fed group. (Bi) Urea 
nitrogen levels in F5-fed group were comparable with that of vehicle-fed group. (Bii) The lactate 
dehydrogenase (LDH) and creatinine kinase levels in both the groups did not show any abnormal 
differences. (Biii) The biomarkers of liver, alkaline phosphatase (ALP), alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) were comparable for both the groups. 
 
2.5 Discussion 
The management of advanced prostate cancer or prostate cancer after androgen therapy 
failure poses a critical challenge because options such as radiotherapy and chemotherapy are 
associated with serious side effects. Several studies in recent years have convincingly shown that 
chemopreventive agents affect the process of carcinogenesis by targeting pathways such as 
carcinogen activation, detoxification, DNA repair, cell cycle progression, differentiation and 
induction of apoptosis in transformed cells. Besides displaying potent anticancer activity, the 
’golden-rule’ for an agent to qualify as a chemopreventive is that it should be well-tolerated, 
non-toxic, easily available and inexpensive.  
Fruits and vegetables are excellent sources of chemotherapeutic and chemopreventive 
agents (Block et al., 1992) and there is a uniformity of opinion emphasizing consumption of five 
or more servings of fruits and vegetables daily to minimize the risk of cancer (Williams, 1995). 
Several plant-based food extracts have been shown to be effective in cancer therapy and 
prevention such as ripe berry extracts and grape seed extracts (Kaur et al., 2009; Li et al., 2009; 
Sharma et al., 2004; Xie et al., 2009). Essentially, the beneficial effects of fruits and vegetables 
are due to their constituent phytochemicals that include polyphenolics, anthocyanins, 
carotenoids, alkaloids and nitrogen and sulfur compounds. These phytochemicals have been 
shown to target multiple events of neoplastic stages to confer therapeutic benefits and reduce 
overall cancer risk (Boyer and Liu, 2004; Ulrich et al., 2006). In addition, several reports indicate 
that a variety of naturally occurring compounds such as grape seed extract, silibinin, green tea 
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catechins and apples also play an important role in the prevention and treatment of prostate 
cancer (Bettuzzi et al., 2006; Chen et al., 2004; Raina et al., 2007a; Raina et al., 2007b). 
Although widely consumed as a vegetable in several parts of the world such as West 
Africa and Asia (Mosha and Gaga, 1999), SPG represent an untapped food resource in the USA. 
According to a United States Department of Agriculture report, the greens can be consumed in 
several forms including raw, cooked, steamed and processed. In addition, the polyphenolic 
content in leaves is much higher than in other parts of sweet potato such as the petioles, outer 
skin and storage root (Islam, 2006). Several other reasons exist that merit the encouragement of 
SPG as a more common vegetable in the USA. Firstly, oxalic acid content, which is a concern in 
vegetables because of its predisposition to form crystals within the kidneys is roughly one-fifth 
in SPG compared with spinach. Secondly, as a crop, SPG is more tolerant to diseases, pests and 
moisture than any other leafy vegetable grown tropically. SPG may be grown even during 
monsoon season of the tropics thus making it the only vegetable that can be grown right after 
floods or typhoons. Finally, this vegetable can be harvested several times during the year (Islam 
et al., 2002b). Because of these attributes, sweet potatoes one of the crops selected by US 
National Aeronautics and Space Administration (NASA) to be grown in a controlled ecological 
life support system as a primary food source (Wilson et al., 1998).  
Several groups, mostly from Japan, have characterized various polyphenolics and 
anthocyanins present in SPG (Islam et al., 2002a). A recent study reported the growth-
suppressive activity of sweet potato leaves in colon cancer cells (Kurata et al., 2007). Given the 
several health-promoting attributes of SPG, the principle objective of the present study was to 
evaluate and establish the anticancer efficacy and associated mechanisms of SPGE treatment in 
human prostate cancer cells in vitro and to translate these findings to an in vivo preclinical cancer 
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model. Our study reveals that SPGE causes cell growth inhibition induces G1 phase arrest 
accompanied by upregulation of p21 and induction of apoptosis in PC-3 cells. In these studies, 
downregulation of cell cycle effectors, in particular the G1 cyclins, including cyclins D1, A and 
E is revealed as a plausible antiproliferative mechanism of SPGE in PC-3 cells.Selective 
induction of apoptosis is a highly desirable trait of ideal chemopreventive and chemotherapeutic 
regimens. Our data showed that SPGE efficiently induces apoptosis in PC-3 cells as determined 
by Annexin-V- and TUNEL-staining assays. Insights into molecular mechanisms reveal that 
SPGE-induced apoptosis is largely mitochondrially mediated and associated with the collapse of 
the transmembrane potential which results in the expulsion of key apoptogenic molecules such as 
cytochrome c from the mitochondria. Oral feeding of SPGE remarkably inhibits tumor growth, 
which is accompanied by antiproliferative and proapoptotic effects together with a decline in 
cyclin levels, increased expression of p21 and activated caspase-3. 
Although dismaying, it is true that present day chemotherapeutic approaches for cancer 
patients can be as deadly as the disease itself. Toxicity normally includes myelosuppression, 
immunosuppression, cardiotoxicity and peripheral neuropathy. To assess safety of SPGE, we 
evaluated hematologic and histopathological toxicity and found no deviations in hematologic 
variables andorgan-associated toxicities in treated mice compared with controls. In addition, the 
acid–base and electrolyte balances in SPGE-treated animals were also normal compared with 
controls. Finally, evidence for the potential usefulness of SPGE as a chemopreventive agent in 
humans was postulated using a body surface area normalization method (Reagan-Shaw et al., 
2008). Using calculations involving the effective in vivo dose (400 mg/kg) data, the human 
equivalent dose was determined to be 30 mg/kg SPGE. For an average, 70 kg adult, this 
translates to an equivalent dosage of 2.1 g SPGE. Considering these facts and the United States 
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Department of Agriculture’s Food Guide Pyramid, the human equivalent dose can be obtained 
from 85 g, or about a half-cup of raw greens, which can be easily incorporated in a normal daily 
diet.  
The presence of polar acids eluting early (ChA and CA) with retention time, 10 min 
(Gundala et al., 2013), and relatively non-polar compounds eluting later (peaks with retention 
times >30 min) (Gundala et al., 2013), might facilitate fractionation of SPGE into two fractions 
via HPLC–UV, using semipreparative higher diameter HPLC columns (allowing higher sample 
loading) to further identify and characterize the bioactive constituent(s) present in SPGE. In the 
light of a recent paradigm shift which recognizes that the anticancer attributes of fruits and 
vegetables are due to an additive or synergistic interplay of the complex phytochemical mixtures 
in whole foods (Liu, 2003), it is perhaps likely that the whole SPG extract works through 
complementary and overlapping mechanisms to offer the most optimal benefits (Liu, 2003, 
2004). In this case, single bioactive constituents may show anticancer activity at much higher 
doses that may be toxic, whereas a mixture of multiple compounds may show enhanced activity 
at lower non-toxic doses. 
Although studies reporting the bioactive components of SPGE (Islam et al., 2002a; Islam 
et al., 2002b; Truong et al., 2007; Yoshimoto et al., 2002) exist, variability in the extraction 
methods employed preclude reliable interpretation of those bioactivity studies. In this study, we 
have employed a relatively simple and holistic approach to make SPGE and have followed a 
bioactivity-guided fractionation of the whole leaf extract to obtain and identify active 
fractions/constituents. Our strategy using mobile-phase systems of varying polarity to elute 
SPGE down the classical silica gel column to fractionate and elute components of different 
polarities in different solvent systems has identified a medium-polar fraction, F5, (eluted via 
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50:50 and 40:60 ethyl acetate and methanol system) that exhibited the highest antiproliferative 
efficacy in prostate cancer cells (Figure 2.7C-D). F5 was determined to be ~100 fold more potent 
compared to the parent, SPGE, which prompted us to further investigate F5’s composition. 
Among the repertoire of bioactive polar phenols enriched in F5 we have identified quinic, 
chlorogenic and caffeic acids in a distinct ratio (Figure 2.8A-Ai). The analytical data revealed 
higher abundance of QA, and ChA over CA in F5 compared to the whole extract. As it can be 
observed in Figure 2.8Ai, the pattern of QA:ChA:CA in F5 is similar to that in SPGE, but these 
compounds are highly enriched in F5 compared to the parent whole extract. On the contrary, the 
signature of isochlorogenic acids in SPGE differs from F5 (Figure 2.8Aii) wherein the most 
abundant in the whole extract is 3,5-di-CQA and 3,4-di-CQA is maximally present in F5.  
Furthermore, a seven-day stability study suggested a stable shelf-life of F5 when stored at 4oC, 
as there were no variations in the concentrations of individual constituents that make up this 
most-active fraction. 
The in vitro efficacy of F5 was supported by the synergy study performed with the pure 
standards in combinations (Figure 2.9C). This strengthened the concept that QA, ChA, CA, 4,5-
di-CQA, 3,5-di-CQA and 3,4-di-CQA act synergistically among themselves and with other 
unknown components to exert maximum efficacy, and emphasized the importance of the ratio of 
phytochemicals for the observed antiproliferative activity. This observation is further supported 
by the quintessential green tea polyphenol concoction, Polyphenon E, which has been proven to 
confer optimal anticancer benefits via a specific combination of five different catechins, 
including epicatechin, gallocatechin gallate, epigallocatechin, epicatechingallate, and most 
abundantly, EGCG (Bode and Dong, 2009). This specific formulation of green tea is in clinical 
cancer trials funded through the National Cancer Institute to investigate the benefits of tea 
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catechins in humans. Furthermore, sub-fractions of F5 could not outperform F5, suggesting the 
potential additive or synergistic interactions among F5 phytochemicals (Figure 2.9B) supporting 
our speculation. A similar observation made by Liu, et al., where the sub-fractions of black 
raspberry extract’s active fraction, WBR-95, showed diminished antiangiogenic efficacy 
compared to the refined parent (Liu et al., 2005), lends support to our observations as seen in 
Figure 2.9. 
Several studies suggest that individual foods or extracts may offer advantages over their 
isolated constituents, suggesting that factors within foods may improve the absorption, 
metabolism or retention of the bioactive food components, or that multiple bioactive compounds 
within the food/extracts can exert additive or synergistic effects. However, in other scenarios, the 
whole food or its extract itself may not be as effective as its isolated components, suggesting that 
the food may contain other constituents, which can attenuate the response by negatively 
modifying the absorption, metabolism, or site of action of the bioactive food constituent. 
Surprisingly, we found that the in vivo efficacy of F5 was only slightly higher than the whole 
parent SPGE extract, which may be due to the inherent complexity of in vivo physiological 
systems. Though bioluminescence imaging measurement showed a ~75% tumor growth 
inhibition observed in F5-fed group (Figure 2.10) compared to the vehicle-treated group, this 
most-active fraction of SPGE could only improve the efficacy of the parent by a small ~10% 
increment (Karna et al., 2011b).  We speculate that this could be because of the disorganization 
of the plant matrix or disruption of ‘natural milieu’ during the fractionation process, which could 
have led to the loss of bioactive components that played a crucial role in dictating favorable 
pharmacokinetic characteristics. We cannot exclude the possibility that F5 may require 
interreactivity or dependency on other components in the whole food source to augment oral 
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bioavailability, which means that systemic levels of the polyphenols achieved may be several-
fold less than their effective concentrations in in vitro systems.  
Although the rationale of pharmacological efficacy of single-isolated compounds over 
whole foods exists, there are several factors like dose, bioavailability, metabolism and toxicity 
favoring the latter. In particular, specific factors affecting phenolic bioavailability include matrix 
of food sources, processing condition during food preparations, chemical compositions, and 
molecular physicochemical properties of the phenolic molecules (Epriliati, 2012). The diverse 
molecular forms of phenolics due to alterations in sugar moiety such as glycone or aglycone 
analogs are known to cause variations in bioavailability levels (Epriliati, 2012). Furthermore, 
gastrointestinal pH and enzymatic secretion levels, microbiota, and age have been established as 
crucial factors affecting digestion and absorption of phytochemicals. Equally, the role of 
interactions amongst food components and their interplay with gastrointestinal secretions 
contribute significant effects in determining bioavailability of phytochemicals (Epriliati, 2012).  
Quinic acid, enriched in F5 compared to the parent extract, is a common constituent of 
our diet. Reports suggest that although quinic acid is not responsible for any efficacy, it 
nutritionally supports the in situ synthesis of essential metabolites like tryptophan and 
nicotinamide in the gastrointestinal (GI) tract. Hence, it in turn leads to DNA repair enhancement 
and NF-kB inhibition via increased nicotinamide and tryptophan production (Pero et al., 2009). 
The other phenolic acids in F5, namely CA and ChA, belong to the most abundant class of 
polyphenols called hydroxycinnamic acids, that are widely present in a large variety of fruits and 
vegetables (Clifford, 1999; Manach et al., 2004). Caffeic acid is the major representative of this 
class and extensively exists as a conjugate with quinic acid as seen in chlorogenic acid (Clifford, 
1999). Several reports have established that the bioavailability and efficacy of these 
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hydroxycinnamic acids depend on their uptake and metabolism in the gut mucosa (Crespy et al., 
2003; Lafay et al., 2006; Manach et al., 2004). Literature suggests that while CA is readily 
absorbed in the small intestine and can be detected in the blood plasma (Azuma et al., 2000; 
Scalbert et al., 2002; Simonetti et al., 2001), ChA is poorly absorbed. However, ChA, is detected 
only in the urine with no structural changes (De Maria, 2004; Ito et al., 2005), indicating its 
differential metabolism as compared to CA. Though the metabolism of ChA is not well studied 
and is controversial (Lafay et al., 2006), some groups believe that it is usually hydrolyzed into 
CA and O-methylated metabolites in the lower intestine due to enzymatic reactions by the gut 
microflora (Azuma et al., 2000; Lafay et al., 2006), suggesting that the bioactivity could be due 
to CA. Considering this evidence, our quantitation data (Figure 2.8Ai) leaves us pondering if 
higher levels of ChA in F5 are limiting its in vivo bioavailability and thus leveling its efficacy to 
that observed for the whole extract. Another line of thought that seems plausible is that the 
remarkable activity of F5 (containing high ChA) as observed in vitro is not recapitulated in vivo 
due to limited absorption and metabolic conversions of ChA. Nonetheless, detailed 
pharmacokinetic evaluation is warranted to delineate the discrepancy between the in vitro and in 
vivo data.  
Hence, as the natural balance of polyphenol content in SPGE is perturbed during the 
fractionation process, the differences in the in vitro and in vivo absorption and metabolism 
efficiencies due to this perturbation are likely to be responsible for the discrepancy observed 
between the in vitro and in vivo efficacy. Intriguingly, our unpublished data reveal that the 
composition of whole sweet potato greens extract and its sub-fractions thereof, is dependent on 
the variety (Jewel or TU155), age of leaves at the time of harvest (30, 45, 60 or 75 days) and the 
mode of processing of the leaves (air-dried, frozen or freeze-dried). Several other confounding 
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variables such as cultivation season, soil, rainfall etc. are highly likely to play a role in 
influencing the nature and composition of the plant extract. We thus envision that these varietal 
differences in the total phenolic content, QA/ChA/CA and isochlorogenic acid content among 
other unknown components may possibly affect the antiproliferative efficacy of the whole 
extract and its derived fractions.  
Nevertheless, the idea of non-toxic dietary supplements of specific phytochemicals in 
defined ratios as in F5, would be beneficial to bypass the potential limitations in absorption and 
assimilation of active whole food components, like variations in human genetic profiles affecting 
nutritional absorption (German, 2005). Also, it is highly likely that the variability of unidentified 
components in F5 and their standardization to constitute a therapeutic blend might provide 
valuable insights for a clinical dietary intervention. It is extremely encouraging that F5 was able 
to retain the anticancer attributes of the whole extract while demonstrating increased solubility, 
generating impetus to propose its usefulness as a non-toxic dietary supplement, comprised of 
specific phytochemicals in distinct ratios.  
Our study is the first of its kind to provide evidence that phytochemicals, when present in 
specific compositions, can impart superior efficacy and generates enthusiasm for testing the 
efficacy of F5 in preventing disease recurrence as well as imparting chemopreventive benefits. 
Our study reiterates the importance of the ‘natural milieu’ created by Mother Nature that exists 
in whole foods and is perhaps preserved and enhanced in fractionated extracts for excellent 
anticancer benefits. In conclusion, our study strengthens the evidence that plant polyphenols 
exhibit synergism to confer efficacy to fruits and vegetables. This approach, attempting to 
deconstruct the possible inherent synergies among the mixture of phytochemicals present in 
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SPGE fractions, unveiled specific enrichment of components in F5 that nestle together to exert 
superlative activity.  
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3     IMPORTANCE OF SYNERGISTIC INTERACTIONS AMONG CONSTITUENT 
PHYTOCHEMICALS OF WHOLE FOOD EXTRACTS3 
3.1 Abstract 
It is appreciated far and wide that increased and regular consumption of fruits and 
vegetables is linked with noteworthy anticancer benefits. Extensively consumed as a spice in 
foods and beverages worldwide, ginger (Zingiber officinale Roscoe) is an excellent source of 
several bioactive phenolics, including non-volatile pungent compounds such as gingerols, 
paradols, shogaols and gingerones. Ginger has been known to display anti-inflammatory, 
antioxidant and antiproliferative activities, indicating its promising role as a chemopreventive 
agent. In this chapter, we show that whole ginger extract (GE) exerts significant growth-
inhibitory and death-inductory effects in a spectrum of prostate cancer cells. Comprehensive 
studies have confirmed that GE perturbed cell-cycle progression, impaired reproductive capacity, 
modulated cell-cycle and apoptosis regulatory molecules and induced a caspase-driven, 
mitochondrially mediated apoptosis in human prostate cancer cells. Remarkably, daily oral 
feeding of 100 mg/kg body weight of GE inhibited growth and progression of PC-3 xenografts 
by approximately 56% in nude mice, as shown by measurements of tumor volume. Tumor tissue 
from GE-treated mice showed reduced proliferation index and widespread apoptosis compared 
with controls, as determined by immunoblotting and immunohistochemical methods. Most 
importantly, GE did not exert any detectable toxicity in normal, rapidly dividing tissues such as 
gut and bone marrow. Nevertheless, the nature of interactions among the constituent ginger 
                                                
3 This chapter has been published verbatim in Br J Nutr 2012 as Benefits of whole ginger 
extract in prostate cancer, Nutr Cancer 2013 as Ginger phytochemicals exhibit robust synergy 
to inhibit prostate cancer cell proliferation and Carcinogenesis 2014 as Enterohepatic re-
circulation of bioactive ginger phytochemicals is associated with enhanced tumor growth-
inhibitory activity of ginger extract. 
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biophenolics, viz. 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogoal, remains elusive. We report 
the antiproliferative efficacy of the most-active GE biophenolics as single-agents and in binary 
combinations, and investigate the nature of their interactions using the Chou-Talalay 
combination index (CI) method. To appreciate synergy among phytochemicals present in GE, the 
natural abundance of ginger biophenolics was quantitated using LC-UV/MS. Our data 
demonstrate that binary combinations of ginger phytochemicals synergistically inhibit 
proliferation of PC-3 cells with CI values ranging from 0.03 to 0.88. However, no study has yet 
examined the in vivo collaboration among ginger phytochemicals or evaluated the importance, if 
any, of the natural “milieu” preserved in whole extract. Hence, we comparatively evaluated in 
vivo efficacy of GE with an artificial quasi-mixture (Mix) formulated by combining four most-
active ginger constituents at concentrations equivalent to those present in whole extract. Orally-
fed GE showed 2.4-fold higher tumor growth-inhibitory efficacy than Mix in human prostate 
tumor xenografts. Pharmacokinetic (PK) evaluations and bioavailability measurements addressed 
the efficacy differences between GE and Mix. Plasma concentration-time profiles revealed 
multiple peaking phenomenon for ginger constituents when they were fed as GE as opposed to 
Mix, indicating enterohepatic recirculation (EHR). Bioavailability of 6G, 8G, 10G and 6S was 
1.6, 1.1, 2.5 and 3.4 fold higher, respectively, when dosed with GE compared to Mix. In 
addition, gingerol glucuronides were detected in feces upon intravenous administration 
confirming hepatobiliary elimination. These data ascribe the superior in vivo efficacy of GE to 
higher AUCs, greater residence time, and enhanced bioavailability, of ginger phytochemicals, 
when fed as a natural extract compared to artificial Mix, emphasizing the usefulness of 
consuming whole foods over single agents. 
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3.2 Introduction 
Prostate cancer is the most common non-cutaneous malignancy in American men, 
afflicting one in six men. It is estimated that in the USA, one new case occurs every 2.4 min and 
a death results every 16.4 min from prostate cancer. Clinically significant prostate cancer appears 
to develop over 20–30 years, thus presenting a ‘large window’ of opportunity for interventional 
chemopreventive strategies (Nelson et al., 2003; Syed et al., 2007). Although the traditional 
focus has been on treating existing tumors with chemotherapeutic agents that most often exert 
toxic side effects, development of chemopreventive approaches that can prevent, suppress or 
reverse progression to invasive cancer represents a relatively young field with tremendous 
promise to reduce cancer burden (Mann et al., 2005; Sporn, 1976). Laboratory and 
epidemiological research during the past three decades has provided indisputable evidence, 
indicating that high intake of fruits and vegetables is linked to a reduced cancer susceptibility 
including prostate cancer risk (Cooke et al., 2005; Kaur et al., 2009; Yang et al., 2001). Several 
National Cancer Institute (NCI) initiatives continue to underscore the importance of including 
fruits and vegetables in the daily diet as a cancer chemopreventive measure (Colli and Amling, 
2009; Kaur et al., 2009; Steinkellner et al., 2001; Traka et al., 2008). Fruits and vegetables 
contain phytochemicals (carotenoids, polyphenolics, anthocyanins, alkaloids, N and S 
compounds) that have been shown to target multiple neoplastic stages to reduce overall cancer 
risk (Craig, 1999). About thirty-five plant-based foods identified by the NCI to be effective in 
cancer prevention include garlic, ginger, turmeric, cruciferous vegetables (broccoli, brussel 
sprouts, cabbage) and grape seed extracts (Surh, 2003).  
Although the clinical armamentarium of chemotherapeutic drugs has been expanding 
with remarkable momentum, the rate of cancer incidence and mortality is exponentially 
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increasing. The barriers to the development of “tumor-eradicating” drugs can perhaps be 
attributed to the fact that carcinogenesis in humans is a complex, multistep process that involves 
dysfunction of several molecules including oncogenes and tumor suppressors (Hanahan and 
Weinberg, 2000). These molecules exquisitely control multifarious signaling circuitries that 
dictate cell survival and death pathways and their genetic alterations vary temporally; 
consequently, the acquisition of malignant phenotypes can be quite variable across different 
cancer types. Thus, it appears that the current mono-targeted therapy approach using rationally 
designed pharmacological inhibitors against a particular target has its own limitations. 
Furthermore, because tumors represent a heterogeneous population, a multi-targeted approach 
using single agent or a combination regimen might offer an edge over the more prevalent mono-
targeted strategy. Therefore, an ideal chemopreventive or therapeutic regimen should be 
relatively nontoxic and concurrently hit multiple targets to achieve superior anticancer benefits.  
Several reports suggest that the anticancer benefits of fruits and vegetables are due to an 
additive or synergistic interplay of the complex mixture of phytochemicals present in them (Liu, 
2003, 2004). This emerging notion further lends support to the premise of concomitantly 
targeting multiple pathways. For example, studies of green tea polyphenols have demonstrated 
that EGCG and at least 4 other catechins are necessary for maximum in vivo efficacy, suggesting 
that synergistic interreactivity or dependency on other components of the whole food is required 
for optimal activity (Bode and Dong, 2009). Similarly, the highest antioxidant activity was 
realized with the combination of polyphenols in pomegranate juice as opposed to the constituent 
polyphenols alone (Seeram et al., 2005). In a comparable investigation of cranberry extract, 
enhanced antiproliferative activity was attributed to the synergistic and additive interactions of 
its main components, including anthocyanins, proanthocyanidins, and flavanol glycosides 
71 
(Seeram et al., 2004). Such studies thus offer a plausible explanation as to why clinical trials 
with pure, single phytochemicals, such as α-tocopherol, β-carotene, and vitamin C, have met 
with limited success (Greenberg et al., 1994; Liu, 2004; Tsao et al., 2004). It is thus likely that 
disrupting the natural balance of phytochemicals as it exists in fruits and vegetables by extracting 
individual phytochemicals from the “food matrix” (Jacobs et al., 2009; Jacobs and Tapsell, 2007) 
may result in suboptimal health benefits. 
Thus, it is plausible that isolating a single compound from complex foods may not be 
effective even at high, relatively toxic doses, whereas combinations of lower, less-toxic doses of 
each compound may be effective. This might also explain why clinical trials with pure single 
phytochemicals such as α-tocopherol, β-carotene, and vitamin C have failed in the past, 
reinforcing the futility of isolating a single constituent from a phytochemical mixture as it may 
lose its bioactivity or even cause undesirable cancer-promoting effects, as in the case of β-
carotene. Concomitantly, it highlights the importance of the lesser-known, relatively under-
studied, minor components of the complex mixtures of fruits and vegetables that have been 
mistakenly ignored in evaluating the superior bioactivity of whole extracts. 
Fruits and vegetables present a treasure trove of polyphenolic compounds that upon 
ingestion undergo extensive metabolism during passage through the gastrointestinal system 
primarily to prevent unwanted accumulation and to prompt their elimination from the system 
(Manach et al., 2004; Manach et al., 2005; Silberberg et al., 2006; Williamson and Manach, 
2005). Most phytochemicals are metabolically modified within the gut before entering the blood 
circulation. The conjugated sugar groups, if any, are cleaved in the intestinal lumen, followed by 
glucuronidation, sulfation and/or methylation of the aglycones, to facilitate elimination of 
phytochemicals subsequent to conjugation mechanisms that enhance their polarity (Manach et 
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al., 2005; Williamson and Manach, 2005). However, the residence time of phytochemicals in 
systemic circulation is responsible for their beneficial activity. Recently, identification of a vast 
array of phenolic metabolites in circulation has offered useful insights and allowed us to realize 
and explore the bioavailability, especially of poorly absorbable compounds, such as the 
phenolics (Calani et al., 2012; Silberberg et al., 2006).  
An extensively consumed spice worldwide, Ginger (Zingiber officinale Roscoe) is an 
excellent source of several bioactive phytochemicals. A variety of active components have been 
identified in the oleoresin, the non-volatile pungent fraction of ginger, mainly including 
gingerols and shogaols (Govindarajan, 1982a, b; Tao et al., 2009; Vasala, 2004). The other active 
ginger constituents include 6-paradol, 6- and 10-dehydrogingerdione, 6- and 10-gingerdione, 4-, 
6-, 8-, and 10-gingerdiol, 6-methylgingerdiol, zingerone, 6-hydroxyshogaol, 6-, 8-, and 10-
dehydroshogaol, and diarylheptanoids (Govindarajan, 1982a, b; Vasala, 2004; Yoshikawa et al., 
1993). Nevertheless, gingerols and shogaols are most abundant in ginger compared to any of the 
other constituents. Extensive literature has successfully shown that 6-gingerol (6G), 8-gingerol 
(8G), 10-gingerol (10G) and 6-shogaol (6S) are the main bioactive components of ginger (Chen 
et al., 2009; Dugasani et al., 2010; Govindarajan, 1982a, b; Jeong et al., 2009; Kundu et al., 
2009; Lee et al., 2008; Lumb, 1994; Park et al., 1998; Park et al., 2006; Shukla and Singh, 2007; 
Wang et al., 2003; Zick et al., 2008; Zick et al., 2010). While several reports exist on the 
antioxidative, anti-inflammatory, and antitumor properties of ginger, only marginal benefits of 
ginger constituents as single-agents are yet known from clinical trials (Zick et al., 2008; Zick et 
al., 2010). Although the constituent phytochemicals present in ginger, in particular, gingerols, 
shogaols and paradols, are being rigorously tested for their anticancer properties, it is becoming 
increasingly recognizable that the gainful effects of fruits and vegetables are due to an additive 
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and/or synergistic interplay of the composite mixture of phytochemicals present in whole foods 
rather than the constituent single agents alone. In the context of ginger root, sufficient evidence 
suggests that achievable plasma concentrations of individual phytochemicals are in a very low 
micromolar range (2 mg/ml or less). In addition, these phytochemicals are found primarily in the 
form of their non-active glucuronide or sulphate metabolites, and therefore the anticancer effects 
observed with much higher concentrations in vitro may not be relevant in the in vivo milieu. A 
careful examination of several studies reveals that the effective in vitro doses of these ginger 
phytochemicals are much higher than their achievable plasma concentrations, which impose 
serious limitations on their potential efficacy and utility as chemopreventive supplements in 
humans (Chen et al., 2009; Dugasani et al., 2010; Jeong et al., 2009; Kim et al., 2005; Kundu et 
al., 2009; Lee et al., 2008; Park et al., 1998; Park et al., 2006; Wang et al., 2003). Thus, 
sufficient accumulating evidence suggests that the repertoire of phytochemicals present in 
dietary agents works together through complementary and overlapping mechanisms to present 
optimal cancer chemopreventive and therapeutic benefits.  
 
With this mindset, we sought to undertake a detailed evaluation of the in vitro and in vivo 
anticancer activity of whole ginger extract (GE) in prostate cancer. To the best of our knowledge, 
there is not even a single report that presents a thorough mechanistic investigation to develop GE 
for prostate cancer management. Herein, we examined the in vitro and in vivo anticancer effects 
of GE in prostate cancer by evaluating its effects on cellular proliferation, cell-cycle progression 
and apoptosis. Further, we evaluated the antiproliferative efficacy of the most active ginger 
phytochemicals (6G, 8G, 10G, and 6S) as single agents as well as in binary combinations in 
prostate cancer PC-3 cells. The dose reduction index (DRI) that quantitates the magnitude by 
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which the dose level of whole GE can be reduced on using a combination regimen of GE and 
ginger phytochemicals was calculated to emphasize the translational relevance of GE in prostate 
cancer prevention and therapy.  
 
Whether or not this in vitro synergistic collaboration among the most-active ginger 
phenolics holds up in in vivo to elicit much higher therapeutic efficacy than the observed tumor 
inhibition efficacy of GE is yet an uncharted territory. Clearly, it is comprehensible that in vitro 
methods fail to account for in vivo complexities such as absorption of ginger phenolics from 
gastrointestinal tract, their metabolic biotransformation, systemic bioavailability and clearance 
and thus preclude a logical explanation of in vivo therapeutic efficacy. Hence, we demonstrate 
the remarkably superior efficacy of GE compared to an artificial quasi-mixture (Mix) produced 
by combining the most active individual phytochemicals in the same ratios as they appear in the 
natural setting. Then, we asked whether these active ginger phenolics solely collaborate among 
themselves or recruit other ginger phenolics in their complex in vivo agenda to ultimately elicit 
optimal therapeutic activity. Given the significance of metabolism and bioavailability to dictate 
the in vivo biological effects of phytochemicals, we addressed the discrepancy in the efficacy 
outcomes of GE and Mix using pharmacokinetic approaches. We monitored absorption and 
bioavailability of 6G, 8G, 10G and 6S upon oral feeding of GE compared to the Mix to 
underscore the presence of beneficial in vivo interactions among GE biophenolics that are largely 
absent in the Mix. In addition, we developed a sensitive, accurate and robust LC/MS/MS method 
for the quantitation of 6-, 8-, 10- gingerols and 6-shogaol to study their collaborative interactions 
when present in their natural milieu and the consequential pharmacological significance.  
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3.3 Materials and Methods 
3.3.1 Cell lines, media, antibody and reagents 
Normal prostate epithelial cells (PrEC) and prostate cancer (LNCaP, C4-2, C4-2B, 
DU145 and PC-3), breast (MDA-MB-231 and MCF-7) and cervical (HeLa) cancer cell lines 
obtained from American Type Culture Collection (Manassas, VA) ATCC, were used in the 
present study. The medium used to culture these cells was Roswell Park Memorial Institute-1640 
(RPMI-1640) or Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine 
serum and 1% antibiotic (penicillin/streptomycin). Primary antibodies to p21, cyclin E and BAX 
and horseradish peroxidase-conjugated secondary antibodies were from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Cyclin D1, cdk4, p-Rb, Bcl2, cytochrome c, cleaved 
caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP) were from Cell Signaling 
(Beverly, MA, USA), Ki67 was from Zymed (South San Francisco, CA, USA) and β-actin was 
from Sigma (St Louis, MO, USA). The MTT dye (thiazolyl blue tetrazolium bromide, 98% TLC) 
and dimethyl sulfoxide (DMSO) were from Sigma-Aldrich (St. Louis, MO). Cells were cultured 
at 37◦C with 5% CO2. Ginger extract (GE) was a gift from Sabinsa Corportation, NJ. 
Acetonitrile (ACN), and methanol (MeOH) were obtained from Fisher Scientific (Pittsburgh, 
PA). The silica used for classical chromatography was from EMD Biosciences (Billerica, MA). 
Thin-layer chromatography (TLC) plates were from EMD chemicals (Billerica, MA). 
Luciferase-expressing PC-3 cells (PC3-luc) were from PerkinElmer (Hopkinton, MA) and were 
maintained in MEM medium with 10% FBS, Hyclone, (Pittsburgh, PA). Carboxy methyl 
cellulose (CMC) and β-glucuronidase were from Sigma (St. Louis, MO). The active ginger 
constituents, 6-gingerol (6G), 8-gingerol (8G), 10-gingerol (10G) and 6-shogaol (6S) were 
extracted from ginger extract (GE) and was characterized for >99% purity. 
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3.3.2 Preparation of GE stocks and isolation of ginger phenolics 
Ginger extract (GE) powder from Sabinsa Corporation, was used to make a GE stock 
solution by dissolving 100 mg GE in 1 mL of dimethyl sulfoxide, and various concentrations 
were obtained by appropriate dilutions. However, the variation among different batches of ginger 
extracts was determined based upon the quantitative values of 6G, and 10G.   
The methanolic extract of ~20 g ginger powder (obtained from Sabinsa) was adsorbed on 
silica gel 60-120 mesh size and purified using 50 cm × 6 cm i.d. column packed with stationary 
phase. Gradient elution steps were performed from 100% hexane to 100% ethyl acetate to 
separate 6G, 8G, 10G and 6S by column chromatography. Different fractions were eluted and 
collected and monitored by TLC using p-anisaldehyde stain. All the fractions were then further 
purified by High Performance Liquid Chromatography (HPLC) using semi-preparative reversed 
phase column with mobile phase consisting acetonitrile in water in linear gradient from 45% to 
100% at a flow rate of 1 mL/min with a run time of 55 min. Mass spectrometry was employed to 
analyze the purified 6G, 8G, 10G and 6S.  
100 mg of the remaining fraction of GE containing trace amounts of 6S after isolating 
6G, 8G, 10G and 6S was loaded onto preparative TLC plate and was developed in a glass 
chamber consisting a binary mobile phase of ethyl acetate and hexane (2:8). Pure 6S was used as 
a standard to separate and remove the 6S from this fraction. The rest of the fraction was scraped, 
dissolved in methanol, filtered, and concentrated for testing. HPLC analysis of this fraction 
confirmed the absence of 6G, 8G, 10G and 6S. This fraction devoid of the active ginger 
phytochemicals, known as GE-Mix, was employed in future studies. 
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3.3.3 In vitro proliferation and colony survival assay  
Cells were plated in ninety-six-well plates and treated with gradient concentrations (1–
1000 µg/ml) of GE the next day. After 72 h of incubation, cell proliferation was determined 
using the Alamar blue cell proliferation assay. The magnitude of the fluorescent signal is 
proportional to the number of live cells, and is monitored using 530–560 nm excitation 
wavelength and 590 nm emission wavelength. For the colony assay, PC-3 cells were treated with 
250 µg/ml of GE for 48 h, washed and replaced with regular RPMI medium. After 10 d, colonies 
were fixed with 4% formaldehyde, stained with crystal violet and counted.  
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay was also 
used to evaluate the proliferative capacity of cells. Essentially, MTT is a colorimetric assay, 
which uses the colorless tetrazolium dye and converts it into a colored formazan salt, which can 
be quantified by measuring absorbance at 570 nm. Briefly, a 96-well format was used to seed 
100 µl medium containing cells at a density of 5 × 103 cells per well. After 24 h of incubation, 
cells were treated with gradient concentration of GE, gingerols, and shogoal, which were 
dissolved in DMSO. The final concentration of DMSO in the culture medium was maintained at 
0.1%. After 48 h of incubation, the spent medium was removed and the wells were washed twice 
with PBS. 100 µl of fresh medium and 10 µl of MTT (5 mg/ml in PBS) was added to the wells 
and cells were incubated at 37◦C in dark for 4 h. The formazan product was dissolved by adding 
100 µl of 100% DMSO after removing the medium from each well. The absorbance was 
measured at 570 nm using a Spectra Max Plus multi-well plate reader (Molecular Devices, 
Sunnyvale, CA). 
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3.3.4 Cell-cycle progression studies by flow cytometry 
For cell-cycle analysis, PC-3 cells were treated with vehicle (dimethyl sulfoxide) or GE 
at various doses (50, 100, 250, 500 and 1000 µg/ml) for 24 h or at a fixed dose of 250 µg/ml for 
various time points (12, 24, 48 and 72 h). At the end of incubation, cells were fixed with 70% 
ethanol overnight, stained with propidium iodide containing RNase A, followed by data 
acquisition on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) and 
analyses using Flo-Jo software (Ashland, OR, USA).  
3.3.5 Immunoblot analysis  
GE-treated cell lysates were collected at various time points, lysed, sonicated and 
estimated for protein content. Proteins were then resolved by polyacrylamide gel electrophoresis 
and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The 
membranes were blocked in Tris-buffered saline containing 0·05% Tween-20 and 5% fat-free 
dry milk and incubated first with primary antibodies and then with horseradish peroxidase-
conjugated secondary antibodies. Specific proteins were visualised with enhanced 
chemiluminescence detection reagent according to the manufacturer’s instructions (Pierce 
Biotechnology, Rockford, IL, USA).  
3.3.6 Mitochondrial and cytosolic fractionation  
To determine the release of cytochrome c from the mitochondria to the cytosol by 
immunoblotting, control or GE-treated (250 µg/ml) PC-3 cells were incubated on ice for 5 min in 
100 µl of ice-cold cell lysis and mitochondria intact buffer (250mM-sucrose, 70mM-KCl and 
100 µg digitonin/ml in PBS). The cells were pelleted and the supernatant containing cytosolic 
protein was stored at -80oC. The pellets were incubated at 4oC for 10 min in immunoprecipitation 
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buffer (50mM-Tris-HCl (pH 7·4), 150mM-NaCl, 2mM-EDTA, 2mM ethylene glycol tetra-acetic 
acid, 0·2% Triton X-100, 0·3% Nonidet P-40, 1 x Complete protease inhibitor; Roche 
Diagnostics Corporation, Indianapolis, IN, USA). The samples were centrifuged at high speed 
for 10 min at 48oC, and the supernatant containing mitochondrial protein was stored at -80oC. 
Proteins were subjected to immunoblot analysis as described above. 
3.3.7 Immunofluorescence microscopy 
After treatment with 250 µg/ml of GE, PC-3 cells taken on glass coverslips were fixed 
with ice-cold methanol, followed by blocking with 2% bovine serum albumin in PBS. Ki67, 
cleaved caspase-3 and PARP antibodies (1:250 dilution) were incubated with coverslips for 2 h 
at 37oC. The cells were washed with 2% bovine serum albumin/PBS for 10 min at room 
temperature before incubating with a 1:500 dilution of Alexa 488- or Alexa 555-conjugated 
secondary antibodies. Cells were mounted with Prolong Gold antifade reagent that contains 4,6-
diamidino-2-phenylindole (Invitrogen, Carlsbad, CA, USA).  
3.3.8 JC-1 staining for mitochondrial transmembrane potential  
Control and 250 µg/ml of GE-treated cells were labeled with JC-1 reagent for 15 min at 
37oC. After washing, cell fluorescence was measured on a flow cytometer using orange–red 
emission filters.  
3.3.9 Caspase-3/7 activity assay  
Control or 250 µg/ml of GE-treated lysates were tested for caspase-3-like activity using 
Ac-DEVD-7-amino-4-trifluoromethyl-coumarin, which detects the activities of caspase-3 and 
caspase-7 according to the manufacturer’s protocol (Calbiochem, San Diego, CA, USA). The 
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results were evaluated using a fluorescence microplate reader and are expressed as relative 
fluorescence units. 
3.3.10 Experimental design of the binary combination studies 
IC50 values of GE, 6G, 8G, 10G, and 6S were obtained and a series of combinations at 
varying concentrations were tested against PC-3 cells. For 6G, 8G, 10G, and 6S the 
concentrations used in combinations were 0.075 (IC50/2), 0.125 (IC50/2), 0.25 (IC50/2), 0.5 
(IC50/2), 0.75 (IC50/2), 1 (IC50/2), and 1.25 (IC50/2). For GE, the concentrations were 0.075 
(IC50), 0.125 (IC50), 0.25 (IC50), 0.5 (ICv), 0.75 (ICv), 1 (IC50), and 1.25 (IC50). Gingerols and 
shogoal were added in combination with GE and with one another at the aforementioned 
concentrations. In each combination, a constant ratio of the IC50 for each drug was maintained. 
The following combinations were tested: 6G + 8G, 8G + 10G, 10G + 6G, 6S + 6G, 6S + 8G, 6S 
+10G, GE + 6G, GE + 8G, GE + 10G, and GE + 6S. 
3.3.11 Determination of CI and DRI 
Dose effects were analyzed using the computer software, CalcuSyn (Biosoft, Cambridge, 
UK), beginning with single agent dose-response curves, followed by dose-response curves 
involving combinations of 2 test agents (Pannu et al., 2011). The Chou-Talalay drug combination 
method was used to yield the combination index (CI) and DRI values. The CI values thus 
obtained are based on the multiple drug-effect equation of the enzyme kinetic models of Chou-
Talalay. For mutually exclusive drugs exhibiting similar modes of action, where (Dx)1 and 
(Dx)2 are the doses of drug 1 and drug 2 alone, respectively, causing × % inhibition, the 
combination index is described as CI = (D)1/(Dx)1 + (D)2/(Dx)2. A CI value <1, = 1 or close to 
1, or >1 indicates synergistic, additive, or antagonistic interaction, respectively. Further, the 
factor by which the dose of each agent may be reduced at a given effect when in combination 
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compared with the dose when each agent is used alone can be measured by the DRI value. This 
value holds clinical importance because the dose reduction could result in reduced toxicity while 
retaining the therapeutic efficacy. The dose-effect relationship was derived through mathematical 
induction method using enzyme kinetic models. The correlation between the dose and effect in 
its simplest form can be described as, Fa = 1/[1 + (Dm/D)m], where D is the dose of the agent, 
and Fa is the fraction affected by the dose. Dm is the median-effect dose signifying the potency 
and m is an exponent signifying the sigmoidal shape of the dose-effect curve, where the former 
is determined from x-intercept and the latter by the slope of the median-effect plot. A DRI >1 is 
ideal, as the greater the DRI value, the higher the dose reduction is for a given therapeutic effect. 
The number of agents in combination as well as the combination ratio affects the DRI value. 
3.3.12 High-Performance Liquid Chromatography and Mass-Spectrometric Detection 
Liquid chromatographic separations were achieved on a HP1100 series Instrument 
(Agilent Technologies, Wilmington, DE) equipped with a photodiode array detector, using an 
Agilent XDB reversed phase C-18, 1.8 µm, 4.6 × 50 mm, ODS-2 column. The solvent gradient 
system consisted of solvent A (2.5% formic acid in water) and solvent B [2.5% formic acid in 
acetonitrile (ACN)]. The gradient elution was 20% B for 45 min, followed by 80% B for 20 min 
and 95% B over the next 5 min, which was held at an isocratic composition of 95% B for 20 min, 
reconditioning to initial mobile phase concentration for 10 min with a flow rate of 0.2 ml/min. In 
addition, 0.5 mg/ml of GE, 6G, 8G, 10G, and 6S dissolved and filtered in pure methanol (10 µl) 
were injected into the system and the resultant spectra were observed at 280 nm. Standard 
calibration curves for gingerols and shogaol were obtained and the area under the curve was 
considered to quantify their amount in GE. 
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The HPLC-MS analyses were performed in tandem with HPLC-UV using the same 
column and mobile phase as described above on HP1100 series instrument (Agilent 
Technologies, Wilmington, DE) interfaced to an Agilent 6400 Series Triple Quadrupole LC-
MS/MS equipped with an electrospray ionization source, which was operated in negative-ion 
mode. The MS analysis was performed in multiple reaction monitoring (MRM) mode. The 
nebulizer and collision gases were nitrogen and helium, respectively, and the former was set at 
40 psi. A drying gas temperature of 300◦C, drying gas flow rate of 9 liter/min and capillary 
voltage of ±3 kV were the spray chamber parameters to quantify the ginger phytochemicals in 
GE. The quantitation of 6G, 8G, 10G, and 6S in GE was performed using MRM, where each of 
these phytochemicals were identified based on their fragmentation patterns using the transitions; 
6G 293→99, 8G 321→127, 10G 349→153, and 6S 275→139. Collision energy of 15 eV was 
used to obtain the product ions at a fragmentor voltage of 135V. 
3.3.13 Formulation recipe of GE, Mix and GE-Mix for in vivo PK studies  
Required amount of GE, Mix and GE-Mix were weighed and appropriate volume of 
ethanol (10%) and polyethylene glycol 300 (30%) were added, vortex mixed and sonicated for 5 
min. The volume was made up with 0.25% Tween 80 in 0.5% CMC in Milli-Q® water q.s. For 
Mix, pure standards of 6G, 8G, 6S and 10G were mixed in the same proportion as in GE. 
3.3.14 Choice of in vivo dose for efficacy and pharmacokinetic studies 
The choice of 250 mg/kg dose is based on the human PK studies performed by Zick et al 
(Zick et al., 2008; Zick et al., 2010), where free forms of ginger biophenolics were detected in 
the human blood plasma upon oral administration of 2 g ginger extract.  Upon normalizing for a 
75 kg bw, this 2 g dose is equivalent to 25 mg/kg. Given the faster metabolic rate in mice 
compared to humans and the allometric scaling factor of 10 (Reagan-Shaw et al., 2008), a dose 
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of 250 mg/kg bw was chosen for mouse studies. Furthermore, the total amount of the active 
ginger biophenolics (6G, 8G, 10G, 6S) present in GE used in this study was similar to that used 
in the clinical studies (5%, i.e., ~13 mg in 250 mg of GE). Since dose toxicology studies are 
often conducted for 7, 14 or 28 days (Gad, 2007), we chose to observe the tumor growth 
inhibition upon oral administration of GE/Mix/GE-Mix over a period of 28 days.  
3.3.15 In vivo tumor growth and treatment 
Male Balb/c nude mice (6 weeks old) were obtained from the NCI (Frederick, MD, 
USA), and 106 PC-3 cells in 100 ml PBS were injected subcutaneously in the right flank without 
any basement membrane extracts such as Matrigel. The animals were given autoclave-sterilized 
standard diet pellets and water ad libitum. When tumors were palpable, mice were randomly 
divided into two groups. From each group, six mice were housed individually in one cage. The 
control group received vehicle and the treatment group received 100 mg/kg body weight of GE 
daily by oral administration. Tumor growth was monitored weekly using a vernier caliper and 
body weight was also recorded.  
PC-3-luc cells (1x106) were subcutaneously injected on either flank of six-week old male 
BALB/c nude mice (Harlan Laboratories, Inc., Indianapolis, IN). When tumors were palpable, 
mice were randomly divided into four groups of five mice each. Control group received vehicle 
and the treatment groups received 250 mg/kg GE, Mix and GE-Mix by oral gavage daily for 28 
days. Tumor growth was monitored by measuring the luciferase activity in live mice by 
bioluminescent imaging in real-time using the IVIS in vivo imaging system (PerkinElmer, Inc., 
Hopkinton, MA) with the Live Imaging software. Briefly, mice anesthetized with isoflurane 
were intraperitoneally injected 30 mg/mL luciferin and imaged with a CCD camera. An 
integration of 20 s with four binnings of 100 pixels was used for image acquisition. The relative 
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photon counts at the tumor sites of the mice from vehicle or GE, Mix and GE-Mix treated groups 
were quantitated twice a week along with tumor volume measurements for four weeks. Body 
weights were recorded twice a week to evaluate the general-health and well-being of animals 
during treatment. Mice in treatment groups exhibited normal weight gain with no signs of 
discomfort. All animals in control group were euthanized after 4th week due to tumor overburden 
in compliance. All animal experiments were performed in compliance with institutional IACUC 
guidelines.   
3.3.16 Histopathological and immunohistochemical staining  
After 8 weeks of vehicle or 100 mg/kg GE treatment, tumour, lung, spleen, adrenal, liver, 
gut, brain, kidney, heart, testes and bone marrow were formalin-fixed, paraffin-embedded and 
5mm thick sections were stained with Ki67, cleaved caspase-3, PARP and hematoxylin and 
eosin. Terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) staining of 
tumor tissue sections was performed using the DeadEnd Fluorometric TUNEL System (Promega 
Inc., Madison, WI, USA) according to the manufacturer’s instructions. 
 
3.3.17 Pharmacokinetic studies of GE versus Mix 
Pharmacokinetic studies were performed in male C57BL6J mice following a single oral 
(PO) administration of GE and Mix at 250 mg/kg and intravenous (IV) dose administration at 1 
mg/kg of pure 6G, 8G, 10G and 6S individually. All animals were acclimatized for 3 days before 
dosing in the experimental area. Mice were fasted for 3 h before dose administration and food 
was provided 3 h post dose. Water was provided ad libitum through the study period. Animals 
were marked and housed (three per cage) in polypropylene cages and maintained in controlled 
environmental conditions with 12 h light and dark cycles. The temperature and humidity of the 
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room was maintained between 22 ± 3oC and 30 to 70%, respectively, and approximately 10-15 
fresh air change cycles per hour. A sparse sampling design was used to collect blood samples 
from animals at 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h and 24 h into 
K2EDTA coated tubes. Plasma was harvested from blood by centrifugation of samples at 8000 g 
for 10 min. Feces samples were collected from mice treated with intravenous dose of individual 
gingerols at 0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-12 h and 12-24 h intervals. All samples were stored 
below -60oC until bioanalysis. 
3.3.18 Enzymatic hydrolysis of gingerol conjugates 
To confirm the presence of glucuronide conjugates, plasma (200 µL) and feces samples 
(homogenized with buffer 1:3, 200 µL) were treated with β-glucuronidase (50 µL, 500 units) and 
incubated at 37°C for 1 h.  
3.3.19 Plasma Protein Binding Assay 
Binding potential of 6G, 8G, 10 G and 6S in GE and Mix was assessed using ultra-
centrifugation technique. The study was conducted at 0.3 mg/mL, 1 mg/mL and 3 mg/mL in 
triplicate. Appropriate volumes of GE or Mix stock solution (10 µL) were spiked into plasma 
(990 µL) to attain the final concentrations. The microfuge tube was mixed by inversion and 
incubated at 37oC for 30 min. An aliquot (50 µL) of the incubated samples was collected in 
microfuge tube. The remaining samples were subjected to ultra-centrifugation at 40,000 g for 1 h 
and aliquots of supernatant (50 µL) were carefully collected into microfuge tubes. 
3.3.20 Bioanalysis 
All in vitro and in vivo samples were processed by protein precipitation method. An 
aliquot (50 µL) of sample was added with 20 µL internal standard (capsaicin), 180 µL ACN, and 
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vortex mixed for 3 min. The tubes were centrifuged at 8000 g for 10 min and an aliquot of 
supernatant was transferred into auto-sampler vials for analysis. 
The stock solutions of 6G, 8G, 10G, 6S and capsaicin (internal standard) were prepared 
in ACN:water (95:5) at 1 mg/mL. A calibration curve range of 0.002 µg/mL to 2 µg/mL was 
employed for the quantification of analytes and internal standard concentration was 100 ng/mL 
for each analysis. The calibration curve consisted of blank, blank with internal standard and 6 
non-zero calibration standards. The calibration standards were within ±15% of the nominal 
concentration and lower limit of quantification was within ±20% of nominal.  
All samples were analyzed using liquid chromatography tandem mass spectrometric 
method (Agilent 6410 series). A positive ionization mode with multiple reaction monitoring 
(MRM, m/z Q1/Q3) of 6-gingerol (m/z 277.2/177.2, RT 5.8 min), 8-gingerol (m/z 305.2/137.2, 
RT 9.4 min), 10-gingerol (m/z 333.2/137.2, RT 14.6 min), 6-shogaol (m/z 277.2/137.1, RT 10.9 
min), IS (m/z 306.2/137.1, RT 6.8 min) was employed. The ion spray voltage was set at 3000 V, 
ionization temperature set as 200°C and drying gas flow rate was 10 L/min. Data acquisition and 
quantitation were performed using Mass Hunter software (Agilent Technologies). Separation 
was achieved using HP1100 series LC (Agilent Technologies, Wilmington, DE) equipped with a 
photodiode array (PDA) detector, using an Agilent Zorbax reversed-phase (SB-C18, 3.0×250 
mm, 5.0 µm) column. A gradient method was employed to separate the individual GE 
components using mobile phase A (0.1% formic acid in water) and mobile phase B (ACN). The 
gradient elution method with 60% B at 0 min, 90% B at 20 min, held for 10 min, back to 60% B 
at 40 min with a flow rate of 0.4 mL/min. An injection volume of 10 µL was used for analysis. 
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3.3.21 Pharmacokinetic analysis 
Pharmacokinetic parameters were calculated from the concentration-time data using the 
non-compartmental analysis tool of validated WinNonlin® software (Version 5.2, Pharsight, 
USA). The area under the concentration time curve (AUClast and AUCinf) was calculated by the 
linear trapezoidal rule. Following oral administration, peak concentration (Cmax) and time for the 
peak concentration (Tmax) were the observed values. The clearance (CL) and volume of 
distribution (Vss) were estimated following intravenous dose administration. The elimination rate 
constant value (k) was obtained by linear regression of the log-linear terminal phase of the 
concentration-time profile using at least 3 declining concentrations in terminal phase with a 
correlation coefficient of >0.8. The terminal half-life value (T1/2) was calculated using the 
equation ln2/k. Oral bioavailability was calculated by taking the ratio of dose normalized AUClast 
following oral administration to intravenous administration.  
3.3.22 Statistical analysis 
All the experiments were repeated at least three times. Results are expressed as mean 
values of at least three independent experiments and standard deviations (mean values ± SD), 
and P values (Student’s t test) were calculated in reference to control values using Excel 
software. The criterion for statistical significance was P < 0.05. Furthermore, a two-way analysis 
of variance (ANOVA) was performed to evaluate the differences between vehicle- and GE/Mix-
fed groups for in vivo efficacy studies and P-values were obtained from two-sided tests for 
statistical significance. 
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3.4 Results 
3.4.1 Ginger extract displays selective antiproliferative activity, arrests cell-cycle progression, 
and induces apoptosis in prostate cancer cells 
Although the whole GE has been shown to inhibit proliferation of breast (Lee et al., 
2008) and colon (Jeong et al., 2009) cancer cells, there are no available reports that have tested 
the potential usefulness of GE in prostate cancer. Thus, we first asked whether GE affected the 
proliferation of prostate cancer cells. To this end, we investigated the effect of GE on PC-3, 
LNCaP, C4-2, C4-2B and DU145 cells, which are well-characterized representatives of 
androgen-responsive (LNCaP) and androgen independent (PC-3, C4-2 and C4-2B) human 
prostate cancers. Cells were treated with increasing gradient concentrations of GE or vehicle 
(0·1% dimethyl sulfoxide) for 72 h, and cell survival was assessed by the Alamar blue assay. Our 
data showed that GE inhibited cellular proliferation of all prostate cancer cells, with a half-
maximal concentration of growth inhibition (IC50) in the order C4-2 (512 µg/ml). PC-3 (250 
µg/ml), C42-B (240 µg/ml), DU145 (95 µg/ml), LNCaP (75 µg/ml) (Figure 3.1A and 3.1B). 
These data suggested the generality of the growth inhibition effect of GE on prostate cell lines 
with varying genotypic backgrounds. Hereupon, we focused on PC-3 cells for further 
experimentation to delineate molecular mechanisms of growth inhibition and cell death. We also 
performed a complementary trypan blue assay to examine cell viability on GE treatment in a 
concentration and time-dependent manner in PC-3 cells.  
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Figure 3.1 GE has potent antiproliferative activity 
Human prostate cancer LNCaP, DU145, PC-3, C4-2, C4-2B cells, as well as normal prostate 
epithelial cells (PrEC) and human dermal primary fibroblasts (HDF) were treated with gradient 
concentrations of GE for 72 h. The percentage of cell proliferation at indicated concentrations, 
compared with untreated control cells, was measured by the in vitro cell proliferation assay, as 
described in Materials and methods. (A) Plot of percentage of cell survival vs. GE concentrations 
used for the determination of half-maximal concentration of growth inhibition (IC50) values. 
Values are means of three independent experiments performed in triplicate, with standard 
deviations represented by vertical bars (P<0·05). (B) Bar graph representation of the IC50 of the 
indicated cell lines. (C) Bar graph representation and photograph of crystal violet-stained 
surviving colonies from the control and GE-treated (250 and 1000 µg/ml) groups. (D) 
Fluorescence micrographs of control and GE-treated PC-3 cells stained for (Di) Ki67 (green) or 
(Dii) 4’,6-diamidino-2-phenylindole (DAPI, blue). Scale bar, 20 µm. (Diii) Quantification of 
Ki67-postive or DAPI-stained cells in control and 250 µg/ml of GE-treated PC-3 cells from 
random image fields totaling 200 cells. Values are means, with standard deviations represented 
by vertical bars. Mean values were significantly different from the controls (P<0·05). 
 
Yet another screen of an array of cancer cell lines from different tissue types, namely 
breast and cervical cancer, showed that GE affected the proliferative capacity of these cancer 
cells, suggesting generalization of GE effects on cell lines from other tissue types. Tumor cell 
selectivity is a highly desirable trait of any chemopreventive or chemotherapeutic regimen. To 
investigate whether GE-mediated suppression of PC-3 cell growth was selective to cancer cells, 
we determined the effect of GE treatment on a normal PrEC and serum-starved human dermal 
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primary fibroblast (HDF) cells. Our choice of cell lines was based on the fact that PrEC and HDF 
exhibit features most consistent with the epithelial cells of prostate and dermal origin, 
respectively. The present results showed that the viability of PrEC or HDF was not significantly 
affected by GE treatment at concentrations in the range of 100–750 µg/ml (Figure 3.1B). The 
IC50 of PrEC (1750 µg/ml) and HDF (1000 µg/ml) was approximately 6.9- and approximately 4-
fold higher, respectively, compared with PC-3 cells, reflecting the wide therapeutic window that 
imparts tumor selectivity. Collectively, these results indicated that PC-3 cells, but not normal 
prostate epithelial or primary fibroblast cells, were significantly sensitive to growth inhibition by 
GE treatment. 
Next, we performed a clonogenic cell survival assay to determine the ability of cells to 
proliferate indefinitely upon drug removal, thereby measuring their reproductive capacity to form 
colonies. Our data showed that 250 µg/ml of GE decreased colony numbers by approximately 
66% (Figure 3.1C) compared with vehicle-treated controls. Representative pictures of surviving 
crystal violet-stained PC-3 cell colonies from control and GE-treated cells are shown in Figure 
3.1C. Several model systems have shown that Ki67 expression shows a good direct relationship 
with growth fraction, and thus serves as a reliable method for evaluating actively proliferating 
cell populations. Immunostaining with an antibody that reacts with the Ki67 nuclear antigen 
showed significantly intense staining in control cells compared with 250 µg/ml of GE-treated 
cells (Figure 3.1Di). Figure 3.1Diii is a bar graph representation of Ki67-positive cells scored as 
an average in both control and GE-treated samples from at least ten fields of vision totaling 200 
cells. These data correlated with our previous in vitro proliferation and colony survival data, thus 
confirming the antiproliferative activity of GE. Several characteristics of apoptosis, such as 
morphological and cellular changes, including chromatin condensation, membrane blebbing and 
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DNA fragmentation, lend themselves to assessment. Thus, we microscopically examined DAPI 
stained control and 48 h GE-treated (250 µg/ml) cells to observe condensed chromatin material 
and other morphological features reminiscent of apoptosis. Representative fluorescence 
micrographs are shown in Figure 3.1Dii and their bar graph quantification is depicted in Figure 
3.1Diii. 
 
Figure 3.2 GE and ginger phytochemicals inhibit proiferation of prostate cancer cells. 
PC-3 cells were treated with gradient concentrations at (A) 1, 10, 25, 50, 75, 100, and 250 µM 
for 6-gingerol (6G) (0.29, 2.94, 7.36, 14.72, 22.07, 29.43, and 73.58 µg/ml, respectively), 8-
gingerol (8G) (0.32, 3.22, 8.06, 16.12, 24.18, 32.24, and 80.61 µg/ml, respectively), 10-gingerol 
(10G) (0.35, 3.51, 8.76, 17.53, 26.29, 35.05, and 87.63 µg/ml, respectively), and 6-shogoal (6S) 
(0.28, 2.76, 6.91, 13.82, 20.73, 27.64, and 69.09 µg/ml, respectively); and (B) 1, 10, 25, 50, 75, 
100, and 250 µg/ml, respectively, of GE for 48 h. The percent cell survival upon various 
treatments was measured using MTT assay, as described in Materials and Methods. A and B: 
Plot of percentage of cell survival versus concentrations used for determination of halfmaximal 
concentration of growth inhibition (IC50). Data shown above represent the means of 3 
independent experiments performed in triplicate, with standard deviations represented by vertical 
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bars (P < 0.05). (C) Chemical structures of ginger phytochemicals (i) 6G, (ii) 8G, (iii) 10G, (iv) 
6S. 
Because the major bioactive constituents of ginger are gingerols and shogaols, the 
antiproliferative activity of GE could be attributed to these components of ginger extract, viz., 
6G, 8G, 10G, and 6S. Thus, we first determined the half-maximal growth inhibitory 
concentration (IC50) for GE and its phytochemicals in prostate cancer, PC-3 cells. To this end, 
we used an in vitro cell proliferation assay, MTT, to quantify the percent survival of PC-3 cells 
in the presence of test agents. The IC50 values obtained were 75 µM (22.07 µg/ml) for 6G, 10 µM 
(3.22 µg/ml) for 8G, 50 µM (17.53 µg/ml) for 10G, 4 µM (1.12 µg/ml) for 6S (Figure 3.2A), and 
250 µg/ml for GE (Figure 3.2B). The carbon chain length of ginger phytochemicals (Figure 
3.2C) has been reported to play a role in the differential potencies of the gingerols and shogaols 
(27). On similar lines, the results observed in our study showed a variability of IC50s in the 
context of prostate cancer cells. In addition, our data suggested a significant difference in the 
IC50 values of ginger constituents compared to whole GE. As evident from Figure 3.2A and 
3.2B, the constituent ginger phytochemicals were more potent than GE. 
Several dietary agents have been shown to arrest the cell cycle, leading to growth 
inhibition and apoptosis. For example, grape seed proanthocyanidins, green tea polyphenols, 
epigallocatechin-3-gallate, resveratrol (red grapes, peanuts and berries), silymarin/silibinin (milk 
thistle), genistein (soyabean), curcumin (turmeric) and ginger (gingerols) affect cell-cycle 
progression at various stages by specifically modulating cell-cycle-associated proteins 
(Aggarwal and Shishodia, 2006). Specific gingerols, such as 6-gingerol and 8-gingerol, have 
been shown to perturb cell-cycle progression as a chemopreventive strategy (Park et al., 2006). 
Thus, our next aim was to gain mechanistic insights into GE-mediated antiproliferative activity 
by determining the specific cell-cycle stage at which GE intervenes. To this end, we examined 
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the cell-cycle distribution profile of GE-treated PC-3 cells by employing a flow cytometric assay 
using the DNA intercalator dye, propidium iodide. Figure 3.3A shows the effect of varying GE 
dose levels on cell-cycle progression of PC-3 cells at 24 h of treatment in a three-dimensional 
disposition. Next, we used the half-maximal sub-G1 dose (250 µg/ml) to explore in depth the 
effect of GE on each cell-cycle phase at the time of treatment (Figure 3.3B). The present results 
showed that GE at a dose level of 250 µg/ml caused accumulation of cells in the G1 and S phase 
at as early as 6- and 12 h of GE treatment, respectively. The cell-cycle arrest was followed by an 
emergence of a hypodiploid sub-G1 population, a hallmark of dying apoptotic cells.  
We next sought to determine molecular mechanisms underlying GE-induced cell-cycle stasis and 
subsequent apoptosis. Essentially, cell-cycle progression involves sequential activation of cdks 
by their cyclical association with cell-cycle phase-specific regulatory cyclin molecules. To 
examine GE-induced alterations, we first determined the effect of 250 µg/ml of GE on protein 
levels of G1/S-specific cyclins and cdks by immunoblotting methods. GE treatment caused a 
marked decrease in cyclin D1 levels in PC-3 cells, which was evident as early as 12 h post-
treatment (Figure 3.3C). In addition, GE-treated PC-3 cells exhibited a slight decrease in cdk4 
levels (Figure 3.3C). Our data also showed that GE caused a significant reduction in cyclin E 
levels, which drive the cell cycle primarily through the S phase in association with cdk2. 
Elevated levels of p21, a cdk inhibitor, function to stall the cell cycle. Essentially, p21 plays a 
crucial role in the regulation of the G1/S and G2/M transition by binding to and inhibiting the 
kinase activity of cyclin/cdk complexes. To explore further, we determined the effect of GE 
treatment on protein expressionand/or phosphorylation of p21 and Rb by immunoblotting 
methods. As shown in Figure 3.3C, GE treatment caused an induction of p21 protein expression 
in PC-3 cells, which was evident at 12–24 h. In addition, GE treatment caused suppression of Rb 
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phosphorylation in PC-3 cells (Figure 3.3C) 
 
 
Figure 3.3 GE effects cell cycle progression kinetics by causing S and G2/M arrest followed 
by an increase in sub-G1 cell population 
Cell-cycle progression over (A) dose (0–1000 µg/ml) and (B) time (0–72 h) are depicted in a 
three-dimensional format. Cell populations in G0/G1 appear as 2N (unduplicated) DNA content 
and G2/M populations are indicated by 4N (duplicated) DNA content. (C) Immunoblots of cell 
lysates treated in the absence or presence of 250 mg/ml of GE for cyclin D1, cdk4, cyclin E, p21 
and p-Rb. Uniform loading was confirmed by β-actin. (Di) Flow cytometric histogram profiles 
showing percentage of cells with cytosolic monomeric JC-1-associated green fluorescence 
(indicating collapse of mitochondrial membrane potential) in PC-3 cultures treated with dimethyl 
sulfoxide (DMSO; control, pink profile) or GE (blue profile) for 24 h. Representative data from a 
single experiment are shown. (Dii) Quantification of the increase in mean fluorescence intensity 
(MFI, i.e. the percentage of green JC-1-stained cells) in PC-3 cultures treated with DMSO 
(control) or GE for 24 h. (Ei) Histogram profiles showing a spectral shift and loss of red 
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fluorescence, consistent with the loss of transmembrane potential on GE treatment (control, 
green; GE, red). (Eii) Quantification of the decrease in mean fluorescence intensity (i.e. the 
percentage of red JC-1-stained cells) in PC-3 cultures treated with DMSO (control) or GE for 24 
h. Values are means of three independent experiments performed in triplicate, with standard 
deviations represented by vertical bars (P<0·05). 
 
 Multiple apoptotic pathways are recruited by cells for executing their own demise via 
apoptosis. Among them, one major mechanism involves the loss of mitochondrial membrane 
integrity and transmembrane potential (Ψm). We thus asked whether GE affected mitochondrial 
transmembrane potential. To this end, we stained GE-treated cells with JC-1, a cationic dye that 
displays potential-dependent accumulation in the mitochondria. A decrease in the red:green 
fluorescence intensity ratio suggested mitochondrial depolarization (Figure 3.3Di). The increase 
in the green JC-1 monomeric form, indicative of collapse of transmembrane potential, was 
quantitatively determined using flow cytometry. Quantification of fluorescence-activated cell 
sorting data indicated an approximately 3.6-fold increase (Figure 3.3Dii) in the mean 
fluorescence intensity of GE-treated JC-1-stained cells compared with controls (Figure 3.3Dii). 
A spectral shift and loss of red fluorescence, which is consistent with decreased polarization, was 
also observed (Figure 3.3Ei and Eii). The collapse of Ψm is closely associated with alterations in 
the ratio of antiapoptotic: pro-apoptotic members of the Bcl2 family, which determines 
susceptibility to apoptosis. Particularly, loss of Ψm is coupled with hyperphosphorylation and 
thus inactivation of the anti-apoptotic molecule Bcl2, which promotes recruitment of BAX onto 
the outer mitochondrial membrane. BAX incorporation results in uncoupling of the respiratory 
chain and efflux of small pro-apoptotic factors, such as cytochrome c, leading to the activation of 
key executioner caspases, caspase-3/7.  
 
Thus, our next step was to investigate the effect of GE treatment on levels of Bcl-2 
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family proteins by immunoblotting and the results are shown in Figure 3.4A. GE treatment 
caused a rapid and marked increase in BAX expression over time, whereas levels of total Bcl2 
were decreased (Figure 3.4A). The GE-mediated alterations in the pro-apoptotic/anti-apoptotic 
molecules were evident as early as 12 h post-treatment and increased thereafter (Figure 3.4A). 
Biochemical events, such as the release of cytochrome c from the mitochondria into the cytosol, 
caspase activation and PARP cleavage, predominantly occur during mitochondria-mediated 
apoptotic cell death. Thus, we asked whether GE-induced cell death promoted the release of 
apoptogenic factors from the mitochondria that triggered the downstream executioner events of 
apoptosis. Our data showed that cytochrome c was detectable at 12 h and peaked at 48 h of GE 
treatment in the cytosolic fraction, as observed using immunoblotting methods (Figure 3.4A).  
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Figure 3.4 GE induces mitochondrially mediated intrinsic apoptosis 
(A) Immunoblot analyses for BAX, Bcl2, cytoplasmic cytochrome c (Cyt c), cleaved caspase-3 
and poly(ADP-ribose)polymerase (PARP). β-Actin was used as a loading control. (B) 
Quantification of the time-dependent increase in caspase-3 (Casp-3) activity on GE treatment. 
Cells were created with GE for 0, 12, 24 and 48 h, and caspase-3 activity was analysed using the 
fluorogenic substrate Ac-DEVD-7-amino-4-trifluoromethyl-coumarin. Values are means of three 
independent experiments performed in triplicate, with standard deviations represented by vertical 
bars (P<0.05). Immunofluoresence micrographs of control and 250 µg/ml of GE-treated cells 
stained for cleaved (Ci) caspase-3 and (Di) PARP. (Cii, Dii) Quantification of activated caspase-
3-positive and cleaved PARP-positive cells. 
 
Our next aim was to explore the involvement of caspases that are activated by the release 
of cytochrome c and are known to cleave a variety of substrates. Since caspase-3 activation is 
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considered as a hallmark of apoptosis, we monitored the active form of the cysteine protease 
using a small, conserved, and modified peptide substrate that becomes fluorogenic upon 
cleavage. As shown in Figure 3.4B, GE stimulated a time-dependent increase of caspase-3 
activity in PC-3 cells. However, treatment of cells with a specific inhibitor of caspase-3 
significantly blocked GE-induced apoptotic cell death (data not shown). Furthermore, 
immunoblots showed a time-dependent increase in expression levels of activated caspase-3, 
suggesting that GE-induced cell death is caspase-3 dependent (Figure 3.4A). On caspase-3 
activation, a number of cellular proteins are cleaved, including PARP. The present results 
showed a time-dependent increase in cleaved PARP levels, a substrate of caspase-3. An increase 
in the expression of both activated caspase-3 and cleaved PARP was also confirmed in GE-
treated cells by immunofluorescence microscopic methods (Figure 3.4Ci and Cii).  
3.4.2 Oral ginger extract feeding achieves inhibition of PC-3 tumors in nude mice and in 
vivo mechanisms of ginger extract-mediated inhibition of tumor growth 
Having identified significant antiproliferative and pro-apoptotic activity of GE, an 
intriguing question was to determine whether the anticancer effects of GE were restricted to in 
vitro cultures or extended to in vivo systems. To validate this, we examined the efficacy of GE to 
inhibit human prostate PC-3 xenografts subcutaneously implanted in athymic nude mice. 
Animals in the treatment group were fed daily with 100 mg/kg GE. GE was dissolved in PBS 
containing 0·5% Tween-80 and was fed by oral administration for 8 weeks; responses to GE 
treatment were followed by tumor volume measurements every consecutive day using vernier 
calipers (Figure 3.5A). Tumors in vehicle-treated control animals showed unrestricted 
progression (Figure 3.5A), whereas GE feeding showed a time-dependent inhibition of tumor 
growth over 8 weeks (Figure 3.5A). A reduction in tumor burden by approximately 56% was 
99 
observable after 8 weeks of 100 mg/kg per d oral feeding, and the difference between the mean 
final tumor volumes in animals receiving GE and those receiving vehicle orally was statistically 
significant (P<0.05). All animals in the control group were euthanised by day 60 post-
inoculation, in compliance with the IACUC guidelines. To assess the overall general health and 
well-being of animals during GE treatment, body weights were recorded twice a week. GE-
treatment was well tolerated, and mice maintained normal weight gain (Figure 3.5B) and showed 
no signs of discomfort during the treatment regimen. At the end point of the animal experiments 
(week 8), the excised tumors were weighed and an approximately 53% reduction in tumor 
weight was observed in the GE-treated group compared with controls.  
 
Figure 3.5 GE caused in vivo inhibition of tumor growth 
(A) Progression profile of tumor growth in control vehicle-treated and GE-treated mice at the 
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time of treatment. (B) GE treatment was well tolerated, and the body weights of the control and 
GE-treated groups were comparable. Values are means, with standard deviations represented by 
vertical bars (n=6, P<0.05). (C) Tumor micrographs from control and GE-treated mice, 
respectively, at 100X and 200X magnification. GE-treated tumor micro sections reveal large 
areas of tumor cell death, consistent with the therapeutic effects of GE. Micro sections from 
control tumor tissue show sheets of tumor cells with high-grade pleomorphic nuclei with 
minimal cell death. (D) Western blot analysis of tumor tissue lysates from control and GE-
treated mice for cyclin B, cyclin D1, cyclin E, p21 and cleaved caspase-3. 
 
To investigate the in vivo mechanisms of tumor inhibition, we first examined 
hematoxylin- and eosin-stained tumor sections from control and GE-treated mice. Tumor micro 
sections from GE-treated mice showed large areas of tumor cell death, seen as tumor necrosis 
adjacent to normal-looking healthy cells. Significant loss of tumorigenic cells in GE-treated 
animals (Figure 3.5C) was consistent with the therapeutic effect of GE. However, some viable 
tumor cells were observed at the periphery of cell death zones. In contrast, micro sections from 
control tumor tissues revealed sheets of tumor cells with high-grade pleomorphic nuclei (Figure 
3.5C). We next evaluated the in vivo effect of GE feeding on the antiproliferative response 
associated with the inhibition of tumor growth. To this end, tumor tissue lysates were analyzed 
for cyclins (D1, E and B1) and a cyclin-dependent kinase inhibitor, p21, using immunoblotting 
methods (Figure 3.5D). GE treatment caused a decrease in cyclin D1, cyclin E and cyclin B1, 
whereas it increased p21 expression levels, which allied with the present in vitro findings in PC-
3 cells (Figure 3.3C). Alterations of these cell-cycle regulatory molecules in tumor tissue from 
GE-treated mice suggest a potential mechanism for inhibition of tumor proliferation, in keeping 
with the inhibition of cell-cycle kinetics observed in vitro (Figure 3.3A and B). In vivo apoptotic 
responses of GE feeding in mice bearing PC-3 tumor xenografts were evaluated by 
immunoblotting of tumor lysates for cleaved caspase-3 expression. 
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We further correlated the in vivo molecular mechanisms of GE treatment by 
immunostaining for Ki67, a marker for cell proliferation, as well as apoptotic markers such as 
cleaved caspase-3, cleaved PARP and TUNEL (Figure 3.6A). Tumor samples from the treated 
groups receiving GE showed marked reduction in Ki67-positive cells compared with controls 
(Figure 3.6A). There was a significantly higher expression of cleaved caspase-3 (approximately 
12-fold) and PARP (approximately 35-fold) in tumor-tissue from the GE-treated groups 
compared with controls (Figure 3.6A and B). We found an approximately 18-fold increase in 
TUNEL-positive cells in GE-treated tumors compared with controls (Figure 3.6A and B). Figure 
3.6B shows bar graph quantitative representation of the immunostaining data from the control 
and GE-treated groups. 
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Figure 3.6 GE induced in vivo apoptosis 
(A) Immunohistochemical staining of paraffin-embedded tumour tissue sections from the control 
and ginger extract (GE)-treated groups for proliferation marker (Ki67) and apoptotic markers 
(cleaved caspase-3 (casp-3), cleaved poly(ADP-ribose)polymerase (PARP) and terminal 
deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL)). (B) Quantification of Ki67, 
cleaved casp-3, cleaved PARP and TUNEL-positive cells counted from several randomly 
selected fields for a total of 200 cells. Values are means, with standard deviations represented by 
vertical bars (P<0.05). 
 
Toxicity, particularly in tissues with actively proliferating cells, remains a major concern 
in the chemotherapy of prostate cancer patients. We observed that there was no gross toxicity 
(data not shown), as measured in terms of body weight, grooming or lethargy in GE-treated 
mice. Our data showed that there were no detectable differences in the histological appearance of 
tissues, including in the gut, liver, spleen, lung, brain, heart, testes and bone marrow, from 
vehicle- and GE-treated tumor bearing mice (data not shown). To determine whether GE 
treatment affected proliferation of normal tissues with rapidly proliferating cells, colonic crypts 
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from GE-treated and vehicle-treated mice were stained with Ki67, a marker for proliferative 
index. We found that colonic crypts from both mice groups showed comparable nuclear Ki67 
staining. These data suggested that GE did not affect normal tissues with rapidly proliferating 
cells. In addition, serum biochemical markers (alanine transaminase, alkaline phosphatase, g-
glutamyl transpeptidase for hepatic function, and creatinine and electrolytes, e.g. K, Na, Ca and 
Cl, for renal function) were similar between the control and GE-treated groups, indicating the 
absence of apparent toxicity (data not shown). 
3.4.3 HPLC-UV Quantification of Ginger Phytochemicals in GE and determination of 
synergy among GE phytochemicals 
To gain further insights into the obvious differences in the IC50s of ginger 
phytochemicals and GE, our next step was to quantitate the natural abundance of constituent 
phytochemicals in ginger extract. HPLC-UV analysis was used to investigate the relative 
abundance of 6G, 8G, 10G and 6S in GE (Figure 3.7). We first obtained the calibration curves of 
commercially available pure ginger phytochemicals at various concentrations using the analytical 
method described in Materials and Methods. Next, GE was injected into the system to obtain the 
HPLC-UV profile, where all the peaks corresponding to individual ginger phytochemicals were 
identified and manually integrated. The areas under the curve for each of these peaks in GE were 
used to calculate their abundance (Figure 3.7). The quantitation table in Figure 3.7 indicates that 
6G is the most abundant phytochemical. This result is consistent with literature reports, which 
suggest that 6G is the most abundant constituent of fresh ginger.  
Accounting for the natural abundance of 6G at ∼6% in GE, its contribution to the IC50 of 
GE calculates to be 15 µg/ml. This is equivalent to a ∼32% reduction in the IC50 of 6G when it is 
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present in the “food matrix” with other ginger phytochemicals compared to 6G as a single agent. 
Similarly, 10G at an abundance of 2.61% in GE exhibited a ∼57% reduction in IC50 when in its 
native environment compared to 10G as a single agent. These data suggested the existence of a 
synergistic relationship between ginger phytochemicals, which is perhaps responsible for their 
enhanced efficacy at lower-dose levels when present in GE.  
 
Figure 3.7 Quantitation of gignerols in GE. 
6G, 8G, 10G and 6S were quantified employing LC/MS/MS with electrospray ionization in 
positive-ion mode. The presence of 6G [MRM: 277.2/177.2, RT: 5.8 min, 8G (MRM: 
305.2/137.2, RT: 9.4 min), 10G (MRM: 333.2/137.2, RT: 14.6 min) and 6S (MRM: 277.2/137.1, 
RT: 10.9 min) were confirmed using analytical standards and quantified using calibration curve 
for each individual component (shown in the inset). 
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To explore the nature of interactions among ginger constituents, we designed binary 
combination regimens at fixed ratios of pure ginger phytochemicals (Materials and Methods). 
The concentrations chosen were lower than their respective IC50 values. PC-3 cells were treated 
with combinations of 6G + 8G, 8G+10G, 10G+6G, 6S+6G, 6S+8G, 6S+10G, GE+6G, GE + 8G, 
GE + 10G, and GE + 6S at various concentrations, and the fractions of cells affected (Fa) upon 
these treatments were determined using the MTT assay. These data were then computed using 
the CalcuSyn software (Version 2.1) to obtain the corresponding CI values. A drug combination 
showing CI < 1 is considered as synergistic, >1 as antagonistic, and equal to 1 as additive. Our 
results showed that the combination of 6G + 8G (Figure 3.8A) exhibited significantly strong 
synergistic interactions for concentrations 0.25 (IC50/2), 0.5 (IC50/2), 0.75 (IC50/2), with CI 
values of 0.276, 0.158, 0.191, respectively. Interestingly, the corresponding CI vs. Fa graph in 
Figure 3.9A demonstrated that 2 out of the 5 concentrations tested lie above the red dotted line, 
signifying that their interactions were antagonistic, with CI values >1.  
106 
 
 
Figure 3.8 Ginger phytochemicals act in concert to confer antiproliferative activity. 
Bar graph representation of fraction of cells affected (Fa) upon treatment with (A) 6-gingerol 
(6G) and 8-gingerol (8G), (B) 8G and 10-gingerol (10G), (C) 10G and 6G, (D) 6-shogaol (6S) 
and 6G, (E) 6S and 8G, and (F) 6S and 10G as single agents and in binary combinations. The 
concentrations of the ginger phytochemicals (in µM) are plotted on the x-axis, while the fraction 
affected is represented on the y-axis. The choice of concentrations for combinations tested has 
been described in Materials and Methods. PC-3 cells were treated with the phytochemical binary 
combinations for 48 h. Data shown above represent the means of 3 independent experiments 
performed in triplicate, with standard deviations represented by vertical bars (P<0.05). 
 
Similarly, the combination of 8G + 10G (Figure 3.8B) at concentrations 0.125 (IC50/2), 
0.25 (IC50/2), 0.5 (IC50/2), 0.75 (IC50/2), resulted in CI values less than 0.3, indicating strong 
synergism. The CI vs. Fa line plot in Figure 3.9B demonstrated that all combinations tested 
displayed synergy. Three out of the five 10G+6G combinations (Figure 3.8C) exhibited 
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synergism, with CI values > 0.5, whereas the other 2 were observed to be antagonistic in nature. 
Similar to 8G + 10G, we found that all combinations of 6G + 6S (Figure 3.8D) were strongly 
synergistic, as the CI values (0.05–0.11) lie below the red dotted line. Furthermore, at low 
concentrations of 0.075 (IC50/2), 0.125 (IC50/2), synergistic interactions were observed for 10G + 
6G combinations (Figure 3.8E) with CI values of 0.44 and 0.49, respectively. In comparison, 
slight synergism was observed at a concentration of 0.5 (IC50/2), with CI value of 0.87. The 
concentrations 0.25 (IC50/2) and 0.75 (IC50/2) interacted in a nearly additive manner lying right 
below the red line (Figure 3.9E), with CI values of 0.96 and 0.94, respectively. Finally, strong 
synergism was observed for 6S+10G (Figure 3.8F) at a concentration of 0.075 (IC50/2) with a CI 
value of 0.24. Instead, concentrations of 0.125 (IC50/2) and 0.25 (IC50/2) exhibited moderate 
synergism with CI values of 0.44 and 0.58, respectively. The concentration 0.5 (IC50/2), showed 
a high CI value of 0.87, which indicated slight synergy. However, the concentration 0.75 (IC50/2) 
was nearly additive as its CI value lies above the red dotted line at 1.07 (Figure 3.9F). 
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Figure 3.9 Line plots of combination index (CI) versus fraction of cell affected (Fa). 
The various concentrations of the combinations correspond to Fig. 3A–3F). The degree of 
synergistic interaction was calculated using Calcusyn software and quantitated in terms of CI. 
The red dotted line indicates a CI value of 1, below which the combination of ginger 
phytochemicals are considered to show a synergistic effect. 6G = 6-gingerol; 8G = 8-gingerol; 
10G = 10-gingerol; 6S = 6-shogaol. 
 
These observations suggest that the majority of binary combinations of ginger 
biophenolics affected cell proliferation in a synergistic manner. The CI versus Fa plots in Figure 
3.9 indicate that 83% of gingerol combinations (6G + 8G, 8G + 10G, and 6G + 10G) inhibited 
PC-3 proliferation, with Fa values ranging between 0.4 and 0.5 (Figure 3.9A-C) synergistically. 
Furthermore, 90% of the gingerol and 6-shogaol combinations, (6S + 6G, 6S + 8G, and 6S + 
10G) exhibited synergism irrespective of the fraction of cells affected. In fact 80% of the 6G + 
6S combinations were observed to display very strong synergism (CI < 0.1). Having determined 
significant synergism between pure phytochemicals derived from ginger at low concentrations, 
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we next asked if an increase in the efficacy of GE could be achieved by increasing the ratio of 
these biophenolics in the extract. 
 
To discern the importance of the natural ‘milieu’ of GE and in vivo interactions between 
the most-active ginger phytochemicals, we artificially created a quasi-mixture of the active GE 
constituents, 6G, 8G, 10G and 6S, hereafter called as Mix. Essentially, the first step was to 
isolate, purify and spectrally characterize the aforementioned GE biophenolics using column 
chromatography. Further, to formulate the quasi-mixture (Mix), the purified ginger 
phytochemicals (6G, 8G, 10G and 6S) were then mixed exactly in the same ratio and 
concentrations at which they appear in the ginger extract (GE). The quantitation of individual 
ginger phytochemicals in GE was performed using LC/MS/MS which indicated that 1 mg of GE 
consists of 30.03 µg of 6G, 6.86 µg of 8G, 7.77 µg of 10G and 5.96 µg of 6S (Figure 3.7). 
Having formulated a quasi-mixture with matched concentrations of the most-abundant and active 
ginger phytochemicals, we asked if oral feeding with Mix recapitulated or surpassed GE’s 
remarkable in vivo efficacy. To this end, we performed an in vivo experiment to evaluate tumor 
inhibition by Mix compared to GE in a real time non-invasive bioluminescent prostate cancer 
model. 
3.4.4 GE is superior to the quasi “Mix” of active GE constituents in inhibiting prostate 
tumor growth 
We compared the in vivo tumor growth-inhibiting efficacy of GE and Mix in human 
prostate cancer xenografts implanted subcutaneously in the right flanks of athymic nude mice. A 
human prostate cancer PC-3 cell line stably expressing luciferase enzyme (PC-3-luc) was 
employed, which facilitates real-time non-invasive monitoring of prostate cancer growth. 
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Animals were randomized and divided into three groups of five mice each for the study. The 
study included one vehicle-fed control group and 2 treatment groups fed daily with 250 mg/kg of 
GE and Mix via oral gavage for four weeks. Our results indicated that both treatment groups 
exhibited a time-dependent inhibition of tumor growth (Figure 3.10A-C), compared to vehicle-
treated controls. Quantitative comparison of the relative total photon flux that reflected tumor 
volume revealed that GE caused ~68% inhibition of tumor growth compared to Mix, which was 
only ~28% as measured at the end of week 4 (P<0.05, Figure 3.10B, C, E).  
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Figure 3.10 Oral administration of GE exhibited enhanced inhibition of human prostate 
tumor xenograft growth in nude mice compared to Mix. 
Male nude mice were subcutaneously injected with 106 PC-3-luc cells. (A) Representative 
bioluminescent images of one animal per group indicating progression of tumor growth over four 
weeks. (B) Graphical representation of quantitative radiance measured as the number of photons 
leaving a square cm of tissue and radiating into a solid angle of 1 steradian (photons/sec/cm2/sr) 
from control vehicle, GE and Mix fed mice for four weeks. (C) Tumor growth monitored (by 
vernier calipers) and presented as tumor-volume in mm3, over a period of 4 weeks. (D) Graphical 
representation of body weight of vehicle, GE- and Mix-treated mice. (E) Graphical 
representation of tumor weight. (F) Representative photographic images of excised tumors (*, 
P<0.05 (two-way analysis of variance), as compared to controls; B, C and E). Error bars refer to 
± SD. Statistical significance in percent tumor growth between control and treatment groups was 
achieved after week 3. 
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3.4.5 GE biophenolics exhibit potential enterohepatic recirculation in vivo, while other less 
abundant GE phenolics collaborate with main GE constituents to enable delivery of 
optimal in vivo benefits 
Intriguingly, despite identical concentrations of the four major active biophenolics in both 
GE and Mix, we found a remarkable difference (40%) in the inhibitory efficacy of GE and Mix. 
To gain insights into this discrepancy, we evaluated the levels of these four ginger biophenols in 
the plasma following oral administration of GE and Mix (250 mg/kg) in C57/BL6J mice (3 mice 
per group). All the plasma samples were then evaluated for the presence of 6G, 8G, 10G and 6S 
followed by their quantitation using LC/MS/MS (Figure 3.11A-C). To assess the bioavailability 
of these components, 6G, 8G, 10G and 6S, were dosed individually at an intravenous dose of 1 
mg/kg. The pharmacokinetic parameters of individual GE biophenolics following intravenous 
and oral administration were calculated using the plasma concentration time profiles (Figure 
3.12A-B). Following oral administration, the clearance of all gingerols was more than normal 
liver blood flow in mice (90 mL/min/kg). The volume of distribution was 20-fold higher than 
normal body water (0.7 L/kg) suggesting extensive distribution of these components. The half-
life of gingerols varied between 0.8 h to 6 h. Following oral administration, all gingerols showed 
Cmax at 10 min with GE and 5 min with Mix (Figures 3.11A-B, 3.12B).  
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Figure 3.11 GE feeding results in enterohepatic recirculation causing multiple peaking 
phenomenon. 
Plasma concentration-time profiles of gingerols following oral administration of 250 mg/kg (A) 
GE, (B) Mix and following intravenous administration of 1 mg/kg (C) individual gingerols (D) 
comparison of plasma concentration-time profiles of gingerols achieved at each time point upon 
feeding GE and Mix. Error bars refer to ± SD. 
 
Furthermore, a comparison of mean plasma concentration time profile of 6G, 8G, 10G 
and 6S as shown in Figure 3.11D, revealed that these components, when fed as a Mix without the 
“natural milieu” are eliminated at a faster rate compared to GE. Upon oral feeding, 10G achieved 
a higher Cmax (756.62 ± 7.62 ng/mL) in case of Mix compared to GE (327.26 ± 40.12 ng/mL) 
and was statistical significant (P<0.001, Figure 3.12B). Similarly 8G also showed statistically 
significant (P=0.02) difference in Cmax between Mix (44.71 ± 0.49 ng/mL) and GE (71.74 ± 
32.61 ng/mL).  However, 6G, and 6S) showed similar Cmax when fed as GE or Mix (P>0.05, 
Figure 3.11, Figure 3.12B). Interestingly, the exposure (AUClast) of 6G, 10G and 6S was 2 to 3-
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fold higher when GE was fed orally compared to Mix except for 8G which showed a similar 
profile for both. No statistical analysis was performed on AUClast as it was a sparse sampling 
design with composite profile. Surprisingly, a second and third Cmax peak was observed for all 
ginger phytochemicals in case of GE at 2 h and 6 h, a phenomenon usually observed in case of 
enterohepatic recirculation of molecules from the intestine back to systemic circulation (Roberts 
et al., 2002). A similar profile was observed in case of intravenous administration of pure 
standards (Figure 3.11C). Surprisingly, this multiple peaking phenomenon was not observed in 
case of Mix, thus setting grounds for further investigation of GE’s peculiar PK profile.  
 
Figure 3.12 Pharmacokinetic parameters of GE versus Mix. 
The pharmacokinetic parameters were calculated using non-compartmental analysis tool of 
validated WinNonlin software (version 5.2). The bioavailability of individual gingerols when fed 
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as GE is more compared to when fed as Mix at same concentration. The Cmax values of 6G, 8G, 
10G and 6S in blood plasma samples obtained following oral administration of GE and Mix were 
compared using independent sample t-test. There was no significant difference in Cmax values of 
6G and 6S (P>0.005) but were different for 8G (P=0.02) and 10G (*, P<0.001). No statistical 
analysis was performed on AUClast as it was a sparse sampling design with composite profile. 
 
Following intake of drugs or natural products, the disposition of these molecules occurs 
by several pathways, of which biotransformation is the most notable. Also, the drug or natural 
product metabolites may even be excreted into the bile or to general circulation. Multiple peaks 
were observed in case of 6G, 8G and 10G upon GE feeding at 2 h and 6 h following an initial 
Cmax at 5 min. This multiple peaking phenomenon is perhaps the consequence of enterohepatic 
re-circulation (EHR) of GE phenolics, where their glucuronidated forms that are ready to be 
eliminated via feces are broken down by the glucuronidase enzymes in the intestine to be 
released as free forms of gingerols, which are then available for reabsorption. To confirm this, 
plasma and feces samples obtained after intravenous administration of pure GE biophenolics 
were subjected to β-glucuronidase hydrolysis, an enzyme responsible for de-conjugation of 
glucuronide metabolites in the intestine. The hydrolyzed samples were then analyzed and 
quantitated for 6G, 8G, 10G and 6S using HPLC-MS. Their amounts (ng/mL) in enzyme-treated 
and untreated samples were then compared (Figure 3.13Ai, Aii). The presence of significant 
amounts of 6G and 8G in enzyme-treated plasma samples at 5, 10 and 15 min (Figure 3.13Ai) 
indicate these gingerols undergo conjugation in the intestine/liver to enable elimination. On the 
other hand, 10G and 6S were present in very low amounts in their glucuronidated forms. 
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Figure 3.13 Proof of enterohepatic recirculation of active ginger constituents. 
(Ai) Comparison of plasma concentration-time profile of 6G, 8G, 6S and 10G in untreated and β-
glucuronidase treated plasma samples following IV dose administration of individual ginger 
phytochemicals. The values of 6G, 8G, 10G and 6S in the enzyme-treated plasma samples were 
compared to the untreated samples using independent sample t-test. There was no significant 
difference in values of 8G, 10G and 6S (P>0.005) but were different for 6G (*, P<0.005). (Aii) 
Comparison of concentration-time profiles of 6G, 8G, 6S and 10G in untreated and β-
glucuronidase treated feces samples following IV dose administration. The values of 6G, 8G, 
10G and 6S in treated feces samples were compared to untreated samples using independent 
sample t-test. There was no significant difference in values of 6G, 8G and 10G (P>0.005) but 
were different for 6S (*, P<0.001). (B) Plasma protein binding of gingerols in GE vs Mix. 
Percentage of unbound gingerols in GE is more than in Mix when compared at different 
concentrations. Error bars refer to ± SD. 
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While the plasma concentration profile of ginger conjugates indicate their rapid 
elimination from the system, the data from feces samples subjected to β-glucuronidase 
hydrolysis (Figure 3.13Aii) corroborated that all the 4 components are conjugated and eliminated 
through bile. In the treated feces samples, the free forms of 6G, 8G, 10G and 6S upon 
quantitation were found to exist in very high amounts. This observation clearly indicates that 
upon GE feeding, even though the ginger biophenolics are conjugated as early as 5 min and for a 
possible elimination (Figure 3.13Ai), they can undergo systemic circulation for prolonged time 
(Figure 3.11C, 3.13Aii), thus resulting in higher exposure and greater residence times in the 
system. It is thus clearly evident from the above observations that GE biophenolics undergo 
enterohepatic re-circulation (Figure 3.11C). The PK profiles of GE and Mix containing the same 
amounts of 6G, 8G, 10G and 6S (Figure 3.11A, B) clearly indicate that in their natural setting, 
these GE phenolics undergo EHR, while in a quasi-mixture, they get eliminated within 2 h. Thus, 
we next asked as to why these components exhibit different behavior when present in different 
matrices.  
Binding of a drug to plasma proteins plays a major role in influencing efficacy, drug 
distribution, and toxicity. Extensive literature underscores that only unbound drugs circulating in 
the blood have better access to target tissues. To discern the differences in plasma protein 
binding of ginger phytochemicals present in GE and Mix, we conducted a plasma protein 
binding study. We found that the binding of 6G, 8G, and 10G to plasma proteins was lesser in 
GE compared to Mix.  With an increase in concentration from 10 µg/mL to 100 µg/mL, the free 
fraction increased except for 6S, which showed similar binding profile in both GE and Mix 
(Figure 3.13B). To summarize, GE phenolics when present in GE are primarily present in free 
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form (more unbound) thus facilitating their free transportation to the target tissues, which thus 
contributes towards the better efficacy of GE compared to Mix. 
 
Figure 3.14 Oral administration of GE-Mix also exhibited inhibition of human prostate 
tumor xenograft growth in nude mice. 
Male nude mice were subcutaneously injected with 106 PC-3-luc cells. (A) Representative 
bioluminescent images of one animal per group indicating progression of tumor growth over four 
weeks. (B) Graphical representation of quantitative radiance measured as the number of photons 
leaving a square cm of tissue and radiating into a solid angle of 1 steradian (photons/sec/cm2/sr) 
from vehicle and GE-Mix fed mice for four weeks. (C) Tumor-growth monitored (by vernier 
calipers) and presented as tumor-volume in mm3, over a period of 4 weeks. (D) Graphical 
representation of body weight of vehicle control and GE-Mix treated mice (*, P<0.05 (two-way 
analysis of variance), as compared to controls; B, and C). Error bars refer to ± SD. Statistical 
significance in percent tumor growth between control and treatment groups was achieved after 
week 3. 
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Given that 6G, 8G, 10G and 6S in GE are present in their natural plant matrix along with 
other ginger phytochemicals like 6-paradol, 8-, 10- shogaol, zingerone, zerumbone etc. (Baliga et 
al., 2011; Govindarajan, 1982a, b; Tao et al., 2009; Vasala, 2004; Yoshikawa et al., 1993), we 
cannot exclude the contributions from these minor components. To rule out their input, we 
prepared another fraction lacking in 6G, 8G, 10G and 6S, which we referred to as GE-Mix (aka 
GE minus Mix). Essentially, it was obtained by combining all the ginger sub-fractions collected 
after isolating 6G, 8G, 10G and 6S from GE. We tested the in vivo efficacy of GE-Mix to 
account for the activity of the residual ginger extract components (Figure 3.14). Intriguingly, 
GE-Mix fed animals showed ~35% inhibition in tumor growth compared to vehicle-fed controls 
indicating that several other ginger phytochemicals beyond the most abundant ones too can exert 
anticancer activity, possibly through additive/synergistic interactions. 
3.5 Discussion 
‘An ounce of prevention is worth a pound of cure’ goes the famous adage that holds true 
for cancer chemoprevention strategies using dietary agents such as fruits and vegetables. 
Phytochemical extracts from fruits and vegetables are increasingly being shown to exert potent 
antioxidant and antiproliferative effects (Liu, 2003). It is widely becoming appreciated that 
chemopreventive agents offer superior potential in the long term than chemotherapeutic agents, 
as lifestyle and dietary habits have been identified as major risk factors, particularly in prostate 
cancer growth and progression (Kelloff et al., 1999). Ginger rhizome is extensively used in the 
form of a fresh paste or dried powder to flavor food and beverages in places such as India and 
China (Shukla and Singh, 2007). The present study reports a novel finding that oral consumption 
of the extract of whole ginger, a commonly consumed vegetable worldwide, significantly inhibits 
prostate tumor progression in both in vitro and in vivo mice models. The anticancer effect of GE 
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was coupled with its significant antiproliferative, cell-cycle inhibitory and pro-apoptotic activity 
in cell culture as well as in prostate tumor xenograft models. In addition, we also identified that 
GE strongly suppressed in vitro and in vivo expression of cyclins/cdks that intricately orchestrate 
cell cycle progression. 
 
Ginger is rich in both hydrophilic and hydrophobic constituents, with the hydrophobic 
portion mainly comprising different kinds of mono terpenes, oxygenated mono terpenes, 
sesquiterpenes, zingerone, paradols, gingerols and shogaols other than essential oils (Karna et al., 
2011a). Shogaol is a dehydrated product of structurally similar gingerols. Just as large quantity 
of gingerols is found in fresh ginger, shogaols are abundant in dried and thermally treated ginger; 
on the other hand, the hydrophilic portion of GE mostly has a variety of polyphenolic 
compounds (Karna et al., 2011a). Quantitative reports have suggested that the main constituents 
such as 6-gingerol, 8-gingerol, 10-gingerol and 6-shogaol are present in GE to an extent of 2·15, 
0·72, 1·78 and 0·37 %, respectively (Zick et al., 2010). Recent studies have shown that 6-
gingerol, the major pungent constituent of ginger, suppresses carcinogenesis in skin, 
gastrointestinal, colon and breast (Jeong et al., 2009; Lee et al., 2008; Omenn et al., 1996; Park et 
al., 1998; Yoshimi et al., 1992). The effective in vitro dose level for 6-gingerol in a variety of 
cancer cells has been reported to be in the range of 300–400 µM (Park et al., 2006), which 
translates to 88–177 µg/ml. This is interesting as on the basis of our whole GE data (IC50 value ¼ 
250 µg/ml), IC50 for 6-gingerol computes to only 5·38 µg/ml (approximately 18µM). These 
observations raise the possibility of the presence of more active ingredients or existence of an 
additive and/or synergistic relationship between the bioactive constituents in GE. Furthermore, 
pharmacokinetic studies have reported the maximum achievable plasma concentrations of 6-
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gingerol as 1.90 (SD 0.97) µg/ml (approximately 6.4 (SD 3.3) µM) on oral administration of 120 
mg/kg of 6-gingerol in rats (Wang et al., 2009). This suggests that the maximum levels of 6-
gingerol achievable in the plasma are much lower compared with the reported in vitro effective 
half-maximal dose (300–400 µM), thus limiting its potential efficacy in humans. This notion is 
in agreement with accumulating data that suggest that the additive/synergistic effects of the 
constituent phytochemicals in fruits and vegetables are accountable for their potent antioxidant 
and anticancer activities (Liu, 2003, 2004). This emerging paradigm is further supported by 
clinical trials with pure single phytochemicals such as α-tocopherol, β-carotene and vitamin C 
(Liu, 2004; Omenn et al., 1996) that have met with limited success, reinforcing the fact that an 
isolated single constituent of a complex mixture of phytochemicals present in foods may lose its 
bioactivity. 
In the light of these arguments, the remarkable anticancer activity of whole GE, without 
any detectable toxicity in the present study, certainly underscores the importance of using whole 
food extracts. Essentially, the beneficial effects of constituent phytochemicals at much lower 
dose levels when present together compared with high, relatively toxic doses when used as single 
agents may be ascribable to complex inter-reactivity or interdependence existent among various 
constituent phytochemicals. This may also be attributable to the fact that the various 
phytochemicals comprising whole foods vary in their molecular size, hydrophilicity and 
solubility. Thus, there is a strong likelihood that a particular combination of phytochemicals 
perhaps offers the optimal pharmacokinetic and pharmacodynamic properties that dictate 
favorable anticancer responses. However, if the constituents that participate in the ‘optimal 
combination’ are singled out, it may result in altered bioavailability and distribution of the 
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phytochemicals in different macromolecules, subcellular organelles, cells, organs and tissues to 
yield suboptimal or an absence of favorable therapeutic responses (Liu, 2004). 
 
Given our anticancer therapeutic doses of GE in reducing tumor burden in mice bearing 
human prostate xenografts, we performed allometric scaling calculations to extrapolate the mice 
data to humans, and the human equivalent dose of the GE was found to be approximately 567 mg 
for a 70 kg adult (Reagan-Shaw et al., 2008), which perhaps can be obtained from about 100 g of 
fresh ginger. Although various other pharmacokinetic and pharmacodymanic factors need to be 
considered before any such conclusions on dose extrapolations can be drawn, our data present 
the potential usefulness of GE in prostate cancer and warrant further studies. In conclusion, the 
present study is the first report to describe identification and detailed evaluation of in vitro and in 
vivo anticancer activity of whole GE in the therapeutic management of human prostate cancer. 
 
Several studies have reported synergistic interactions among phytochemicals at low 
concentrations, which would mimic their natural abundance (Mertens-Talcott et al., 2003; Yang 
and Liu, 2009). Therefore, the dose ranges we chose to implement with these binary 
combinations involved sub-half maximal inhibitory concentrations of each phytochemical to 
assess “real” synergy. These findings are consistent with previous studies that have also shown 
that increasing the abundance of a phytochemical within an extract enhances its anticancer 
activity. Although these combination studies have revealed strategies to significantly improve 
activity, the mechanisms underlying this improved inhibition are yet to be unraveled. The 
robustly enhanced activity of combination therapy could yield avoidance of single-agent drug 
resistance in cancer cells and offer a multi-targeted approach in inhibiting proliferation. 
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Extensive literature suggests that each ginger phytochemical functions via a multitude of 
different mechanisms, as ginger polyphenols possess several pharmacological and physiological 
properties. For example, 6S has been shown to exhibit antioxidant and anti-inflammatory 
properties by enhancing the free-radical scavenging activity selectively in cancer cells (Dugasani 
et al., 2010). Further, 10G has been reported to slowly increase the intracellular calcium Ca2+ 
levels in a concentration-dependent manner, leading to death in colon cancer SW480 cells by 
releasing Ca2+ from the endoplasmic reticulum (Chen et al., 2009). The major pungent 
phytochemical, 6G, possesses anti-inflammatory and antioxidant properties and has been shown 
to exert anti-prostatic activity through various mechanisms like depolarization of mitochondrial 
membrane potential, thereby increasing the expression of proapoptotic molecules like Bax and 
Bak (Baliga et al., 2011; Govindarajan, 1982a, b; Yoshikawa et al., 1993). Quantitative reports 
from randomized human clinical trials (Desai et al., 1990; Lumb, 1994) have indicated the safety 
profile of GE, suggesting that a daily dose of ginger extract as high as 5 g in its dry form does 
not cause any toxicity with the exception of mild stomach upset in individuals who infrequently 
consume spicy foods. 
However, human subjects administered with large doses (∼6 g daily) showed signs of 
gastric irritation and loss of protective intestinal mucosa (Desai et al., 1990). A recent 
pharmacokinetic study indicates that human subjects dosed with 250 mg GE containing about 
5.38 mg of 6G, achieved a mean maximal blood plasma concentration of 0.9 µg/ml 6G. 
Assuming a linear increase in the achieved plasma level, a dose of 250 mg GE with 6G at a ∼6% 
level would yield ∼2.5 µg/ml of 6G in plasma. Because the in vitro IC50 of 6G in PC-3 cells is 
75 µM (Figure 3.2A), it translates to 22 µg/ml based upon a molecular weight of 294 for 6G. 
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Thus, a human blood plasma level of 2.5 µg/ml 6G is possibly achievable on consuming 250 mg 
of GE. However, this concentration would not match up with the half-maximal dose-effect in 
vitro. To obtain a 6G plasma concentration that corroborates with its IC50 in prostate cancer cells 
(22 µg/ml), one perhaps would need to consume a large quantity (2.2 g) of GE. Further, if 6G 
was to be consumed alone, and assuming that bioavailability is not a limiting factor, a daily dose 
level of 6 g/kg bw of 6G would be required to achieve its in vitro IC50 dose. Such high doses of 
individual phytochemicals may not be relevant to the in vivo anticarcinogenic process, thus 
limiting the potential efficacy of individual ginger phytochemicals in humans.  
Several lines of evidence indicate that a single constituent isolated from a complex 
phytochemical mixture present in whole foods or their extracts may even lose its bioactivity or 
cause undesirable cancer-promoting effects, as in the case of β-carotene (Greenberg et al., 1994; 
Liu, 2004; Omenn et al., 1996; Tsao et al., 2004). Contrastingly, several studies have reported 
that intake of whole foods rich in β-carotene, such as carrots, may reduce the risk of lung cancer 
(Galeone et al., 2007; van Breda et al., 2005). For example, a case-controlled study involving the 
consumption of carrots exhibited an inverse relationship to lung cancer (van Breda et al., 2005). 
Another study showed that C57BL/6 mice fed with carrots had the highest expression of 
anticarcinogenic genes when compared to the control group (Galeone et al., 2007). Therefore, it 
is likely that isolating a single compound from complex foods may not be effective even at high, 
relatively toxic doses. However, combinations of lower, less-toxic doses of each compound, as 
found in whole foods, may be effective. The natural abundance, low cost, and nontoxicity of this 
very common spice, are strong attributes that favor ginger as a chemopreventive as well as a 
potential chemotherapeutic alternative in the treatment of prostate cancer. Population-based 
studies suggest that Southeast Asians, who regularly consume ginger, have a decreased risk for 
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breast, prostate, gastrointestinal, and colon cancers when compared to Americans and Europeans 
(Aggarwal and Shishodia, 2006; Dorai and Aggarwal, 2004), thus strengthening the notion that 
ginger phytochemicals work together through common and complementary mechanisms to 
produce chemopreventive benefits. Specifically, prostate cancer is a potential target for 
chemoprevention because of its high prevalence in American men, treatment-associated 
morbidity, long latency prior to premalignant lesions, and defined molecular pathogenesis 
(Baliga et al., 2011). We strongly believe that dietary supplements of synergistic combinations of 
GE and ginger phytochemicals could prove to be both effective chemotherapeutic and preventive 
agents and warrant further preclinical evaluation. 
 
Over the past several years, the debate on the use of whole foods versus single agents to 
achieve optimal health benefits has spurred numerous studies that have consistently proven that 
consumption of whole food extracts underlies improved therapeutic efficacy over single-isolated 
constituents. Primarily, this has been speculatively attributed to the presence of 
additive/synergistic interactions among the phytochemicals in the former along with other factors 
including solubility, physiochemical characteristics and pharmacokinetics of the compounds 
(HemaIswarya and Doble, 2006; Jacobs et al., 2009; Jacobs and Tapsell, 2007; Liu, 2003, 2004; 
Ulbricht and Chao, 2010; Wagner, 2011). Nonetheless, attempts to improve the efficacy of 
whole extracts by isolating the most-active fraction(s) or single agents alone are also being 
intensely investigated. Given the perplexing phytocomplexity of plant extracts, several questions 
arise. Is it even possible to selectively isolate only the components responsible for efficacy, while 
ignoring the insignificant partners? Would the resultant “most-active” fraction(s) show 
significant improvement, while working via the same pathways as the parent extract? Would the 
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“single-isolated component” or “most-active fraction” be absorbed by the body in the same way 
as the whole extract? These are some of the stimulating questions that led us to formulate this 
study, wherein we provide compelling in vivo evidence that ginger biophenolics collaboratively 
interact with each other to deliver maximum health benefits.  
 
Given the existence of additive and/or synergistic interactions among the active ginger 
constituents, 6G, 8G, 10G and 6S in vitro (Brahmbhatt et al., 2013), an obvious next step was to 
investigate if these in vitro interactions hold up in an in vivo situation. Our data demonstrate 
existence of in vivo interactions among GE phytochemicals as evidenced by the tumor growth-
inhibiting efficacy of GE (~68%) compared to that of Mix (~28%). The superior efficacy of GE 
by 40% unmasked other partners that contribute towards GE’s remarkable activity in addition to 
6G, 8G, 10G and 6S (Figure 3.10A, B). Further credence to this notion accumulated when we 
“created” a sub-fraction of ginger extract called GE-Mix that lacked the majorly well-known 
four bioactive components, and tested for its in vivo anticancer efficacy. Surprisingly, GE-Mix 
showed ~35% inhibition of tumor growth (Figure 3.14) indicating that the less known partners 
other than 6G, 8G, 10G and 6S also possess significant anticancer potential.  
 
Despite the increasing popularity of whole food extracts, their pharmacokinetic (PK) and 
absorption, distribution, metabolism and excretion (ADME) data are scant or lacking. Many 
components of most food extracts undergo Phase I and/or Phase II metabolism in vivo, with 
cytochrome P450s (CYPs) and uridine diphosphate glucuronosyltransferases (UGTs) majorly 
dictating overall bioavailability of the active components in the human body upon ingestion 
(Calani et al., 2012; Manach et al., 2004; Manach et al., 2005; Silberberg et al., 2006).  To the 
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best of our knowledge, no studies have yet compared the PK and bioavailability of the active 
components when fed as single-agents or fed in their natural extract setting. Indeed, the 
pharmacological activity is gained only when the “active agents” or “active metabolites” attain 
as well as sustain appropriate levels so that they can be optimally distributed to the tumor tissue 
for therapeutic action. In our context, we found no studies that have compared the bioavailability 
of ginger phytochemicals when they are fed as an artificially formulated mixture of single-agents 
(at concentrations identical to those present in the natural extract), to the whole extract 
(phytochemicals present in their natural milieu). Keeping in mind the collaborative interactions 
among GE phytochemicals, we conducted PK studies to recognize any differences in the 
bioavailability of 6G, 8G, 10G and 6S when they are consumed as GE or Mix.  
 
The pharmacokinetic profiling of the four GE components upon oral administration of 
250 mg/kg of GE or Mix revealed that there were multiple Cmax peaks observed in case of GE, 
compared to a single peak in Mix (Figure 3.11A,B). This multiple peaking phenomenon, 
associated with re-circulation of compounds from intestine to systemic circulation after getting 
eliminated through bile was not observed when pure GE phytochemicals were orally gavaged as 
a Mix (Figure 3.11B). Furthermore, the plasma concentrations of the four GE components were 
short-lived, when present in Mix (Figure 3.11D). The β-glucuronidase hydrolysis of both plasma 
and feces samples obtained post-intravenous administration of pure ginger biophenolics (Figure 
3.13Ai, Aii) confirmed that the gingerols re-enter the liver via hepatic portal vein from the 
intestine for re-absorption into the systemic circulation. Gingerols when fed as GE mimicked this 
phenomenon and exhibited multiple Cmax values whereas Mix was eliminated from the body 
within 2 h of feeding. In addition, a higher percentage of unbound gingerols were observed in 
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GE compared to Mix (Figure 3.13B), which may aid in the enhanced availability of ginger 
phenolics at the target sites in the former setting. Our observations clearly indicate that GE 
phytochemicals exert maximum therapeutic properties when present in their natural setting of a 
complex plant matrix along with other indispensable partners. 
 
Figure 3.15 GE is more efficacious than the Mixture of its active constituents. 
After oral dose administration of Mix to mice, gingerols were eliminated at a faster rate 
compared to when GE was dosed. After administering GE, the exposure of gingerols was more 
due to enterohepatic recirculation of gingerols, thus conferring GE improved efficacy in 
inhibiting prostate tumor growth compared to Mix. 
 
However, the intriguing question to ponder is how EHR of 6G, 8G and 10G is facilitated 
in case of oral GE feeding and why is it not the same with Mix? A major challenge associated 
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with consumption of xenobiotics that undergo phase II metabolism like anthocyanins, flavanoids, 
polyphenols etc. is their lack of in vivo bioavailability. The therapeutic benefits of polyphenols 
are often the result of coupled metabolic activities of efflux/uptake transporters and conjugating 
enzymes, which play a major role in drug metabolism, elimination and detoxification (Bravo, 
1998; Jana and Mandlekar, 2009; Olson et al., 1992; Wells et al., 2004). Conjugating enzymes 
like UGTs and sulfotransferases (SULTs) conjugate phenolic compounds to produce hydrophilic 
metabolites (Gregory et al., 2004; McCarver and Hines, 2002; Ritter, 2000), which by the action 
of chemical pumps, also known as efflux transporters, can be diffused out of the cells. Gingerols 
undergo conjugation in various organs including small intestine, liver and kidneys to avoid their 
toxic accumulation and hence get eliminated from the system. However, sometimes, these pumps 
function as gatekeepers of excess metabolism and thus enable enterohepatic recycling of 
phenolics resulting in their re-absorption and improved half-lives. This phenomenon is better 
explained via the “revolving door” theory (Liu and Hu, 2007; Manach et al., 2004), which 
emphasizes that effective elimination of hydrophilic phase II metabolites of xenobiotics depend 
on chemical pumps. When their rate of conjugation exceeds that of elimination, these 
metabolites tend to accumulate inside the cell, which may lead to toxicity. During such adverse 
conditions, a reverse reaction, where the de-conjugating enzymes like glucuronidases present in 
various organs including liver and intestine, release the free forms of these metabolites into the 
system, can be favorable (as illustrated in Figure 3.15). In such cases, the re-absorption of active 
constituents in lower amounts may actually prove to be beneficial than become toxic due to the 
build up (Liu and Hu, 2007).  
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Considering the perks of the revolving door mechanism in the cells of gastrointestinal 
system, we thus strongly believe that the re-absorption of gingerols after oral feeding of GE 
could be responsible for its superior efficacy over Mix (Figure 3.15). It is reasonable to speculate 
that that EHR as seen in case of whole extract (GE) could likely be occurring due to the fact that 
a wide variety of molecules (from GE) undergo conjugation at a given time resulting in a 
possible elimination lag of the “bioactive” components compared to Mix, which is only made up 
of the four bioactive phenolics. It is also likely that the whole extract offers a competition due to 
the varying binding affinities of different molecules for UGTs, and the most-active molecules are 
retained in their unconjugated state at the expense of the “less active” components, which get 
eliminated. This would perhaps explain enhanced transport of free active gingerols to the tumor 
tissues. This intricate “compensatory” or “buffering” mechanism offered by the complex 
phytochemical network is lacking for the gingerols in Mix, and perhaps may result in their faster 
elimination, which might underlie the sharp attenuation of efficacy. Indeed, mechanistic insights 
on the different phase II enzyme systems that occupy ‘center-stage’ in the elimination kinetics of 
ginger phytochemicals will empower us with new knowledge and may result in a conceptual 
advancement to develop logically driven rational chemoprevention.  
 
In conclusion, our study is the first of its kind to provide encouraging evidence that 
several ginger phytochemicals display significant synergistic antiproliferative effects in prostate 
cancer cells when combined at low concentrations with each other. Nonetheless, various binary 
combinations of ginger phytochemicals at defined concentrations relative to each other showed 
antagonistic effects. Our study further emphasizes the existence of a complex collaborative 
interplay among GE phytochemicals to confer maximum therapeutic benefits due to its favorable 
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absorption kinetics and bioavailability. Our observations of possible EHR of gingerols, when 
delivered in their natural matrix are compelling and provide impetus to investigate and design 
futuristic combinations/dietary supplements for prostate cancer management.  
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4     “XENOHORMETIC” PROOXIDANT/ANTIOXIDANT POTENTIAL OF 
DIETARY PHYTOCHEMICALS4 
4.1 Abstract 
Plant extracts, a concoction of bioactive non-nutrient phytochemicals, have long served 
as the most significant source of new leads for anticancer drug development. Explored for their 
unique medicinal properties, the leaves of Piper betel, an evergreen perennial vine, are a 
reservoir of phenolics with antimutagenic, antitumor, and antioxidant activities. Here we show 
that oral feeding of betel leaf extract (BLE) significantly inhibited the growth of human prostate 
xenografts implanted in nude mice compared to vehicle-fed controls. To gain insights into the 
‘active principles’, we performed a bioactivity-guided fractionation of methanolic BLE 
employing solvents of different polarity strengths using classical column chromatography. This 
approach yielded 15 fractions, which were then pooled to 10 using similar retention factors on 
thin-layer chromatographs. Bioactivity assays demonstrated that one fraction in particular, F2, 
displayed a 3-fold better in vitro efficacy to inhibit proliferation of prostate cancer cells than the 
parent BLE. The presence of phenols, hydroxychavicol (HC) and chavibetol (CHV), was 
confirmed in F2 by NMR, HPLC, and mass spectroscopy. Further, the HC containing F2 sub-
fraction was found to be ~8-fold more potent than the F2 sub-fraction that contained CHV, in 
human prostate cancer PC-3 cells as evaluated by the MTT assay. Removing CHV from F2 
remarkably decreased the IC50 of this fraction, indicating that HC is perhaps the major bioactive 
constituent, which is present to an extent of 26.59% in BLE. Further, hydroxychavicol (HC), 
extracted and purified from Piper betel leaves, was observed to significantly inhibit growth and 
                                                
4 This chapter has been published verbatim in Carcinogenesis 2013 as Piper betel leaf 
extract: anticancer benefits and bio-guided fractionation to identify active principles for prostate 
cancer management and	   Toxicol. Appl. Pharm. 2014 as Hydroxychavicol, a betel leaf 
component, inhibits prostate cancer through ROS-driven DNA damage and apoptosis.  
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proliferation via ROS generation in human prostate cancer, PC-3 cells. HC perturbed cell-cycle 
kinetics and progression, reduced clonogenicity and mediated cytotoxicity by ROS-induced 
DNA damage leading to activation of several pro-apoptotic molecules.  In addition, HC 
treatment elicited a novel autophagic response as evidenced by the appearance of acidic vesicular 
organelles and increased expression of autophagic markers, LC3-IIb and beclin-1. Interestingly, 
quenching of ROS with tiron, an antioxidant, offered significant protection against HC-induced 
inhibition of cell growth and down regulation of caspase-3, suggesting the crucial role of ROS in 
mediating cell death. The collapse of mitochondrial transmembrane potential by HC further 
revealed the link between ROS generation and induction of caspase-mediated apoptosis in PC-3 
cells. Our data showed remarkable inhibition of prostate tumor xenografts by ~72% upon daily 
oral administration of 150 mg/kg bw HC by quantitative tumor volume measurements and non-
invasive real-time bioluminescent imaging. HC was well-tolerated at this dosing level without 
any observable toxicity. This is the first report to demonstrate the anti-prostate efficacy of HC in 
vitro and in vivo, which is perhaps attributable to its selective prooxidant activity to eliminate 
cancer cells thus providing compelling grounds for future preclinical studies to validate its 
potential usefulness for prostate cancer management. 
4.2 Introduction 
Demographic studies have reported discernible variations in prostate cancer incidence 
across the globe. Known to be one of the deadliest diseases, its mortality rate is higher in 
Westerners compared to Asians (Parkin et al., 2005). Given the long latency of prostate cancer, it 
is believed that, although the disease initiates concurrently among these cultures, its progression 
is much slower compared to the Western population. Such ethnic disparities have been 
reportedly linked to differences in dietary regimens that impart both chemotherapeutic and 
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preventive benefits (Shukla and Gupta, 2005). Indisputable evidence indicates that a diet rich in 
lycopenes, legumes, cruciferous vegetables, curcumin, and gingerols has been associated with a 
reduced risk of prostate cancer (Chan et al., 2009).  
 
Fruits, vegetables, and spices with their antioxidant and detoxifying properties, can revert 
and delay the progression of prostate cancer mainly due to their abundance in polyphenols that 
offer multifarious health-promoting benefits (Cooke et al., 2005; Craig, 1999; Kaur et al., 2009; 
Surh, 2003; Yang et al., 2001). Polyphenols have been reported to be highly effective in fighting 
various chronic diseases like diabetes and cancer. Recent years have indeed witnessed a revival 
of interest in plant phytochemicals, especially polyphenols, as potential chemopreventive and 
chemotherapeutic agents. Intriguingly, the redox moieties of these compounds display a two-
pronged approach to confer their unique “dual ability” (Quideau et al., 2011). While the 
chemopreventive efficacy at low concentrations in normal cells is due to these compounds’ 
antioxidant properties (Quideau et al., 2011), other species of polyphenols can act as pro-
oxidants at higher concentrations in cancer cells and generate ROS, further inducing DNA 
damage and eventually apoptosis, thereby acting as potential chemotherapeutic agents (Quideau 
et al., 2011). The relative natural abundance of polyphenols, their specificity towards cancer 
cells, and thus lack of side effects has generated tremendous interest in these versatile molecules, 
emphasizing their advantages over traditional anticancer drugs (Kaur et al., 2009).  
 
Although these phytochemicals exist in leaf, root, or bark as a complex mixture offering 
chemical diversity, their relative abundance is influenced by a number of factors such as 
environmental conditions, cultivation, time of collection, means of extraction, etc. (Johnson et 
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al., 2010; Sasidharan et al., 2011). Since the content of pharmacologically-active constituents 
may vary among crude extracts; hence, it is imperative to identify the bioactive compounds as 
well as establish their optimum concentrations for maximum therapeutic activity (Rathee et al., 
2006; Sasidharan et al., 2011). Isolation of these bioactive constituents and optimization of their 
effective concentrations would result in enhanced bioavailability, pharmacokinetics, and thus 
efficacy (in comparison with their respective crude extracts). For example, the major components 
of Curcuma longa (commonly referred to as turmeric) are curcumin, demethoxycurcumin 
(DMC), and bisdemethoxy curcumin (BDMC). Extensive studies have revealed the enhanced 
efficacy of curcumin thus potentiating its use as an anticancer agent (Kunnumakkara et al., 
2008). No wonder curcumin, capsaicin, and gingerols derived from the spices turmeric, red chili, 
and ginger, respectively, have entered clinical trials as potential anticancer agents (Sung et al., 
2012).  
 
Polyphenols are major class of phytochemicals known for their disease-fighting and 
stress-defeating properties. The emerging hypothesis of Xenohormesis, a phenomenon by which 
polyphenols resist stress, combat disease, and confer health benefits (Hooper et al., 2010; Howitz 
and Sinclair, 2008) has propelled the evaluation of the role of reactive oxygen species (ROS) in 
dictating health benefits exerted by phenolic phytochemicals. Extensive literature describes the 
two-pronged approach launched by these phenolic compounds, one that regulates 
chemopreventive benefits by enhancing the antioxidant defenses, while the other confers 
chemotherapeutic efficacy due to induction of cellular stress (ROS levels) leading to cell death 
(Lamming et al., 2004; Surh, 2011; Trachootham et al., 2009). Several studies suggest that 
cancer cells display higher reactive oxygen species (ROS) concentrations compared to normal 
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cells (Schumacker, 2006; Szatrowski and Nathan, 1991; Trachootham et al., 2009) and thus an 
increase in ROS levels can easily tip off the balance in cancer cells due to their higher baseline 
levels of ROS to result in cell death (Trachootham et al., 2009).  
 
Inequalities in basal ROS levels in normal and cancer cells can perhaps be ascribed to 
increased metabolic activity in the latter, which creates a persistent prooxidative condition 
(Trachootham et al., 2009). In cancer cells, while moderate or controlled ROS levels lead to 
survival adaptations that promote their growth and progression, a further increase to higher levels 
can induce cell death. Excessive levels of ROS disrupt the redox balance maintained in cancer 
cells by either irreversibly damaging cellular macromolecules including carbohydrates, lipids, 
proteins and DNA or by interfering with the regulation of redox signaling proteins at 
transduction or transcriptional levels (Gibellini, 2010). Cancer cells can succumb to death due to 
these high ROS levels via several mechanisms including apoptosis, necrosis, autophagy, mitotic 
catastrophe, and even due to the loss of drug-resistance adaptation (Surh, 2003). Intrinsically 
driven apoptosis due to excess ROS is mediated directly through the mitochondria and involves 
the opening of permeability transition (PT) pore complex followed by release of cytochrome c 
into the cytosol, which triggers the caspase cascade culminating in cell death (Gibellini, 2010). 
Thus, drugs that act as prooxidants and tip over the ROS balance in cancer cells by promoting 
the leakage of free radicals from the mitochondria may prove to be valuable anticancer 
therapeutics. Although plant phenolics have been long known to have antioxidant functions, their 
role in enhancing ROS levels is emerging.  
 
Chemically, polyphenols are redox moieties and this property confers on them the unique 
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dual ability to quench as well as generate ROS (Decker, 1997; Sakihama et al., 2002). The 
chemopreventive efficacy of certain polyphenols lies in their antioxidant properties and their 
ability to scavenge ROS thereby reducing oxidative stress. Such species at low concentration and 
in normal cells would act as chemopreventive agents (Bouayed and Bohn, 2010; Surh, 2011). 
Other species of polyphenols can act as prooxidants and generate ROS. The ROS surge induces 
DNA damage and eventually apoptosis thereby exerting a potential chemotherapeutic action 
(Martin and Barrett, 2002; Trachootham et al., 2009). Such species are effective at higher 
concentrations in cells with higher levels of oxidative stress (Azam et al., 2004).  Literature 
suggests that polyphenols with catechol and/or pyrogallol groups can exhibit prooxidant 
properties, either by reducing iron (III) or copper (II) ions while chelation or by the reaction of 
ortho-hydroxyphenoxy radical, produced from their oxidation, with other free-radical species to 
oxidize ortho-quinones and O2- (Mira et al., 2002). Thus, the unique properties that include relative 
abundance in nature, lack of selectivity-related side effects, and patient compliance, which 
potentially underscore their anticancer benefits, have kindled a lot of interest in the recent times 
to further investigate the phenolic phytochemicals.   
 
Piper betel leaves (Piper betel Linn.), also referred to as green gold (Bhide et al., 1991b), 
are widely consumed as a condiment in Africa and Asia (especially India and Taiwan). The 
medicinal properties of Piper betel can be traced back to ancient Vedic literature. Rich in 
phenols and terpenes, these leaves have been reported to exhibit antioxidant, anti-inflammatory, 
immunomodulatory, and antitumor activities (Bajpai et al., 2010; Bhattacharya et al., 2005; 
Kumar, 2010). Literature reports suggest that hydroxychavicol (HC), an active constituent of 
betel leaves, is effective in impeding cell cycle progression of prostate cancer and oral KB 
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carcinoma cells. Also, HC has been shown to impart anti-mutagenicity, antiulcerogenic, and 
antioxidative properties specifically against cancer cells. There have also been speculations 
regarding its stress-inducing properties. However, there is a dearth of data emphasizing the in 
vivo efficacy of HC and its prooxidant nature in prostate cancer cells, which could potentially 
lead to its development as a single-agent chemotherapeutic agent or in an adjuvant setting.  
 
In this chapter we report the previously unknown benefits of betel leaves in prostate 
cancer, as well as a systematic fractionation of the leaf extract to identify the active principles. 
This study presents the first identification of the anticancer attributes of betel leaf extract (BLE) 
in inhibiting prostate cancer growth in mice models, as well as emphasizes hydroxychavicol as a 
major contributor of its in vitro and in vivo efficacy in prostate cancer models. Also, we present 
the prooxidant property of HC obtained from betel leaves, as well as its anticancer mechanisms 
in in vitro and in vivo prostate cancer models emphasizing the HC-induced ROS effects on 
various pathways.  
4.3 Materials and Methods 
4.3.1 Cell culture, chemicals and reagents 
Piper betel leaves were purchased from the local farmer's market in Atlanta, GA. 
Hexanes, ethyl acetate (EtOAC), dichloromethane (DCM), and methanol (MeOH) were obtained 
from Fisher Scientific (Pittsburgh, PA). Thin-layer chromatography (TLC) plates were from 
EMD chemicals (Billerica, MA). Androgen-independent prostate cancer cells, PC-3, DU145, 
C4-2 and 22Rv1 were purchased from American Type Culture Collection (ATCC, Manassas, 
VA) were cultured in RPMI-1640 media supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) and 5% penicillin/streptomycin. The normal prostate epithelial, RWPE-1 cells 
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purchased from American Type Culture Collection (ATCC, Manassas, VA) were cultured in 
Keratinocyte-SFM medium kit (Invitrogen, Grand Island, NY) supplemented with 10% heat-
inactivated fetal bovine serum (FBS). Luciferase-expressing PC-3 cells (PC3-luc) were from 
PerkinElmer (Hopkinton, MA) and were maintained in MEM medium with 10% FBS, Hyclone, 
(Pittsburgh, PA). All the cell lines were made sure to be devoid of mycoplasma contamination 
using Universal Mycoplasma Detection Kit from ATCC (ATCC, Cat#30-1012K, Manassas, 
VA). The MTT dye (thiazolyl blue tetrazolium bromide, 98% TLC), Acridine orange (AO), 
2’,7’-dichlorofluorescein diacetate (DCFDA), chloroquine, 3-methyladenine (3-MA), dimethyl 
sulfoxide (DMSO), Hoechst stain, eugenol (EU), and preparative TLC plates and β-actin 
antibody were from Sigma (St. Louis, MO). Dihydroethidium (DHE), 4,5-dihydroxy-1, 3-
benzenedisulfonic acid disodium salt monohydrate (tiron), 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolyl carbocyanine iodide (JC-1), apocynin, rotenone and cyclosporin A 
were from Fisher Scientific. The concentrations of the above reagents used in the study were: 
100 µM HC, 25 µg/ml of AO, 5 µM DHE, 25 µM DCFDA, 2.5 µg/ml of JC-1, 0.5 mM 3-MA; 1 
mM tiron, 100 nM rotenone, 10 µM apocynin and 5 µM cyclosporin A. Primary antibodies for 
beclin-1, light chain 3 (LC3IIb), cleaved caspase-3, cleaved PARP, γ-H2AX, and cytochrome c 
were from Cell Signaling (Beverly, MA). MitoTracker Red, Alexa 488- or 555-conjugated 
secondary antibodies were from Life Technologies (Grand Island, NY). Horseradish peroxidase-
conjugated secondary antibodies were from Santa Cruz Biotechnology, Inc. Hydroxychavicol 
(HC) was extracted from betel leaves and was characterized for >99% purity.  
4.3.2 Preparation of methanolic betel leaf extract and Isolation of HC from betel leaves  
Freshly cut betel leaves were lyophilized to remove any moisture present. Freeze-dried 
leaves were soaked in methanol overnight for three consecutive days. The supernatant was 
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collected daily, concentrated under reduced pressure, and lyophilized to remove any traces of 
moisture. The dried BLE was then stored at -80oC. Batch-to-batch variation was assessed by 
quantitating HC content via HPLC-UV analysis, and no significant variations were observed in 
the three batches processed. 
Freshly chopped Piper betel leaves were submerged in deionized water and extraction 
was carried out in a boiling apparatus for 3 h followed by collection of the supernatant by 
filtration for three consecutive days. The pooled supernatant was then concentrated to 1/12th of 
the original volume under reduced pressure at a temperature of 50oC. This concentrated aqueous 
extract was further extracted 6 times in a separating funnel with 250 ml of DCM each time, 
followed by vacuum filtration through celite bed. The resultant clear DCM fraction was then 
concentrated under reduced pressure. The residue was then subjected to silica gel column 
chromatography (100-200 mesh) where the elution was initiated with a total of 1400 ml of DCM 
followed by 800 ml of 1% MeOH in DCM. Fractions of 100 ml each were collected and 
subjected to TLC in DCM:MeOH (19:1). The fractions 4-22 were found to contain pure HC and 
thus were pooled and concentrated under vacuum. HC was further characterized by spectral 
analysis for both quantitation and >99% purity via HPLC.   
4.3.3 Fractionation of BLE and identification of constituents using chromatography 
techniques  
We employed column chromatography, a commonly used analytical technique to 
separate the constituents of betel leaves. Three grams of BLE was dissolved in methanol, and 
adsorbed on silica gel (0.063-0.2 mm, 70-230 mesh) using a rotary evaporator. The column (3.5 
cm*45 cm) was filled with silica and the BLE-adsorbed silica mixture was added atop the silica 
followed by a layer of anhydrous sodium sulfate to remove any moisture. The column was then 
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subjected to solvents of increasing polarity, the order being hexane < dichloromethane < ethyl 
acetate < methanol. The eluents were 100, 70, 50, and 30% hexane/ethyl acetate (500 ml each) 
followed by 500 ml of 10, 20, 30, 40, and 50% ethyl acetate/dichloromethane and 99.5, 99, 97, 
95, 90, and 70% dichloromethane/methanol. The 15 fractions eluted were concentrated, and 
traces of solvents were removed by lyophilization and then subjected to thin layer 
chromatography (TLC). Pre-coated alumina TLC silica gel 60 F254 plates were used and the spots 
were analyzed under UV light. Based on similar pattern and retention factors, the fractions were 
pooled together to finally yield 10 fractions. 
Each fraction obtained from column chromatography was spotted on a TLC plate 
(Alumina TLC silica gel 60 F254) along with the standards, HC and EU, and run through a series 
of solvent systems. The solvent systems used for TLC of various fractions were as follows: F1-
F3--70:30 hexane/ethyl acetate; F4-F7--10:90 ethyl acetate/dicholoromethane; F8-F12--5:95 
methanol/dicholoromethane; F13-F15--15:85 methanol/dicholoromethane. Once developed, the 
plates were screened for HC and EU by comparing the bands obtained for each fraction with the 
bands corresponding to the standards. The presence of HC and EU was confirmed by co-spotting 
the fraction with the standard compounds. 
The individual constituents of BLE were further separated using preparative TLC 
method. 100 mg of each fraction was loaded on the plate, a binary mobile phase of 30% ethyl 
acetate in hexane was used as the solvent system, and the plate was developed in a glass 
chamber. The constituents separated as bands were scraped, dissolved in DCM, filtered, and 
concentrated for testing. 
142 
4.3.4 Nuclear magnetic resonance (NMR), High-performance liquid chromatography 
(HPLC) with UV and mass-spectrometric detection 
1H NMR spectra were recorded on Bruker Avance (400 MHz) spectrometer vertical bore 
spectrometer using 5 mm high-resolution probes, using CDCl3, CD3OD, or DMSO-d6 as solvent.  
Mass spectra (ESI-MS, positive ion mode) were recorded on a nanoLC-Q-TOF micro (Waters 
Micromass) mass spectrometer. 
The HPLC-UV analysis of BLE was achieved on a HP1100 series instrument (Agilent 
Technologies, Wilmington, DE) equipped with a photodiode array detector, using an Agilent 
XDB reversed phase (C-18, 1.8 µm, 4.6 x 50 mm, ODS-2) column. The mobile phase system 
consisting of solvent A (1.5% acetic acid in water) and solvent B (1.5% acetic acid in acetonitrile 
(ACN)) was employed to achieve the separations. The gradient elution was set as follows: initial 
8% B for 5 min, achieving 20% B at 60 min, which was held for an additional 5 min; this was 
followed by reconditioning to 8% B at 70 min and holding it for the next 5 min with a flow rate 
of 1 ml/min. 20 µl of BLE (1 mg/ml), dissolved and filtered in pure methanol, was injected into 
the system and the resultant HPLC-UV peaks were detected at 280 nm.  
The HPLC-MS analyses were performed in tandem with HPLC-UV using the same 
column interfaced to an Agilent 6400 Series Triple quadrupole LC/MS equipped with an 
electrospray ionization source, operable in both positive and negative ion modes. The nebulizer 
and collision gases were nitrogen and helium, respectively, with nitrogen set at 40 psi. A drying 
gas temperature of 300oC, drying gas flow rate of 9 l/min, and capillary voltage of ±3000V were 
the spray chamber specifications. The presence of HC (m/z = 151) in BLE was confirmed using 
MS-scan mode against pure standard. 
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4.3.5 Antiproliferative MTT assay 
Androgen-independent human prostate cancer cells, PC-3, DU145, C4-2 and 22RV1, 
were seeded in 96 well plates at a density of 3500 cells per plate. After 24 hours of incubation, 
the medium was aspirated and replaced by media dosed with BLE at concentrations of 1, 10, 25, 
50, 75, 100 and 250 µg/ml and HC at concentrations of 1, 10, 25, 50, 75, 100 and 250 µM. 
Primary stocks were prepared by dissolving each fraction in DMSO at a concentration of 1 
mg/ml BLE and 25 mM HC. The secondary stock of each fraction was made at a concentration 
of 250 µg/ml BLE and 250 µM HC followed by further dilutions. A total volume of 100 µl was 
added to each well.  After 48 hours of incubation the drug-containing medium was aspirated and 
100 µl of MTT (Tetrazolium bromide 5mg/ml) dye dissolved in RPMI was added. Following 4 
hours of incubation, the MTT dye was aspirated and the formazan crystals were solubilized in 
DMSO. Chromophoric groups in MTT (yellow) were reduced to a purple tetrazolium complex 
by viable cells and the absorbance was read at 570 nm using a SpectraMax Plus (Molecular 
Devices, Sunnyvale, CA) multi-well plate reader. 
4.3.6 Trypan blue and colony survival assay 
5000 PC-3 cells plated in a six-well format were treated with 100 µM of HC the next day. 
Following 24 h of HC treatment, cell-proliferation was determined using Trypan blue assay. For 
the colony assay, PC-3 cells were seeded at appropriate dilutions (~100 cells/well) and were 
treated with 100 µM HC for 24 h, washed, and replaced with regular RPMI-medium. The 
crystal-violet colonies (each consisting of at least 50 cells) were counted post fixation with 4% 
formaldehyde solution. 
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4.3.7 Measurement of ROS 
PC-3 cells were seeded in 96 well plates and after 24 h of incubation, the medium was 
aspirated and the cells were pre-treated with either DHE (oxidized by ROS into ethidium 
bromide and fluoresces red) or DCFDA (oxidized by ROS to DCF) for 30 min and then treated 
with HC at concentrations of 50, 100 and 150 µM. Following treatment for 0.5, 1, 3, 6 and 12 h, 
the induction of ROS was measured using fluorimetry. Further, fluorescently labeled cells 
stained with either DHE or DCFDA were analyzed flow cytometrically. Furthermore, DHE and 
DCFDA stained cells on coverslips were examined using fluorescence microscopy. The source 
of ROS was determined by fluorimetry in the presence of inhibitors like rotenone, cyclosporine 
A and apocynin. 
4.3.8 Cell-cycle studies  
PC-3 cells treated with 100 µM HC for 6, 9, 12, 18, and 24 h, were lysed, centrifuged, 
washed with ice-cold PBS, fixed in 70% ethanol and stored at 4°C. Pellets were collected, 
washed twice with PBS and stained with propidium iodide in the presence of RNaseA for 45 min 
in the dark. Cell cycle profile was analyzed by flow cytometry.  
4.3.9 Immunofluorescence Microscopy 
PC-3 cells grown on coverslips were treated with 100 µM HC, and/or followed by live 
staining with MitoTracker (100 nM; Ex:Em::579:599) and were then fixed with ice-cold 
methanol for 10 min. This was followed by blocking with 2% bovine serum albumin/PBS at 
37°C for 1 h. The coverslips were then incubated with γ-H2AX, cleaved PARP, cleaved caspase-
3 and cytochrome c antibodies (1:100 dilution) 37°C for 1 h, which were then washed with 2% 
bovine serum albumin/PBS for 10 min at room temperature and incubated with 1:500 dilution of 
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Alexa 488- (Ex:Em::499:519) or 555- (Ex:Em::553:568) conjugated secondary antibodies. The 
coverslips were then mounted with Prolong Gold antifade reagent containing 4’,6-diamidino-2-
phenylindole (Invitrogen).  
4.3.10 Immunoblotting 
Protein lysates were collected from cells treated with or without 100 µM HC and were 
resolved by SDS-PAGE, followed by a transfer onto polyvinylidene difluoride membrane that 
was incubated with a primary antibody of choice overnight at 4°C. Appropriate secondary 
antibody was used followed by visualization of the immune-reactive bands by 
chemiluminescence detection kit (Pierce). β-actin was loading control. The cleaved caspase-3 
(Figure 3Ai) and beclin-1 (Figure 5Bi) protein expressions were developed from the same blot. 
4.3.11 Detection and Quantification of Acidic Vesicular Organelles (AVOs) 
PC-3 cells grown on coverslips followed by treatment with 100 µM HC for 24 h along 
with controls were stained with 25 µg/ml of AO for 30 min, washed twice with PBS, and fixed 
using ice-cold methanol. The mounted coverslips were examined under a Zeiss (Axioplan-2) 
fluorescence microscope (63X objective) for the presence of AVOs, which were also further, 
confirmed and quantified by flow cytometry.  The fluorescence emissions, green (510–530 nm) 
and red (650 nm), from 5000 cells obtained by illuminating with blue (488 nm) excitation light 
were measured using a FACS Calibur flow cytometer. The red:green fluorescence ratio for each 
cell was obtained using FlowJo software (Karna et al., 2010; Millot et al., 1997). 
4.3.12 Electron Microscopy 
Cells from control and 100 µM HC-treated samples were collected and fixed for 2 h in 
2% paraformaldehyde, 0.1% glutaraldehyde in 0.1 M sodium cacodylate, then fixed for 1.5 h 
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with 1% osmium tetroxide, followed by washing, and staining en bloc in 1% aqueous uranyl 
acetate (pH 3.3) for 1 h. The samples were then washed and dehydrating with a series of ethanol 
solutions (through 3 x 100%). These were then embedded in Spurr epoxy resin (Electron 
Microscopy Sciences) of which ultrathin sections were cut on a RMC-MYX ultramicrotome, and 
examined on a LEO 906e transmission electron microscope after counterstaining with lead 
citrate. 
4.3.13 In vivo tumor growth and bioluminescent imaging 
PC-3-luc cells (1x106) were subcutaneously injected on either flank of six-week old male 
BALB/c nude mice (Harlan Laboratories, Inc., Indianpolis, IN). When tumors were palpable, 
mice were randomly divided into four groups of five mice each. Control group received vehicle 
(PBS with 0.05% Tween-80, pH=7.4) and the three treatment groups received 200, 400, and 650 
mg/kg body weight BLE dissolved in PBS with 0.05% Tween-80 (pH=7.4) by oral gavage daily. 
In another independent experiment the control group received vehicle (PBS with 0.05% Tween-
80, pH=7.4) and the treatment group received 150 mg/kg body weight HC (dissolved in PBS 
with 0.05% Tween-80 (pH=7.4)) by oral gavage daily. Tumor growth was monitored by 
measuring the luciferase activity in live mice by bioluminescent imaging in real-time using the 
IVIS in vivo imaging system (PerkinElmer, Inc., Hopkinton, MA) with the Live Imaging 
software. Briefly, mice anesthetized with isoflurane were intraperitoneally injected 25-30 mg/ml 
luciferin and imaged with a CCD camera. An integration of 20 s with four binnings of 100 pixels 
was used for image acquisition. The relative photon quantitation at the tumor site of the mice 
from vehicle- or BLE-treated or HC-treated groups was quantitated twice a week for six weeks. 
All animal experiments were performed in compliance with institutional IACUC guidelines.  
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4.3.14 Immunofluorescence and immunohistochemical staining 
Paraffin-embedded tumor sections from vehicle and BLE-treated groups were processed 
and immunostained with apoptotic markers, cleaved caspase-3 and cleaved PARP, the 
proliferation marker, Ki67 and hematoxylin and eosin (H&E). Images were captured using 
fluorescence microscopy. Microscopic evaluation was performed by a pathologist in a blinded 
manner. Organs and tumors collected from HC- or vehicle-fed mice after 6 weeks of treatment 
were formalin-fixed or frozen immediately post-euthanasia. The tumor and organ sections were 
cut (5 µm) and stained with hematoxylin and eosin (H&E), cleaved caspase-3 and cleaved 
PARP. A pathologist performed blind-mannered microscopic evaluation of all the sections. 
Complete blood count was performed on blood samples collected from vehicle- and HC-fed 
C47BL6/J mice (3 per group) after consecutive oral administration of vehicle and HC (150 
mg/kg bw) for 3 days. 
4.3.15 Determination of half-maximal lethal dose (LD50) and acute in vivo toxicity  
C47BL6/J mice were fed with very high doses (5g/kg and 2 g/kg bw) of BLE or HC and 
followed by observation of their health conditions. BLE or HC were fed to mice at various doses 
to determine the dose at which 50% of the mice in the BLE- or HC-fed group are alive (LD50).  
4.3.16 Statistical analysis 
All the experiments were repeated at least 3 times. Values from quantitative experiments 
are expressed as the mean ± standard deviation (SD) and were calculated using Microsoft-Excel 
software. The Student’s t-test and a two-way analysis of variance (ANOVA) were performed to 
determine the differences between the control and treatment groups. P-values <0.05 were 
considered as statistically significant.  
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4.4 Results 
4.4.1 BLE induces apoptosis and inhibits proliferation of tumor growth in vivo 
Betel leaves have been shown to exhibit antiproliferative, antimicrobial, and 
immunomodulatory properties. Considering the disease-fighting potential of BLE, we first 
examined its in vivo efficacy to inhibit human prostate tumor xenografts implanted 
subcutaneously in athymic nude mice. We used a stable PC-3 cell line that expresses luciferase 
(PC-3-luc), which enables real-time visualization and non-invasive monitoring of prostate cancer 
growth longitudinally in mice. In an experiment to determine the half-maximal lethal dose 
(LD50), we found that 700 mg/kg bw BLE was not well-tolerated. Animals showed evident signs 
of discomfort and were thus euthanized at day 6.  Next, we performed a dose-dependent study 
comprising five mice in each of four groups that were fed with vehicle (PBS) and 200, 400, or 
650 mg/kg bw BLE daily by oral-gavage for six weeks. Treatment responses were monitored 
twice a week by bioluminescent imaging (Figure 4.1A). Our data show that BLE-treated groups 
display inhibition of tumor growth significantly over six weeks in contrast to vehicle-treated 
control animals (Figure 4.1A, B). Relative photon quantitation revealed that 400 mg/kg bw BLE 
showed a ~61% inhibition in tumor volume at a confidence level of p<0.05 (n=5 Figure 4.1A), as 
measured at week 6 compared to vehicle-treated controls. Body weights were recorded twice a 
week to assess general health and well-being of animals during treatment. Mice in the BLE 
treatment groups exhibited normal weight gain with no signs of discomfort during the treatment 
regimen. All animals in the control group were euthanized by day 42 post-inoculation due to 
tumor overburden, in compliance with IACUC guidelines. At the end of week six, the excised 
tumors (Figure 4.1E) were weighed post-euthanasia, and a ~59% reduction in tumor weight was 
recorded in a subset of mice from 400 mg/kg bw BLE-treated group compared to controls. 
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Though the 650 mg/kg bw BLE-fed group showed significant inhibition of tumor growth, mice 
could not tolerate the dose beyond four weeks of treatment (Figure 4.1Ai). These mice showed 
loss of appetite and weight (Figure 4.1C) and were euthanized at week four.  
 
Figure 4.1 Dietary feeding of BLE showed inhibition of human prostate tumor xenograft 
growth in nude mice. 
Male nude mice were subcutaneously injected with 106 PC-3-luc cells. (Ai) Bioluminescent 
images indicating progression of tumor growth of various dose groups over 6 weeks. (Aii) 
Graphical representation of photon quantitation from vehicle-treated mice and varying doses of 
BLE-treated mice for 6 weeks. (B) Tumor growth monitored by vernier calipers and presented as 
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tumor volume in cubic millimeter, over a period of 6 weeks. (C) Graphical representation of 
body weight of vehicle-treated mice and varying doses of BLE-treated mice. (D) Survival graphs 
of BLE dose-dependent treatment and controls over 9 weeks. (Ei) Photographic images of 
excised tumors and (Eii) Graphical representation of tumor weight. The data points and the error 
bars represent average values and standard deviations, respectively, of all the animals in each 
group (*P < 0.05 compared with controls using two-sample t-test). 
 
The longevity of surviving mice in 400 mg/kg bw fed treatment group was monitored 
based on general health and well-being of the mice after BLE feeding was suspended at week 6. 
Kaplan Meir analysis revealed that this treatment group exhibited 60% survival until nine weeks 
(Figure 4.1D). Furthermore, biochemical analysis of serum markers (alanine transaminase, 
aspartate transaminase, alkaline phosphate, lactic acid dehydrogenase, creatinine kinase, and urea 
nitrogen) was compared between the vehicle- and BLE-fed groups and was found to be within 
the normal range (Figure 4.2). The remarkable efficacy of BLE in inhibiting in vivo tumor 
growth encouraged us to determine the composition of this leaf extract to gain insights into its 
active principles.    
 
Figure 4.2 Organ-associated toxicity was not observed in BLE-fed group. 
 (A) Urea nitrogen levels in BLE-fed group were comparable to that of vehicle-fed group. (B) 
The lactate dehydrogenase (LDH) and creatinine kinase levels in both the groups did not show 
any abnormal differences. (C) The biomarkers of liver, alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), and aspartate aminotransferase (AST) were comparable for both the groups. 
(P<0.06 compared to controls using two-sample t-test). 
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Paraffin-embedded tumor tissue sections from vehicle and BLE-fed mice were processed 
and immunostained for the cell proliferation marker, Ki67 (MIB-1) to evaluate in vivo inhibition 
of tumor growth. Our data showed a decrease in Ki67 expression in tumor sections from BLE-
fed mice suggesting reduction in cell cycle activity upon BLE treatment (Figure 4.3Ai). H&E 
staining of tumor sections from BLE-fed mice revealed large pale pink cytoplasmic areas (Figure 
4.3Aii) indicating clearing of tumor cells. Also, tumor sections from BLE-fed groups showed an 
increase in cleaved caspase-3 and cleaved PARP expression (Figure 4.3Bi-Bii) compared to 
tumor sections from control vehicle-fed groups, implying induction of apoptosis upon BLE 
treatment.  
 
Figure 4.3 BLE induces apoptosis 
(Ai) Ki67 immunostaining, (Aii) hematoxylin and eosin staining and immunofluorescent staining 
for apoptotic markers, (Bi) cleaved caspase-3 and (Bii) cleaved poly (ADP ribose) polymerase of 
tumor sections from vehicle- and BLE-fed mice. 
4.4.2 Identification and quantitation of bioactive constituents of BLE using column 
chromatography 
The non-toxic in vivo attributes of BLE were also confirmed in vitro, wherein the IC50 of 
BLE was found to be ~14 fold higher in normal prostate epithelial RWPE-1 cells (IC50=447 
µg/ml, Figure 4.4) compared to human prostate cancer PC-3 cells (IC50=32 µg/ml, Figure 
4.5C,D). Given the wide therapeutic window, we next aimed to identify and isolate the bioactive 
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constituent/s responsible for the in vivo efficacy of BLE. Thus, we first fractionated BLE using 
classical column chromatography by employing a gradient method to ensure absolute separation 
with a reduced analysis time.  
 
Figure 4.4 Antiproliferative assay of BLE in normal prostate epithelial cells. 
Plot of percentage cell survival vs concentration to measure the half-maximal growth inhibitory 
concentration (IC50) of BLE against normal prostate epithelial, RWPE-1 cells. (P<0.06 compared 
with controls using two-sample t-test) 
 
A series of solvent systems with a gradual increase in polarity were used to elute BLE 
along the silica gel column, and the separated constituents were collected as fractions (Figure 
4.5A). 100% hexane was initially passed through the column to elute non-polar constituents of 
BLE. Ethyl acetate was then introduced into the mobile phase to enhance polarity along with 
dichloromethane, and elution of moderately polar constituents was thus achieved. Finally, 
increasing concentrations of methanol (from 0.5% up to 30%) in combination with 
dichloromethane were used to elute highly polar components (Figure 4.5A). Based on this 
separation scheme, BLE constituents were resolved into 15 fractions followed by subjection to 
analytical TLC. Fractions with comparable retention factor (Rf) values were pooled together to 
finally obtain 10 fractions, F1-F10 (Figure 4.5B), which were tested for their antiproliferative 
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activity using an MTT assay in PC-3 cells. All fractions were concentrated under reduced 
pressure and lyophilized. While processing the first fraction, F1, no visible material was 
observed in the flask and thus this fraction could not be collected.  
 
Figure 4.5 Fractionation of BLE using column chromatography. 
(A) Ten fractions of BLE were obtained from classical chromatography using a gradient method. 
Fifteen fractions eluted were pooled to obtain 10 fractions based on comparable Rf values. H = 
hexane, E = ethyl acetate, D = dichloromethane and M = methanol. (B) TLC of 15 fractions 
using 70:30 hexane/ethyl acetate (1–3), 10:90 ethyl acetate/dichloromethane (4–7), 5:95 
methanol/dichloromethane (8–12) and 15:85 methanol/dichloromethane (13–15) solvent 
systems. Fractions with comparable Rf values were pooled together to obtain 10 fractions. (C) 
Plot of percentage cell survival versus gradient concentration of different fractions. MTT assay 
was performed on fractions F2–F10 and compared with the parent BLE. (D) Bar graphical 
representation of IC50 of each fraction, parent BLE and the standards HC and EU. Data points 
and error bars represent average values and standard deviations, respectively, of three 
independent experiments (P<0.05 compared with controls using two-sample t-test). 
 
The half maximal inhibitory concentrations (IC50) of nine fractions thus obtained are 
shown in Figure 4.5C-D. The least polar fraction, F2, was identified to be the most active with an 
IC50 of 10 µg/ml and showed a 3-fold better activity than the parent extract. The difference in the 
activity of various BLE fractions could be attributed to the presence of constituents varying in 
their polarity, which we attempted to investigate next.  
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Several studies on piper betel leaves have reported that BLE is rich in phenols including 
hydroxychavicol (HC), eugenol (EU), chavibetol (CHV), and allylpyrocatechol (APC) 
(Chakraborty, 2011; Kaur et al., 2009; Rathee et al., 2006). Chemically these compounds 
comprise monocyclic aromatic rings with phenolic and allyl moieties (Paranjpe et al., 2013). 
Preliminary analysis of BLE fractions by TLC using HC and EU as standards (Figure 4.6A) 
revealed that F2 consisted of both EU and HC. However, TLC cannot rule out that the bands 
corresponding to EU and HC in F2 could be compounds with similar polarity including their 
positional isomers like chavibetol (CHV), isoeugenol (IEU), and allylpyrocatechol (APC) 
(Rathee et al., 2006), respectively (Figure 4.6B). While EU was not seen in the later fractions, 
bands corresponding to HC were identified in F3 and F8-F10.   
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Figure 4.6 Qualitative analysis of HC and EU. 
(A) TLC analysis was performed for each fraction and compared with the standards HC and EU. 
Comparable bands revealed that F2 contained both HC and EU. This was confirmed by co-
spotting the fraction with each standard. (B) Chemical structures of polyphenols, EU with its 
positional isomers, isoeugenol and CHV, and HC with its positional isomer, APC. (C) LC-
UV/MS comparison of HC in F2–F10. HC (m/z = 149) was detected in negative ion mode and 
was compared with the pure standard. 
 
Further, co-spotting F2 with HC and EU confirmed the presence of bands corresponding 
to these pure standards. The next step was to examine the presence of HC and EU in all the 
fractions using UV detector equipped high performance liquid chromatography (HPLC-UV) 
coupled with tandem mass spectrometry (MS), an analytical technique with higher sensitivity 
and better separation efficiency. The HPLC-UV/MS analysis of F2-F10 in negative ion mode 
(scan, m/z 100-500) revealed the presence of HC (m/z=149) in all the BLE fractions. However, 
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the abundance of HC in F2 was much higher compared to the rest of the fractions (Figure 4.6C). 
A linear decrease in its abundance was observed in the subsequent fractions and, interestingly, 
F10 was more concentrated in HC compared to F9. The rationale behind the ‘bleed-over’ of HC 
into later fractions could be attributed to the strength of intermolecular hydrogen bonds between 
the stationary silica and HC. With an increase in the polarity of the solvent system, the hydrogen 
bond breakage perhaps results in the spill-over of some residual amounts into the later fractions, 
as detected in HPLC. Seemingly, the final fraction with the highest polarity perhaps completely 
solubilized the residue and thus HC was detectable in F10 as well. In addition, other phenolic 
compounds like chavicol (m/z=133), phenylalanine (m/z=164), hydroxychavicol acetate 
(m/z=191), piperol A (m/z=341), and piperol B (m/z=355) were also detected in the BLE 
fractions. However, the molecular ion peak at m/z=163 could not be confirmed as either EU or 
CHV. Given that the TLC and HPLC/MS data suggested the presence of HC and EU (Figure 
4.6A,C) in F2, we next aimed at identifying the contribution of these individual phytochemicals 
towards F2’s activity.  
4.4.3 Subfractionation of F2 and nuclear magnetic resonance and mass spectrometric 
characterization of F2 subfractions 
Bioactivity-guided fractionation of BLE suggested that F2 (IC50=10 µg/ml) is ~3-fold 
more active than BLE (IC50=32 µg/ml) in human prostate cancer PC-3 cells. We also tested the 
activity of F2 in other prostate cancer cell lines, namely, DU145 and 22Rv1. The IC50 values of 
F2 in DU145 and 22Rv1 were found to be 100 and 39 µg/ml, respectively (Figure 4.7A,B). 
While the IC50 of F2 in DU145 was 1.25 fold lower than that of BLE, 22Rv1 showed only 
slightly lower IC50 of F2 compared to BLE (data not shown). Our results showed that F2’s 
antiproliferative activity is in the following order: PC-3>22Rv1>DU145. PC-3 and DU145 cells 
157 
are androgen-receptor negative and harbor non-functional p53, whereas 22Rv1 cells are 
androgen-receptor positive and harbor wild-type p53. These data suggest that the 
antiproliferative activity was independent of androgen receptor or p53 status in the cell lines 
studied. Having compared the activity of F2 against different prostate cancer cell lines, our next 
step was to determine the bioactive constituents accountable for F2’s activity.  
 
Figure 4.7 Antiproliferative efficacy and subfractionation of F2. 
(A) Plot of cell survival versus concentration of F2 for different prostate cell lines. MTT assay 
was done on additional prostate cell lines, 22Rv1 and DU145, to compare the efficacy of F2. (B) 
Bar graph represents IC50 of F2 for different prostate cancer cell lines DU145, 22Rv1 and PC-3. 
(C) Preparative TLC was done to further separate the constituents of F2. The mobile phase was a 
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binary mixture of 70:30 hexane/ethyl acetate. Six bands were obtained, which were scraped, 
reconstituted in dichloromethane, filtered and concentrated. (D) Plot of cell survival versus 
concentration of F2 sub-fractions for PC-3 cells using MTT assay (*P<0.09 compared with 
controls using two-sample t-test). (E) Bar graph that compares the IC50 of F2 sub-fractions. 
Standards HC and EU were also tested for comparison. (F) Plot of cell survival versus 
concentration of F2 sub-fractions without F2-1. F2-1 (which demonstrated highest IC50) was 
removed from F2 and the remaining fraction (WF2-1) was tested using PC-3 cells. WF2-1 stands 
for F2 without F2-1 (*P<0.09 compared with controls using two-sample t-test). (G) Bar graph 
represents the IC50 of F2 sub-fractions including WF2-1. Standards HC and EU were also tested 
for comparison. 
 
The constituents of F2 were separated using preparative TLC by loading 100 mg of F2 
onto the silica gel plate, followed by placing it in a 70:30 hexane/ethyl acetate system. The most-
active fraction, F2, was resolved into 6 bands (Figure 4.7C), which were collected as sub-
fractions (as mentioned in Materials and Methods section), and MTT assay was performed to 
determine their individual efficacies compared to the parent F2. The IC50 values for sub-fractions 
ranged between 16-251 µg/ml, with F2-2 through F2-6 showing similar potency as F2 (Figure 
4.7D,E). F2-1 however remained an exception and was found to be least active with an IC50 of 
251 µg/ml (Figure 4.7E). The residual bands after initial loading of the sample onto the TLC 
plate could be due to various plant constituents like tannins and lignins, which did not move with 
the solvent system. The next step involved elucidation of chemical structure of the sub-fraction 
component/s.  
Nuclear magnetic resonance (NMR) spectroscopy and tandem mass spectrometry (MS-
MS) were employed for structural elucidation of F2 sub-fraction component/s (data not shown). 
In addition, structure confirmation was also done by appropriate spectral comparisons to the 
information available in literature (data not shown). For F2-1 the molecular ion peak 
corresponded to either EU acetate or CHV acetate, as both isomers show a molecular ion peak at 
207 (MW=206). The F2-2 peaks in the NMR spectra corresponds to HC diacetate, and its 
molecular ion peak appears accurately at 235 (MW=234). The presence of molecular fragments 
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of HC acetate and HC were detected in the mass spectrum. F2-3 was identified to be HC 
diacetate. Two bands of the same constituent could be due to the presence of either ionized or 
other non-specific forms of intra- and intermolecular interactions. F2-4 could not be identified, 
mostly due to the low amounts available; therefore, it remains an unknown in this study. Our 
ongoing efforts are focused on a scale-up purification to identify F2-4. Also, spectral 
characterization and comparison to the standard identified F2-5 as HC, with a molecular ion peak 
at 149 (MW=150). Furthermore, the spectrum did not show a triplet peak, thus ruling out the 
possibility of its positional isomer APC. The structure of F2-6 is still unidentified and will be a 
subject of future studies. 
 
Having analyzed the distinct activity of each sub-fraction, we found that the IC50 of F2-1 
was quite high (251 µg/ml) compared to other sub-fractions. To correlate its contribution to F2’s 
efficacy, all sub-fractions excluding F2-1 were combined and tested in PC-3 cells (Figure 4.7F). 
The resultant IC50 value of this mixture was 6 µg/ml (Figure 4.7G), which was comparable to 
F2’s activity as a whole, thus revealing that F2-1 was not vital for F2’s activity. However, as the 
NMR and MS data suggested an ambiguity regarding the identity of F2-1 (data not shown), 
coupled with our initial observations of EU’s presence in F2 (Figure 4.6A), it was important to 
confirm the identity of F2-1.  
 
To gain deeper insights into F2-1’s identity, 13C NMR analysis was performed (data not 
shown), which revealed that F2-1 was CHV acetate. Comparing the initial TLC data (Figure 
4.6A) and the corresponding IC50 values (Figure 5C,D) of all BLE fractions, we rationalized that 
HC seemed to play a major role in imparting BLE’s in vitro and in vivo efficacy.  
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4.4.4 Determining the contribution of HC to BLE’s antiproliferative activity 
The HPLC analysis of BLE fractions revealed traces of HC in F4-F10 (Figure 4.6C). 
Comparing the efficacy of F2 with that of F4-F10 fractions (Figure 4.5C,D), we reasoned that 
HC could be majorly responsible for F2’s efficacy. To confirm this further, the low-abundance 
HC fractions, i.e., F4-F10, were combined and tested in comparison with F2, which had the 
highest abundance of HC. The resultant efficacy of F4-F10 mixture (25.11 µg/ml) was lower 
than that of F2 (10 µg/ml) (Figure 4.8A,B), thus supporting a major role of HC in F2’s efficacy. 
Though the contributions of other phytochemicals cannot be discounted as they might be 
offering synergy, HC appears to be majorly responsible for F2’s activity. Thus, our data suggest 
that HC might be the major contributor to BLE’s antiproliferative efficacy among all the other 
constituents.  
 
Figure 4.8 Comparison between F2 and combined fractions F4-F10. 
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(A) Line plot of cell survival versus gradient concentrations for F2, F4–F10 and BLE (P<0.05 
compared with controls using two-sample t-test). (B) Bar graphical representation of the IC50 
values of F2, F4–F10 and BLE. (C) HPLC-MS analysis for identification and quantitation of HC 
in BLE. 
 
Next, to determine the presence of HC in BLE, HPLC-UV, and HPLC-MS analyses were 
employed simultaneously in the negative ion mode using ACN: H2O (1.5% acetic acid) solvent 
system. 1 mg/ml of BLE dissolved in pure methanol was injected into the system and the tandem 
mass spectrum thus obtained was scanned for a m/z range of 100 to 500. A significant peak was 
detected with an m/z of 149, matching that of HC as previously described (Figure 4.8C). 
Quantitation of HC was carried out by calibration of a standard curve with known concentrations 
of pure HC, followed by calculating the abundance of HC in BLE. This analysis indicated that 
HC was present at ~26.59% in BLE. Interestingly, F2 contained ~25.25% of HC, thus implying 
that ~95% of the total HC content of BLE was reconstituted in F2. Further, when tested for its 
antiproliferative activity, F2 was found to be 3-fold more active than BLE, suggesting the 
usefulness of HC isolation from betel leaves to evaluate it as a single agent for prostate cancer 
management.  
 
4.4.5 HC inhibits proliferation and perturbs the cell cycle progression of human prostate 
cancer cells  
The long latency time of prostate cancer offers a “wide window” of opportunity for 
chemopreventive intervention by dietary agents. Thus, we first asked if HC inhibited the growth 
of various androgen-independent prostate cancer cells in a concentration gradient dependent 
manner. Our data showed that HC significantly inhibited cellular proliferation of all prostate 
cancer cells with IC50 values in the range of 30-320 µM (Figure 4.9Ai-Aii). The order of 
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sensitivity was 22Rv1>C4-2>PC-3>DU145, with C4-2 being the most sensitive and DU145 the 
least. DU145 cells were found to be least sensitive against HC treatment likely due to the 
expression of MDR (multidrug resistance) phenotype and p-glycoprotein (Pgp) in hormone-
independent cancer cells like PC-3 and DU145, which are widely known for inducing drug 
resistance. The IC50 of HC in normal prostate epithelial RWPE cells was found to be 398 µM 
(Figure 4.9B), which was ~4-13 fold higher than for cancer cells suggesting that HC specifically 
targets cancer cells while sparing normal cells. HC exhibited similar antiproliferative activity in 
other cancer cells like MiaPaCa-2, Panc-1, MDA-MB 231 and HeLa (Figure 4.9C) with IC50 
values of 76, 224, 126 and 71 µM respectively. 
 
The resistant cell line against HC (as observed in Figure 4.9Ai, i.e., highest IC50), PC-3 
was selected to further understand HC’s mechanisms of action. A trypan blue assay performed to 
quantitate cell viability upon HC treatment, showed reduced cell viability of PC-3 cells in a time-
dependent manner (Figure 4.9Di). We next performed a clonogenic or colony formation assay 
that determines the capacity of a cell to proliferate indefinitely upon drug removal to form a 
colony (Figure 4.9Dii). While control cells proliferated profusely to produce several colonies, 
only a fraction of treated cells restored their ability to form colonies (Figure 4.9Dii) upon 
treatment with 100 µM HC on the relative clonogenicity. Representative micrographs of colonies 
in control and HC-treated cells (Figure 4.9Dii, top right) when counted, quantitated to a ~4-fold 
reduction in number and size of surviving colonies upon HC treatment.  
163 
 
Figure 4.9 HC inhibits proliferation and perturbs the cell cycle progression of human 
prostate cancer cells. 
 (Ai) Determination of IC50 of HC. PC-3 cells were treated with HC at increasing concentrations 
(1–250 µM) for 48 h. The percentage cell proliferation was measured by MTT assay. (Aii) HC 
shows enhanced inhibition of proliferation in various prostate cancer cells. Bar-graphical 
representation of IC50 values (mentioned above) of HC tested in C4-2, DU145, 22Rv1, and PC-3 
cells. Cells were treated for 48 h with increasing gradient concentrations of HC. The percentage 
of cell proliferation was measured by MTT assay. (B) HC does not effect the proliferation of 
normal cells. The normal prostate epithelial, RWPE, cells were treated with increasing 
concentrations of HC and the percent cell proliferation was determined by MTT assay.  (C) HC 
shows inhibits the proliferation of various cancer cells. Bar-graphical representation of IC50 
values (mentioned above) of HC tested in MiaPaCa-2, Panc1, MDA-MB 231, and HeLa cells. 
Cells were treated for 48 h with increasing gradient concentrations of HC. The percentage of cell 
proliferation was measured by MTT assay. (Di) HC effects the cell viability of PC-3 cells. Bar 
graphical representation of percent cell viability of PC-3 cells treated with HC as demonstrated 
by trypan blue assay, (*, P<0.05, compared with controls). (Dii) HC inhibits the clonogenic 
capacity of prostate cancer cells. Bar-graphical representation and photograph of crystal violet-
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stained surviving colonies from control and HC-treated groups. (E) HC perturbs the cell cycle 
progression of prostate cancer cells. (Ei) Cell cycle distribution of PC-3 cells in a three-
dimensional disposition as determined by flow cytometry at different time points upon treatment 
with 100 µM HC. (Eii) Bar-graphical representation of the percent G2-M, S, G1 and Sub-G1 
populations at different time points. Values and error bars shown in the graphs represent mean 
and SD respectively. (*, P<0.05, compared with controls). 
 
We next asked if HC-mediated growth suppression was due to its cell-cycle intervention. 
To this end, we evaluated the effect of HC exposure on cell-cycle kinetics of PC-3 cells over 
time. Figure 4.9Ei shows time-course of HC-treatment in a three-dimensional format. HC caused 
cells to accumulate in the G1 phase as early as 6 h until 24 h, followed by an increase in Sub-G1 
population, indicating the possible onset of apoptosis. 
4.4.6 HC induces ROS-dependent mitochondrially-mediated intrinsic  apoptosis, DNA 
damage and autophagy 
HC has been previously reported to generate reactive oxygen species (ROS) and exhibit 
prooxidant property in epithelial cancer cells (Chang et al., 2002; Lee-Chen et al., 1996), and 
hence to test if HC could induce ROS in prostate cancer cells, we stained PC-3 cells with 
DCFDA and DHE and analyzed them flow cytometrically as well as observed microscopically 
(Figure 4.10A-C). DCFDA is cell permeable and it is cleaved intracellularly by non-specific 
cellular esterases. DCFDA reacts with peroxides to yield the fluorescent product, DCF, which is 
a direct measure of the peroxides generated. The DCF fluorescence was measured at 485 nm 
(excitation) and 535 nm (emission). HC-treated cells exhibited a significant increase in DCF 
staining compared to controls (Figure 4.10Ai) as well as an increase in mean fluorescence (right 
shift) at 6 and 9 h compared to the controls (Figure 4.10Aii). However at 12, 18 and 24 h, the 
intensity was similar to that of controls suggesting that the induction of peroxides by HC was 
within 12 h of treatment.  
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Another ROS probe, DHE, which reacts with superoxides was used to further confirm the 
generation of ROS due to HC. DHE converts to ethidium bromide upon oxidation and appears in 
the nucleus as red fluorescence. Microscopical examination of HC-treated PC-3 cells revealed 
the generation of superoxides by HC (Figure 4.10Bi). Flow cytometric data also suggested the 
increase in red fluorescence (right shift, Figure 4.10Bii), read at 580 nm emission wavelength. 
There was a slight increase in the mean fluorescence intensity from 6 to 18 h and a significant 
increase at 24 h post-treatment.  
 
Figure 4.10 HC induces reactive oxygen species in prostate cancer cells. 
 (Ai) Fluorescent micrographs of DCDA stained-control and HC-treated cells (blue – nucleus; 
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green-DCFDA). (Aii) Flow cytometric evaluation of DCFDA stained-control and HC-treated 
cells at various timepoints. (Bi) Fluorescent micrographs of DHE stained-control and HC-treated 
cells (blue – nucleus; red-DHE). (Bii) Flow cytometric evaluation of DHE stained-control and 
HC-treated cells at various timepoints. (C) Source of HC-induced ROS. Mean fluorescent 
intensity quantitation of ROS produced by ROS in the presence and absence of specific 
inhibitiors, rotenone (mitochondrial electron transport chain) and apocynin (NOX). (D) Growth 
inhibition by HC is ROS-dependent. Cells were treated for 48 h with 100 µM HC in the presence 
and absence of ROS scavenger, tiron. The percentage of cell proliferation was measured by MTT 
assay. Values and error bars shown in the graphs represent mean and SD respectively (*, P<0.05, 
compared with controls).  
 
It is well known that mitochondria and NADPH oxidase (NOX) are the major 
endogenous sources of ROS generation in cancer cells (Lee et al., 2006; Sauer et al., 2001). To 
this end, we raised a question to delineate the source of ROS generation upon HC treatment. 
Employing specific inhibitors of these sources, we examined the change in mean fluorescence 
intensity of DCFDA upon treating with apocynin (NOX inhibitor) and rotenone (mitochondrial 
complex I inhibitor) (Karna et al., 2010). Interestingly, we observed that simultaneous treatment 
of PC-3 cells with both inhibitors (Apo+Rot) significantly ablated endogenous ROS levels. 
However, despite this quenching upon HC treatment, there was a slight increase in ROS levels 
(Figure 4.10C) suggesting a mitochondrial and NOX independent induction of oxidative stress. 
This could most likely be attributed to the presence of catechol group in HC, known for 
imparting prooxidant property (Mira et al., 2002; Paranjpe et al., 2013). We then asked if the cell 
death observed upon treatment with HC was dependent on its ROS-generation activity. To this 
effect, the cell survival of HC-treated PC-3 cells was measured in the presence and absence of 
tiron, a ROS scavenger (Karna et al., 2010). There was a significant increase in cell survival 
(50%) in cells pre-treated with tiron, followed by HC as compared to only HC-treated cells 
(Figure 4.10D), thus indicating the involvement of HC-induced ROS in triggering cellular death.  
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Having identified that HC-induced cell death is ROS-dependent, we next evaluated if the 
it is via apoptosis. Our data showed that treatment of PC-3 cells with HC resulted in increased 
expression of cleaved caspase-3, further supported by increase in cleaved PARP expression at 18 
h of HC treatment (Figure 4.11A-B) suggesting that HC induces apoptosis. Immunofluorescence 
micrographs of cells treated with HC also show the enhanced expression of apoptotic markers, 
cleaved caspase-3 and cleaved PARP (Figure 4.11Aii and 4.11Bii) compared to their controls. 
Furthermore, the pro-apoptotic role of ROS was confirmed by evaluating the cleaved PARP 
expression in tiron pre-treated (2 h) PC-3 cells that were then subjected to HC treatment. 
Immunoblot analysis of these lysates demonstrated an increased cleaved PARP expression in 
case of 12, 18 and 24 h samples as compared to their complementary tiron-treated samples, thus 
indicating that the HC-induced ROS were involved in triggering apoptosis in PC-3 cells.  
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Figure 4.11 HC induced apoptosis is ROS dependent. 
Immunoblot and fluorescent microscopic analysis of control and HC-treated cell lysates for 
apoptotic markers, (Ai-Aii) cleaved caspase-3 and (Bi-Bii) cleaved PARP, respectively. Cleaved 
PARP expression was analyzed in the presence and absence of tiron (blue – nucleus; green – 
cleaved caspase-3 and cleaved PARP). (C) HC disrupts the mitochondrial membrane potential in 
prostate cancer cells. Flow cytometric evaluation of control and HC-treated cells stained with JC-
1, a cationic dye. (Di) Immunoblot analysis of mitochondrial proteins, p-Bcl-2, and total Bcl-2. 
β-actin was loading control. (Dii) HC induces release of cytochrome c from mitochondria. 
Control and HC-treated PC-3 cells were triple stained with MitoTracker (red), which co-localizes 
in the mitochondria, anti-cytochrome c antibody (green) and Hoechst dye, which stains the 
nucleus (blue). Overlay of the three stains illustrates the release of cytochrome c from the 
mitochondria in the HC-treated cells. 
 
It is a well-known fact that the release of cytochrome c into the cytosol due to disruption 
of mitochondrial membrane triggers intrinsic apoptosis (Tait and Green, 2010). Considering our 
observation that HC induces mitochondrial ROS, evaluating any possible disturbances in the 
mitochondrial membrane potential seemed to provide a plausible reason for HC-induced 
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apoptosis in cancer cells. To this effect, we further confirmed intrinsic apoptosis by measuring 
the collapse of mitochondrial transmembrane potential (Ψm) (Figure 4.11C) and examining 
release of mitochondrial cytochrome c into the cytosol (Figure 4.11D). JC-1, a cationic-dye, 
characterized by membrane potential-dependent mitochondrial accumulation (Cossarizza et al., 
1993), was used to stain cells treated with HC for 6, 9, 12, 18 and 24 h along with control cells 
and an increase in JC-1 monomeric form indicative of Ψm collapse was observed (Figure 
4.11C).  This effect was quantitatively determined using flow-cytometry. As seen in Figure 3C, 
100 µM HC-treated cells at 6 h showed a right-shift in the mean-fluorescence intensity of green 
JC-1 monomers compared to controls and similar trend was observed for other timepoints as 
well. Furthermore, as disruption of Ψm is known to be followed by alterations in expression of 
Bcl2 members, we found that at 18 h of HC-treatment, increased the levels of phosphorylated 
Bcl2 was observed, thus indicating its inactivation, while total Bcl2 levels remained unchanged 
(Figure 4.11Di). In addition, cytochrome c is released into the cytosol from the mitochondria 12 
h post-HC treatment, which is illustrated in Figure 4.11Dii indicating induction of intrinsic 
apoptosis. The MitoTracker (red) stains the mitochondria and the anti-cytochrome c (green) in 
the control cells co-localizes with the MitoTracker. However, in the HC-treated cells, the overlay 
of the triple stained cells (MitoTracker (red), cytochrome c (green) and Hoechst dye (blue)) 
clearly shows no co-localization and cytochrome c is released from the mitochondria (Figure 
4.11Dii). 
 
Oxidative damage caused by excess ROS has been linked to DNA based modifications 
like single- and double-strand breaks (Cooke et al., 2003). Based on our observations that the 
growth arrest in HC-treated cells was ROS dependent, we next asked if HC-induced ROS cause 
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DNA damage in PC-3 cells. To this end, we microscopically examined the HC-treated cells over 
time for γ-H2AX foci that form around the DNA breakage sites. γ-H2AX is the phosphorylated 
form of histone H2AX and is a sensitive marker of double-strand breaks, an early indication of 
chromatin modification (Bonner et al., 2008).  
 
Figure 4.12 HC induces ROS-dependent DNA damage. 
(Ai) Immunofluorescent micrographs of control and HC-treated cells stained for γ-H2AX foci in 
the presence and absence of tiron (blue-nucleus; green- γ-H2AX foci). (Aii) Quantitation of the 
γ-H2AX foci in the micrographs from Ai. (B) Immunoblot analysis of γ-H2AX expression in 
control and HC-treated lysates. β-actin was used as loading control. Values and error bars shown 
in the graphs represent mean and SD (*, P<0.05, compared with controls). 
 
γ-H2AX foci were found in HC-treated cells after treatment for 6, 9, 12, 18, 24 h (data 
not shown) and their expression seemed to be at maximum at 18 h (Figure 4.12Ai, Aii). Clearly, 
control cells lacked γ-H2AX foci indicating that the breaks were induced due to HC exposure. 
Corroborating this observation, immunoblot analysis of HC- treated cell lysates also confirmed 
expression of γ-H2AX, as early as 6 h, which further peaked at 18 h (Figure 4.12B) suggesting 
an early and time-dependent effect on DNA damage by HC. Having identified HC-induced DNA 
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damage, we next wanted to confirm if this is ROS-dependent. Hence, PC-3 cells were pre-treated 
for 2 h with tiron, a ROS scavenger, followed by HC-treatment at 9, 18 and 24 h. Approximately 
58% decrease in number of cells with γ-H2AX foci was observed at 18 h treatment followed by 
the attenuation of ROS by tiron (Figure 4.12Ai, Aii) (P<0.05).  
 
Given that HC induced ROS related mitochondrial damage, we were inquisitive to learn 
whether HC also induced autophagy in human prostate cancer PC-3 cells. Electron microscopy, 
the gold standard to identify autophagosomes in the cells (Kondo and Kondo, 2006), was 
employed to demonstrate the effects of HC on PC-3 cells. Transmission electron microscopy was 
used to observe the ultrastructures present in control and 100 µM HC-treated cells. Large double-
membranous cytoplasmic vacuoles resembling autophagosomes with intracellular organelles 
entrapped within them were observed in HC-treated cells (Figure 4.13A, indicated by black 
arrows). The induction of autophagy by HC was further demonstrated by the immunoblot 
analysis of HC-treated cell lysates for classic autophagy markers, beclin-1 and LC3-IIb (Figure 
4.13Bi-ii). Increased expression of beclin-1 was observed at 12 h treatment and the expression of 
converted form of LC3-II was observed to increase over time starting as early as 6 h (4.13Bi). 
This was further supported by the microscopic observations of cells stained for acidic vesicular 
organelles (AVOs), another characteristic feature of autophagy. Cells treated with HC were 
visualized using fluorescent microscopy upon staining with acridine orange (AO), a 
lysomotropic agent. AO, a weak base can cross the biological membrane in an uncharged state 
and exhibits green fluorescence. Its protonated form is found in the acidic compartments of cells 
and has a red fluorescence. As seen in Figure 4.13C, the control cells showed green fluorescence 
indicating the lack of acidic vacuoles and on the other hand, HC-treated cells showed red 
fluorescence signifying the presence of AVOs thus suggesting induction of autophagy. We also 
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evaluated the AO fluorescence flow cytometrically and it was observed that there was a 
significant right shift in cells treated with HC compared to the control as early as 6 h (Figure 
4.13D).  However, at 12 h, the HC-treated cells resembled control cells, as there was no shift in 
the fluorescence intensity. 
 
Figure 4.13 HC induces autophagy in prostate cancer cells. 
(A) Representative transmission electron micrographs showing the ultrastructures of control and 
HC-treated PC-3 cells. The double-membranous cytoplasmic vacuoles resembling 
autophagosomes in HC-treated cells are highlighted by black arrows. Immunoblot analysis of 
(Bi) beclin-1 and LC3-IIb in control and HC-treated cells (Bii) LC3-IIb expression in control and 
HC-treated cells that were pre-treated with tiron. β-actin was loading control. (C) 
Immunofluroscent micrographs of control and HC-treated cells stained with AO (blue – nucleus; 
green – unprotonated AO; red – AVOs). (D) Flow cytometric evaluation of AVOs formation 
upon treatment with HC at various time points. 
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Furthermore, to determine if the autophagy induced by HC was ROS-dependent, we 
performed immunoblot analysis of tiron-pretreated cell lysates. The reduced expression of LC3-
IIb in 12, 18 and 24 h HC-treated samples suggested that ROS were required to induce 
autophagy (Figure 4.13Bii). However, there was minimal expression of LC3-IIb in the control, 
which was further observed to decrease in tiron-treated control (Figure 4.13Bii). 
4.4.7 Oral HC feeding significantly inhibits PC-3 tumor-growth 
Having identified significant in vitro anti-proliferative and pro-apoptotic activity of HC, 
we were curious to examine the in vivo efficacy of HC to inhibit subcutaneous human prostate 
tumor xenografts implanted in athymic nude mice. A PC-3 cell-line stably-expressing luciferase 
(PC3-luc), which allowed real-time visualization and non-invasive observation of prostate cancer 
growth was employed in this study. 150 mg/kg bw HC and vehicle (PBS with 0.05% Tween-80, 
pH=7.4) were fed daily by oral-gavage for six weeks to the mice in treatment and control groups 
respectively. Therapeutic responses were evaluated upon quantifying the relative photon counts 
as revealed by non-invasive bioluminescent imaging (Figure 4.14Ai), and measuring volumes 
(Figure 4.14B) of the tumors in mice from both treatment and controls groups using vernier 
caliper. Approximately 72% reduction in tumor-volume (p<0.05 (n=6, Figure. 4.14Aii)) 
observed at week six in HC-treated mice signified time-dependent tumor growth inhibition 
(Figure 4.14Ai,ii) compared to vehicle-treated group. Further, tumor-volume measurements 
showed that oral feeding of HC for six weeks (42 days) decreased tumor-volume by ~75% 
compared to the control group. Due to tumor over burden, complying with our institutional 
IACUC guidelines, the mice in control group had to be euthanized by the end of six weeks. 
Furthermore, tumors were excised upon euthanasia from control and treatment groups at the end 
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point. The therapeutic response observed was further supported by ~3.3-fold difference in the 
tumor weights (Figure 4.14C) from control and treatment groups.   
 
Figure 4.14 Dietary feeding of HC showed inhibition of human prostate tumor xenograft 
growth in nude mice. 
Male nude mice were subcutaneously injected with 106 PC-3-luc cells. (Ai) Bioluminescent 
images (one animal per group) representing tumor progression over six weeks. (Aii) Quantitation 
of radiance (photons/sec/cm2/sr) measured from tumors of vehicle- and HC-fed mice. (B) 
Tumor-volume (in mm3), (C) Tumor weight comparison along with photographic images of 
excised tumors and (D) Body weight comparison of vehicle, and HC-fed groups. (*, P<0.05 
(two-way analysis of variance, compared with controls). (E) HC induces apoptosis. Immunoblot 
analysis of tumor tissue lysates from vehicle- and HC-fed groups probed for cleaved caspase-3, 
and cleaved PARP. β-actin was loading control.  
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In vivo apoptotic response of HC feeding in PC-3-luc tumor xenografts was evaluated for 
cleaved caspase-3 and cleaved PARP expression using western blot analysis of tumor-lysates. As 
expected, cleaved caspase-3 and cleaved PARP expression (Figure 4.14E) was higher in tumors 
from HC-fed group compared to the control group. 
Toxicity, a major burden for prostate cancer patients during chemotherapy or 
radiotherapy, was barely observed in HC-fed mice, which was confirmed by histopathological 
analysis of various organs posthumously obtained from treatment and control group mice. There 
were no discernible differences in the appearance of intestinal, liver, spleen, lung, kidney, brain, 
heart, testes, adrenal gland and pancreatic tissues from both groups (Paranjpe et al., 2013). 
Comparative evaluation of serum biochemical indicators like blood urea’s nitrogen (BUN), 
lactate dehydrogenase (LDH), creatinine kinase, and hepatic functional markers (ALT, AST, 
ALP) revealed similar profiles for both vehicle- and HC-fed groups (data not shown). 
Furthermore, complete blood analysis was performed to compare the blood collected from both 
HC- and vehicle-fed mice. Evaluation of total count/percentage of various blood components 
including white blood cells (WBC), red blood cells (RBC), hemoglobin (HGB), neutrophils, 
lymphocytes, monocytes, basophils, eosinophils and platelets was found to be comparable with 
no signs of toxicity (data not shown).  In the groups fed with very high doses (5g/kg and 2 g/kg 
bw) of HC, 100% of the C47BL6/J mice died concluding that HC is toxic at such high doses.  
Furthermore, upon testing several doses, 560 mg/kg bw of HC resulted in the death of 50% mice 
confirming the half-maximal lethal dose (LD50). 
 
4.5 Discussion 
Extensive literature suggests that fruits, vegetables, and spices impart several health 
benefits and are thus regarded as potential chemopreventive agents (Chu, 2001; Cooke et al., 
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2005; Shukla and Gupta, 2005; Surh, 2003). It has been widely appreciated that fruits and 
vegetables, with their complex array of phytochemicals, alter the progression of deadly 
neoplasms, particularly slow-growing prostate cancers (Chan et al., 2009; Johnson et al., 2010; 
Shukla and Gupta, 2005; Surh, 2003; Veluri et al., 2006). Betel leaf is traditionally used as a 
mouth freshener in India and China. Consumed regularly by nearly 600 million people in Asia, 
these leaves are a focus of intense research due to their wide repertoire of medicinal properties 
(Bajpai et al., 2010; Kumar, 2010). This chapter reports the beneficial effects of betel leaves and 
HC both in vivo and in vitro in prostate cancer models. We found that oral feeding of 400 mg/kg 
bw BLE is quite effective in tumor growth inhibition with no detectable toxicity compared to 
vehicle-treated controls and other doses employed in this study (Figure 4.1). This is in 
concordance with a similar study where BLE significantly inhibited DMBA (7,12-
dimethylbenz(a)anthracene) induced skin tumors in swiss mice (Azuine et al., 1991) .  
Plant extracts, as a natural blend of phytochemicals, offer immense opportunities for 
discovery of active constituents, an archetype of current pharmaceutical industries. Classic 
examples include isolation of Vinca alkaloids like vinblastine and vincristine from leaves of 
Catharanthus roseus and taxol from the bark of yew tree (Noble, 1990). These drugs are 
currently extensively used for a variety of neoplasms in the clinic (Azuine et al., 1991). 
Fractionation using classical chromatography has been widely used for isolation of active 
ingredients from plant extracts (Sasidharan et al., 2011).  Several plant phytochemicals have 
been extracted and isolated employing a bioactivity-guided approach. For example, fraction F2 
obtained from the methanolic extract of Smilax spinosa, an ethnopharamceutical remedy, 
displayed a higher pro-apoptotic activity than the crude extract (Seelinger et al., 2012). Also, it 
has been reported that the procyanidin-rich fractions obtained from apple juice exhibit radical 
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scavenging properties and have shown to be more efficacious than the apple juice extract itself 
(Zessner et al., 2008). On similar lines of thought, we fractionated BLE into 10 fractions based 
on their TLC profiles (Figure 4.5A,B). Further, the most active fraction was identified (Figure 
4.5C,D) and its active ingredient, HC, was qualitatively and quantitatively characterized using 
preparative TLC, and HPLC (Figure 4.7C and Figure 4.8C respectively). 
Several studies suggest that the synergistic effect of constituent phytochemicals is 
responsible for the efficacy of whole plant extracts (Jacobs et al., 2009; Wagner, 2011). 
Although the concept of synergistic interrelationships between complex phytochemicals explains 
the superior activity of several foods compared to their constituents, isolation of the single 
constituent is favored over complex mixtures when the bulk of activity resides in a single 
ingredient (Raskin et al., 2002). It is likely that such complex mixtures may contain additional 
pigments and polyphenols, which may antagonize the efficacy of the active ingredient (Raskin et 
al., 2002). In addition, the abundance of constituent phytochemicals in whole foods may vary 
due to factors like climate, location, and physical and chemical stimuli. This is exemplified by a 
recent study, which reported that the polyphenolic content of a green tea infusion varied with 
cultivation and the technique of brewing, as an unstandardized infusion with a low dose of active 
principles did not display the expected results in clinical trials and was thus withdrawn from 
future studies (Johnson et al., 2010). On similar lines, a comparative report exists on three 
different varieties of Piper betel (Bangla, Sweet, and Mysore), which suggests that the Bangla 
variety exhibits the best antioxidant activity with the highest polyphenolic content. The other two 
varieties with reduced polyphenol content were effective at much higher concentrations (Rathee 
et al., 2006). Given that several varieties including hybrids are increasingly being cultivated all 
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over the world, it is practically difficult to draw generalizations on the efficacy of these different 
varieties of betel leaves that differ in their variety and geographical location.  
 
We observed that upon fractionation of BLE, F2 constituted ~95% of BLE’s total HC 
content (Figure 4.8C) and also exhibited improved efficacy as compared to the parent (Figure 
4.5C,D). A study comparing the activity of betel leaf extracts made in various solvents supports 
our observation, wherein the extract with highest amount of HC displayed superior antioxidant 
activity. Additionally, the relevance of an optimal composition of phytochemicals for maximum 
therapeutic efficacy has been widely reported in the literature supporting our observations 
(Ferguson et al., 2004; Guha, 2006; Jacobs et al., 2009; Kandil et al., 2002; Miura et al., 2008; 
Raskin et al., 2002; Toi et al., 2003; Veluri et al., 2006; Wagner, 2011; Zessner et al., 2008; Zhao 
et al., 1999). Furthermore, HC has been shown to induce apoptosis in leukemic cells by 
increasing the levels of mitochondria-derived ROS that activated the JNK pathway, thus leading 
to the loss of mitochondrial membrane potential (Chakraborty, 2011). It has also been shown to 
deplete cellular GSH levels, leading to oxidative stress . These mechanisms might contribute to 
the low IC50 value of BLE as observed in our study. Although other BLE components like CHV 
have demonstrated radical scavenging, anti-lipid peroxidation, and radio-protective properties, 
our observations suggest that their contribution towards BLE’s activity is insignificant. This 
could also be attributed to the diverse chemistry and biology of these compounds, as the effects 
of an electron-donating moiety are likely to vary depending upon its nature and position on the 
phenol ring. The presence of a hydroxyl group, an electron-donating moiety at the ortho and para 
positions enhances its reducing property. For example, the methylated phenol, CHV, lacks this 
free catechol, which might result in its lower antioxidant potential. This may better explain the 
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enhanced activity of HC, a phenol with a free catechol group, compared to CHV(Rathee et al., 
2006).  
 
Furthermore, several isolated compounds of plant origin, like HC in our case, have 
proven to be advantageous, as they also set grounds for chemical modifications and rational drug 
discovery for enhanced efficacy and superior pharmacological profiles. For example, artemesisin 
(an antimalarial drug derived from the medicinal herb Artemisia annua) was chemically 
modified to sodium artesunate, which displayed higher solubility and hence ease of 
administration (Houghton, 1995). On similar grounds, the most active classes of anticancer 
drugs, like vincas and taxanes, have all been subjected to extensive structure-activity studies to 
generate superior analogs that have been reported to be effective cancer cell death traps (Fauzee 
et al., 2012; Ranaivoson et al., 2012). These agents not only portend significantly greater tumor 
growth inhibiting activity but also are known for their reduced toxicity as compared to their 
founding molecules. More recent advances in anticancer therapeutics highlight the advent of 
noscapine analogs as “kinder and gentler” microtubule modulating agents (Pannu et al., 2011) 
that perhaps are relatively non-toxic compared to the classical antimicrotubule agents that impart 
toxicity to normal cells.  
 
Our enthusiasm to decipher the mechanisms via which several plant phytochemicals exert 
health-promoting benefits led to the revelation of remarkably congruent yet opposite roles played 
by these chemicals under different physiological conditions. Recent interest in cancer 
chemopreventive research using whole foods and their active constituents, alone or in 
combination with current chemotherapeutic drugs has unfolded the mysterious ways through 
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which nature delivers health benefits to mankind. Plant chemicals have been known to fight 
oxidative stress by quenching the free radicals responsible for mutations leading to genetic 
alterations and malignant transformation of initiated cells (Quideau et al., 2011). However, 
certain phytochemicals also exert prooxidant behavior and when at higher concentrations, they 
tend to induce generation of reactive oxygen species in the cells (Azam et al., 2004; Quideau et 
al., 2011; Sakihama et al., 2002). Literature suggests that phenolic compounds containing 
catechol and pyrogallol moieties (Mira et al., 2002) induce ROS levels in cells and thus dispose 
chemotherapeutic efficacy by leading to death. Given their abundance in nature, it is ideal to 
isolate phenolic compounds that can exhibit pleotropic mechanisms from plant extracts and 
exploit their double-edged behavior. Although there is an ongoing debate on employing whole 
foods vs single active constituents for chemotherapy/chemoprevention, establishing the 
mechanisms via which the whole food extracts or their constituent phytochemicals can induce 
death in cancer cells is of utmost importance.  
Our data demonstrates the in vitro anticancer efficacy of HC specifically in various 
human prostate cancer cell lines like C4-2, DU145, 22RV1 and PC-3 (Figure 4.9Ai-Aii) 
compared to normal prostate epithelial cells, RWPE-1 (Figure 4.9B). Furthermore, HC also 
exhibits antiproliferative activity against a variety of cancer cell lines including MiaPaCa-2 
(pancreatic), Panc-1 (pancreatic), MDA-MB-231 (breast) and HeLa (cervical). The cell cycle 
arrest induced by HC in PC-3 cells (Figure 4.9Ei-Eii) further supported HC’s therapeutic 
efficiency.  
Literature reports suggest that cancer cells possess higher concentrations of reactive 
oxygen species (ROS) compared to normal cells (Schumacker, 2006; Szatrowski and Nathan, 
1991; Trachootham et al., 2009). While moderate levels of ROS are understood to facilitate cell 
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proliferation and survival, an increase in these levels in cancer cells beyond a threshold lead to 
cell death. As such, with a low basal level of ROS, normal cells maintain a redox balance 
between generation and elimination of free radicals, and thus can tolerate a minimal increase in 
this level. In contrast, cancer cells with high basal levels of ROS have reduced margin to sustain 
the elevation in these levels. In such a case, an exogenous interference by ROS-modulating 
agents might enhance the levels beyond toxic threshold, leading to their cell death. This 
‘weakness’ of the cancer cells ensures their selective killing via ROS-mediated mechanisms 
sparing the normal cells. Thus, drugs acting as prooxidants promoting the leakage of free radicals 
from the mitochondria prove to be valuable anticancer therapeutics. Although plant phenolics 
have been long known be antioxidants, their role in enhancing ROS levels is emerging. To the 
best of our knowledge, no studies have yet shown the prooxidant behavior of HC in human 
prostate cancer, PC-3 cells experimentally. Our data showed that HC induced peroxides and 
superoxides in a time-dependent manner (Figure 4.10). Immunofluorescence staining suggested 
that green fluorescence in case of DCFDA indicated the induction of peroxides (Figure 4.10Ai) 
and red fluorescence in case of DHE signified the induction of superoxides (Figure 4.10Bi). 
Flow cytometry using the above-mentioned dyes, further confirmed the time-dependent 
induction of ROS by HC (Figure 4.10Aii and Bii). Further investigation revealed that these HC-
induced ROS triggered cellular death in PC-3 cells (Figure 4.10D).  
 
Excessive ROS in cells are known to induce DNA damage, apoptosis and even 
autophagy, eventually leading to death (Karna et al., 2010). Insights into molecular mechanisms 
reveal the death-inducing effects of HC-induced ROS in PC-3 cells where treatment with HC led 
to increase in the expression of cleaved caspase-3 and cleaved PARP in the presence and absence 
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of ROS inhibitor, tiron (Figure 4.11A). Apoptosis thus induced was intrinsic in nature, 
suggesting a largely mitochondrially-mediated phenomenon, associated with collapse of 
transmembrane potential resulting in the expulsion of apoptogenic molecules, as an upregulation 
in the expression of Bcl-2 and release of cytochrome c levels into the cytosol was observed upon 
treating with HC (Figure 4.11C-D). It was also observed that the HC-induced ROS caused DNA 
damage, as signified by the increase in the expression of γ-H2AX foci that form around the DNA 
breakage sites (Figure 4.12). Additionally, these ROS also induced autophagy in HC-treated PC-
3 cells (Figure 4.13). 	  
 
Autophagy is a type II programmed cell death, which in some cases precedes apoptosis 
(Chen et al., 2000). At a basal level, autophagy functions in maintaining the cellular homeostatis, 
but when stimulated by the cellular stress conditions like oxidative stress, it becomes upregulated 
rapidly. Our observations including the appearance of organelles engulfed in double-membrane 
bound vesicles (Figure 4.13A), AVOs (Figure 4.13C) and overexpression of beclin-1 and LC-
3IIb (Figure 4.13B) revealed that HC-induced ROS triggered the induction of autophagy in PC-3 
cells. Sometimes, under such ‘stressed’ conditions, autophagy functions as a double-edged 
sword, contributing to cell survival by engulfing the damaged organelles. When it is unregulated, 
it leads to cell death by excessive digestion and degradation of cellular components (Karna et al., 
2010). On the other hand, apoptosis, the type I programmed cell death involving the activation of 
catalytic proteases, leads to rapid destruction of cellular structures. Studies have reported a 
crosstalk between these ‘self-eating’ and ‘self-killing’ mechanisms, due to mutual control of the 
autophagic and apoptotic proteins in the cell (Karna et al., 2010). In this context, we are currently 
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investigating the HC-induced ROS-dependent interplay between autophagy and apoptosis to 
impact cellular outcomes in prostate cancer cells.  
 
Furthermore, our in vivo investigation revealed the remarkable tumor growth inhibition 
efficacy of HC, also accompanied by non-toxicity (Figure 4.14). To assess the safety of HC, the 
hematologic and histopathological toxicities were evaluated and there were no deviations in the 
hematologic attributes in samples from treated mice compared to the controls. Using the body 
surface area normalization method (Reagan-Shaw et al., 2008), we hypothesized the use of HC 
as a potential chemotherapeutic or chemopreventive agent in humans, where the human 
equivalent dose of 150 mg/kg in vivo dose equals ~12 mg/kg. For an average, 70 kg adult, this is 
translated to an equivalent dose of <1 g HC, which can be easily supplemented as a part of daily 
diet.  
 
In conclusion, this chapter underlines the remarkable anticancer efficacy of BLE and 
exceptional prooxidant role of Hydroxychavicol, an active constituent abundant in betel leaves to 
confer maximum therapeutic benefits as it induces ROS in human prostate cancer cells thus 
leading to their death. Our observations of this possible prooxidant role of HC are indispensible 
and provide stimulus to further investigate its chemotherapeutic potential and a possible role in 
chemoprevention and prostate cancer management.  
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5     CONCLUSIONS 
Cancer is the most dreaded modern illness with an exponential incidence in the past two 
decades. With baffling questions still surrounding the causes of cancer, there is an urgent need to 
address the challenges of the current prevention and treatment strategies. Several of the novel 
therapeutics have proven to be either highly expensive or even a failure in the clinical setting, 
while the disease has grown to be debilitating with devastating effects. A variety of factors have 
been implicated in the disease pathogenesis, including mutations, environmental factors, lifestyle 
choices and even diet. In this regard, The American Cancer Society published “Guidelines on 
Nutrition and Physical Activity for Cancer Prevention” in 2012, which recommends a healthy 
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diet emphasizing plant foods suggesting that synergistic effects are possible upon consumption 
of whole plant foods.   
In this dissertation, we have shown that plant-based foods display remarkable anticancer 
activity while following the “golden-rule” of being well-tolerated, non-toxic, easily available and 
relatively inexpensive, thus making them new age “magic bullets” in the battle against cancer. 
Sweet potato greens, whole ginger and betel leaves have been shown to possess exceptional 
tumor growth-inhibiting efficacies, facilitated due to the inherent synergistic interactions among 
their respective constituent phytochemicals. Furthermore, our findings in the case of sweet potato 
greens extract (SPGE), whole ginger extract (GE) and betel leaf extract (BLE) provide stronger 
evidence of phytochemical complexity (Gundala et al., 2014; Karna et al., 2011b; Paranjpe et al., 
2013), which is an untapped resource with innumerable benefits. Though these extracts exhibited 
superior efficacies in vitro, we observed a loss of anticancer activity in in vivo prostate cancer 
models upon perturbing the natural balance of phytochemical content in these extracts via 
fractionation processes. This disruption of the natural complex network of phytochemicals could 
most likely be responsible for the discrepancies observed between in vitro and in vivo efficacies. 
Firstly, we investigated the anticancer efficacy of sweet potato greens, a common dietary 
component in the eastern world to signify dietary intervention to treat cancer. This attempt 
revealed that F5, the most-active fraction, obtained via column fractionation of SPGE was at 
least 125 fold more potent than the parent in in vitro models. However, this effect could not be 
translated in the in vivo setting, where there was less than 10% difference in tumor growth 
inhibiting efficacy. Further, analytical quantitation of the parent extract and most-active fraction 
disclosed the presence of three major constituents, quinic acid (QA), chlorogenic acid (ChA) and 
caffeic acid (CA), in varying ratios. Mechanistic evaluations revealed that both SPGE and F5 
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caused cell death due to the induction of apoptosis. Our approach attempted to deconstruct the 
inherent synergies among the constituent phytochemicals of SPGE and it unveiled enrichment of 
components in F5, which is likely responsible for its superlative in vitro activity (Gundala et al., 
2013; Karna et al., 2011b). However, the in vivo anomaly is yet to be addressed.  
Next, our attempts to acknowledge the importance of synergistic interactions among 
constituent phytochemicals of a dietary agent were focused via GE, whose composition has been 
well studied for years. We showed that GE exerts significant growth inhibitory and death-
inducing effects in prostate cancer models while modulating the cell cycle and apoptosis 
regulatory molecules. Daily oral administration of GE to human prostate tumor-bearing mice 
even resulted in ~56% inhibition of tumor growth. Our in vitro study evaluating synergy among 
GE’s most abundant phenolics, 6G, 8G, 10G and 6S, revealed that not only these phenolics 
exhibit synergistic and additive interactions among themselves, but also show similar effects 
when GE was further enriched with each of them. This observation further led to our 
investigation of in vivo synergy among ginger biophenolics.  It was clearly evident that 6G, 8G, 
10G and 6S were not the only ones contributing towards GE’s efficacy, but the remaining 
partners also exhibit synergistic and/or additive interactions to impart remarkable efficacy to GE. 
Furthermore, pharmacokinetic evaluations to understand the fate of GE phenolics indicated that 
6G, 8G, 10G and 6S undergo enterohepatic recirculation, and due to the phytocomplexity of 
constituent entities, the bioavailability of these four active phenolics is enhanced to facilitate 
better absorption, longer retention times and their controlled elimination (Brahmbhatt et al., 
2013; Gundala et al., 2014; Karna et al., 2011a).  
Our investigations employing the xenohormetic betel leaf nutraceuticals unveiled a new 
dimension in employing both antioxidant and prooxidant abilities of phenolic constituents to 
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selectively kill the cancer cells, while sparing the normal cell population. We observed that BLE 
had remarkable tumor growth inhibiting efficacy, and comprised phenolic compounds like 
hydroxychavicol (HC), eugenol (EU), chavibetol (CHV), 4-hydroxycatechol, methyl eugenol, 
carotenes etc. Of all these, HC was found to be the most abundant phytochemical and was 
isolated from betel leaves to further understand its mechanisms of action against prostate cancer 
cells. HC was found to be prooxidant in nature and perturbed cell-cycle kinetics and progression, 
while reducing clonogenecity and mediating cytotoxicity by ROS-induced DNA damage leading 
to the activation of several pro-apoptotic molecules. Additionally, HC elicited ROS-induced 
autophagic response with an increased expression of autophagic markers like LC3-IIb and 
beclin-1, which was found to be ultimately resulting in death via apoptosis. A remarkable 
inhibition of prostate tumor xenografts by ~72% upon oral administration of HC was also 
observed indicating the superior anticancer efficacy of betel leaf nutraceuticals (Gundala and 
Aneja, 2014; Gundala, 2014; Paranjpe et al., 2013).  
 
Furthermore, the above-mentioned dietary agents were found to be non-toxic and 
inexpensive, while strongly exhibiting complex interactions among their constituent 
phytochemicals, which direct the pharmacodynamic and pharmacokinetic synergies contributing 
the superior tumor growth inhibiting efficacies. We believe that our studies have provided 
compelling grounds for future preclinical and clinical studies to validate the potential usefulness 
of such dietary agents for prostate cancer management. 
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6     OVERALL SIGNIFICANCE 
Due to an incomplete understanding of the various roles played by phytochemicals in 
cancer, developing therapeutic regimen employing dietary agents is almost a universal failure. 
There have been several trials in the past employing phytochemicals like β-carotene, α-
tocopherol etc., but with no evidence of health benefits (1994; Azuine et al., 1991; Azuine and 
Bhide, 1992; Bhide et al., 1991b). Rather these clinical trials led to startling observations 
indicating that these treatments increase the risk of disease (lung, colorectal cancers). Vitamins 
and minerals like B6, folic acid, iron, Mg, Zn, Cu were also found to increase total mortality 
(Surh, 2003). However, combinations of supplements in a vitamin/mineral deficient population 
reduced the risk of specific cancers (Potter, 2014), thus suggesting an important role of multi-
targeting interventions, which also could be achieved employing whole extracts considering their 
multi-ailment curing properties.  
 
In the light of our observations employing whole food extracts and their active 
counterparts, especially in the case of SPGE, it is to be understood that attempts to isolate the 
active components from the parent extracts might actually lead to the loss of efficacy. Most 
importantly, the wide gap that exists between in vitro and in vivo results is to be acknowledged 
while determining the best agents. In vitro data obtained as a result of controlled environment 
has limited potential considering the straightforward approach involved. Only a few factors can 
be modulated in studying the cause and effect, thus limiting the scope of actual mechanism(s) 
involved. On the other hand, in vivo system is a complex network where a multitude of factors 
are constantly changing with time. Essentially, such variations have greater impact on the 
metabolism of the drug administered, which are absent in the in vitro environment, thus bringing 
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about the difference in efficacy. These differences were clearly observed in case of SPGE and 
F5, where even though F5 was found to be ~125 fold more active than SPGE in vitro, this 
difference of efficacy was not translated in vivo where the percent tumor growth inhibition 
difference was <10%. It is thus implied that maximum health benefits can be obtained by 
consuming the phytochemicals in their natural forms i.e., whole foods.  
 
Furthermore, our efforts in evaluating the pharmacokinetics of whole food extracts 
indicated the importance of determining the physiological modifications of constituent 
phytochemicals of a whole food with respect to its in vivo efficacy. A single-day PK evaluation 
suggested a possible enterohepatic recirculation mechanism of ginger components. However, a 
multiple day PK can better correlate to efficacy data as the latter is obtained upon daily 
administration of the extract for a period of 4-6 weeks. In the multiple PK experimental design, 
mice were fed with the extract continuously for 7 days and the blood plasma concentrations of 
the ginger phenolics and their respective PK parameters are analyzed and compared on day 1 and 
day 7 (essentially from animals of the same groups). We observed that, after 7 days of daily oral 
administration, the levels of free ginger phenolics in blood plasma on day 7 were found to be 
decreased compared to those on day 1. However, upon quantitating the β-glucuronidase 
treatment, the same samples were found to contain very high levels of the glucuronidated forms 
of ginger phenolics. This discovery is very intriguing as it leads to speculations regarding the 
elements of ginger that impart anticancer benefits. Tissue distribution studies indicated that 
glucuronide of 6S was accumulating at very high concentrations within the tumor tissue. 
Considering the effect being related to tumor growth inhibition, it can be speculated that,  
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(a) the glucuronides of 6S accumulating in the tumor tissues are directly 
responsible for inhibition of the tumor growth 
(b) the opulent reserves of 6S glucuronides are converted into free forms of 6S 
via the action of β-glucuronidase enzyme basally expressed in the tumor cells 
and thus the free forms participate in the tumor growth inhibition. 
With these possibilities, it is important to determine the efficacy of glucuronide forms of 
constituent phenolics along with their free forms. Such an elaborate study would not only explain 
the physiological mechanisms undergone by the phytochemicals in the in vivo setting, but also 
unravel novel entities (active conjugated forms) that are the actual contributors. 
 
On another note, the possibility of improving the bioavailability of constituent 
phytochemcials of whole foods using other dietary agents with specific functions seems 
promising in improving the efficacy. For example, UGT inhibitors like eugenol, capsaicin, 
piperine, curcumin, etc., can be consumed along with the active extracts, in order to interfere 
with the natural conjugation process by the UGTs, and thus resulting in prolonged circulation of 
free forms of constituent phytochemicals. Also, by evaluating the effect of whole food extracts 
and constituent phytochemicals on the phase I and phase II metabolizing enzymes, the safety of 
these extracts to be consumed along with any therapeutic agents can be studied. These studies 
will help in determining the dose limitations of extracts as well as any possible toxic interactions. 
Furthermore, as a part of a two-prong approach, these active extracts can even be administered 
along with therapeutic drugs to enhance the bioavailability of the latter as well as impart efficacy 
via multiple pathways. This approach could also result in administering lower dose levels of the 
therapeutics, thus reducing dose-related toxicity.  
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Plant extracts with their affluence of phytochemicals still are the source of novel 
therapeutics. Most of the current anticancer drugs, taxol, vinca alkaloids etc., were isolated and 
extracted from plant extracts. For example, detailed evaluation of the unidentified compounds 
observed in case of F5, derived from SPGE could lead to the discovery of novel drugs. Similarly 
in ginger and betel leaves, there were several compounds, possibly isomers of gingerols, 
hydroxychavicol, eugenol, cholorogenic acid etc and even dehydrated forms like shogaols. 
Derivatives of known compounds are also to be investigated further for their disease-fighting 
properties. Apart from the possibility of discovering novel therapeutic drugs, detailed evaluation 
of dietary compositions can also lend us the advantage of designing better dosage regimen.   
 
Overall, different kinds of agents employed in numerous studies were reported to have an 
inverse impact on the disease progression, elevating risk of incidence and causing death, due to 
enhanced progression of cancer, or other treatment-associated toxicities. Several reasons for the 
failure of chemoprevention include, choice of test population, age, lifestyle etc. If some sort of 
“poly-pill” might be worth considering suggests that a few agents that can act via multiple 
pathways have shown beneficial efficacy. Targeting multiple pathways is essential as the process 
of carcinogenesis is not a single step process where a single mutation or protein is responsible for 
disease development and progression.. However, this idea of poly-pill or multi-targeted 
approaches seem to have failed due to lack of in-depth knowledge of the capabilities of the 
agents employed (like how many targets, doses at which each target is affected, time of action 
etc).  
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Whatever the means is, either a single agent or a whole fruit/vegetable, the following 
aspects are to be considered: 
(a) There is no ideal model to study chemoprevention in vivo before human trials, 
thus limiting the selection of potential agents. 
(b) Mainly the pharmacokinetics of whole food extracts are not evaluated, which 
can actually direct us to novel ways of approaching the problem, especially the 
dose regimen. 
(c) Very few studies have considered the possible effects of the chemopreventive 
agents on the drug metabolizing agents. Physiological interferences are 
ignored. 
(d) Metabolic evaluation of the phytochemical compositions is not being 
employed as a part of chemotherapy or prevention, which gives rise to an 
essential question, “If the metabolite or the free form is active?” 
 
 
 
 
 
 
 
 
 
 
193 
REFERENCES 
(1994). The effect of vitamin E and beta carotene on the incidence of lung cancer and other 
cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. 
N Engl J Med 330, 1029-1035. 
Aggarwal, B.B., and Shishodia, S. (2006). Molecular targets of dietary agents for prevention and 
therapy of cancer. Biochem Pharmacol 71, 1397-1421. 
Anand, P., Kunnumakkara, A.B., Sundaram, C., Harikumar, K.B., Tharakan, S.T., Lai, O.S., 
Sung, B., and Aggarwal, B.B. (2008). Cancer is a preventable disease that requires major 
lifestyle changes. Pharmaceutical research 25, 2097-2116. 
Aneja, R., Liu, M., Yates, C., Gao, J., Dong, X., Zhou, B., Vangapandu, S.N., Zhou, J., and 
Joshi, H.C. (2008). Multidrug resistance-associated protein-overexpressing teniposide-resistant 
human lymphomas undergo apoptosis by a tubulin-binding agent. Cancer Res 68, 1495-1503. 
Aneja, R., Miyagi, T., Karna, P., Ezell, T., Shukla, D., Vij Gupta, M., Yates, C., Chinni, S.R., 
Zhau, H., Chung, L.W., et al. (2010). A novel microtubule-modulating agent induces 
mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human 
prostate cancer cells. Eur J Cancer 46, 1668-1678. 
Aneja, R., Zhou, J., Vangapandu, S.N., Zhou, B., Chandra, R., and Joshi, H.C. (2006). Drug-
resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule 
agent, EM011. Blood 107, 2486-2492. 
Atsumi, T., Fujisawa, S., and Tonosaki, K. (2005). A comparative study of the 
antioxidant/prooxidant activities of eugenol and isoeugenol with various concentrations and 
oxidation conditions. Toxicology in vitro : an international journal published in association with 
BIBRA 19, 1025-1033. 
194 
Azam, S., Hadi, N., Khan, N.U., and Hadi, S.M. (2004). Prooxidant property of green tea 
polyphenols epicatechin and epigallocatechin-3-gallate: implications for anticancer properties. 
Toxicology in vitro : an international journal published in association with BIBRA 18, 555-561. 
Azuine, M.A., Amonkar, A.J., and Bhide, S.V. (1991). Chemopreventive efficacy of betel leaf 
extract and its constituents on 7,12-dimethylbenz(a)anthracene induced carcinogenesis and their 
effect on drug detoxification system in mouse skin. Indian journal of experimental biology 29, 
346-351. 
Azuine, M.A., and Bhide, S.V. (1992). Protective single/combined treatment with betel leaf and 
turmeric against methyl (acetoxymethyl) nitrosamine-induced hamster oral carcinogenesis. 
International journal of cancer Journal international du cancer 51, 412-415. 
Azuma, K., Ippoushi, K., Nakayama, M., Ito, H., Higashio, H., and Terao, J. (2000). Absorption 
of chlorogenic acid and caffeic acid in rats after oral administration. J Agric Food Chem 48, 
5496-5500. 
Bajpai, V., Sharma, D., Kumar, B., and Madhusudanan, K.P. (2010). Profiling of Piper betle 
Linn. cultivars by direct analysis in real time mass spectrometric technique. Biomedical 
chromatography : BMC 24, 1283-1286. 
Baliga, M.S., Haniadka, R., Pereira, M.M., D'Souza, J.J., Pallaty, P.L., Bhat, H.P., and Popuri, S. 
(2011). Update on the chemopreventive effects of ginger and its phytochemicals. Crit Rev Food 
Sci Nutr 51, 499-523. 
Bettuzzi, S., Brausi, M., Rizzi, F., Castagnetti, G., Peracchia, G., and Corti, A. (2006). 
Chemoprevention of human prostate cancer by oral administration of green tea catechins in 
volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-
year proof-of-principle study. Cancer Res 66, 1234-1240. 
195 
Bhattacharya, S., Subramanian, M., Roychowdhury, S., Bauri, A.K., Kamat, J.P., 
Chattopadhyay, S., and Bandyopadhyay, S.K. (2005). Radioprotective property of the ethanolic 
extract of Piper betel Leaf. Journal of radiation research 46, 165-171. 
Bhide, S.V., Padma, P.R., and Amonkar, A.J. (1991a). Antimutagenic and anticarcinogenic 
effects of betel leaf extract against the tobacco-specific nitrosamine 4-(N-nitrosomethylamino)-
1-(3-pyridyl)-1-butanone (NNK). IARC scientific publications, 520-524. 
Bhide, S.V., Shivapurkar, N.M., Gothoskar, S.V., and Ranadive, K.J. (1979). Carcinogenicity of 
betel quid ingredients: feeding mice with aqueous extract and the polyphenol fraction of betel 
nut. British journal of cancer 40, 922-926. 
Bhide, S.V., Zariwala, M.B., Amonkar, A.J., and Azuine, M.A. (1991b). Chemopreventive 
efficacy of a betel leaf extract against benzo[a]pyrene-induced forestomach tumors in mice. J 
Ethnopharmacol 34, 207-213. 
Block, G., Patterson, B., and Subar, A. (1992). Fruit, vegetables, and cancer prevention: a review 
of the epidemiological evidence. Nutr Cancer 18, 1-29. 
Bode, A.M., and Dong, Z. (2009). Epigallocatechin 3-gallate and green tea catechins: United 
they work, divided they fail. Cancer Prev Res (Phila) 2, 514-517. 
Bonner, W.M., Redon, C.E., Dickey, J.S., Nakamura, A.J., Sedelnikova, O.A., Solier, S., and 
Pommier, Y. (2008). GammaH2AX and cancer. Nat Rev Cancer 8, 957-967. 
Bouayed, J., and Bohn, T. (2010). Exogenous antioxidants - Double-edged swords in cellular 
redox state: Health beneficial effects at physiologic doses versus deleterious effects at high 
doses. Oxidative medicine and cellular longevity 3, 228-237. 
Boyer, J., and Liu, R.H. (2004). Apple phytochemicals and their health benefits. Nutrition 
journal 3, 5. 
196 
Brahmbhatt, M., Gundala, S.R., Asif, G., Shamsi, S.A., and Aneja, R. (2013). Ginger 
phytochemicals exhibit synergy to inhibit prostate cancer cell proliferation. Nutr Cancer 65, 263-
272. 
Bravo, L. (1998). Polyphenols: chemistry, dietary sources, metabolism, and nutritional 
significance. Nutrition reviews 56, 317-333. 
Calani, L., Dall'Asta, M., Derlindati, E., Scazzina, F., Bruni, R., and Del Rio, D. (2012). Colonic 
metabolism of polyphenols from coffee, green tea, and hazelnut skins. Journal of clinical 
gastroenterology 46 Suppl, S95-99. 
Chakraborty, D.a.S., B. (2011). Antimicrobial, anti-oxidative and anti-hemolytic activity of 
Piper Betel leaf extracts. Int J Pharm Pharm Sci 3, 192-199. 
Chan, R., Lok, K., and Woo, J. (2009). Prostate cancer and vegetable consumption. Mol Nutr 
Food Res 53, 201-216. 
Chang, M.C., Uang, B.J., Tsai, C.Y., Wu, H.L., Lin, B.R., Lee, C.S., Chen, Y.J., Chang, C.H., 
Tsai, Y.L., Kao, C.J., et al. (2007). Hydroxychavicol, a novel betel leaf component, inhibits 
platelet aggregation by suppression of cyclooxygenase, thromboxane production and calcium 
mobilization. British journal of pharmacology 152, 73-82. 
Chang, M.C., Uang, B.J., Wu, H.L., Lee, J.J., Hahn, L.J., and Jeng, J.H. (2002). Inducing the cell 
cycle arrest and apoptosis of oral KB carcinoma cells by hydroxychavicol: roles of glutathione 
and reactive oxygen species. British journal of pharmacology 135, 619-630. 
Chen, C.L., Chi, C.W., and Liu, T.Y. (2000). Enhanced hydroxychavicol-induced cytotoxic 
effects in glutathione-depleted HepG2 cells. Cancer Lett 155, 29-35. 
Chen, C.Y., Li, Y.W., and Kuo, S.Y. (2009). Effect of [10]-gingerol on [ca2+]i and cell death in 
human colorectal cancer cells. Molecules 14, 959-969. 
197 
Chen, M.S., Chen, D., and Dou, Q.P. (2004). Inhibition of proteasome activity by various fruits 
and vegetables is associated with cancer cell death. In Vivo 18, 73-80. 
Chou, T.C. (2010). Drug combination studies and their synergy quantification using the Chou-
Talalay method. Cancer Res 70, 440-446. 
Chu, N.S. (2001). Effects of Betel chewing on the central and autonomic nervous systems. 
Journal of biomedical science 8, 229-236. 
Clark, E.A., Hills, P.M., Davidson, B.S., Wender, P.A., and Mooberry, S.L. (2006). Laulimalide 
and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol. Mol 
Pharm 3, 457-467. 
Clifford, M. (1999). Chlorogenic acids and other cinnamates - nature, occurrence and dietary 
burden. J Sci Food Agric 79, 362-372. 
Colli, J.L., and Amling, C.L. (2009). Chemoprevention of prostate cancer: what can be 
recommended to patients? Current urology reports 10, 165-171. 
Cooke, D., Steward, W.P., Gescher, A.J., and Marczylo, T. (2005). Anthocyans from fruits and 
vegetables--does bright colour signal cancer chemopreventive activity? Eur J Cancer 41, 1931-
1940. 
Cooke, M.S., Evans, M.D., Dizdaroglu, M., and Lunec, J. (2003). Oxidative DNA damage: 
mechanisms, mutation, and disease. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology 17, 1195-1214. 
Cossarizza, A., Baccarani-Contri, M., Kalashnikova, G., and Franceschi, C. (1993). A new 
method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-
aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-
198 
tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochemical and biophysical research 
communications 197, 40-45. 
Craig, W.J. (1999). Health-promoting properties of common herbs. Am J Clin Nutr 70, 491S-
499S. 
Crespy, V., Morand, C., Besson, C., Cotelle, N., Vezin, H., Demigne, C., and Remesy, C. (2003). 
The splanchnic metabolism of flavonoids highly differed according to the nature of the 
compound. Am J Physiol Gastrointest Liver Physiol 284, G980-988. 
Crozier, A., Jaganath, I.B., and Clifford, M.N. (2009). Dietary phenolics: chemistry, 
bioavailability and effects on health. Natural product reports 26, 1001-1043. 
Danielsson, M., Rosenthal-Aizman, K., Bergsson, G., and Unden, A. (2011). Pharmacodynamic 
synergy strictly dependent on the co-operative aggregation of enantiomers of cyclic peptides in 
the bacterial cell membrane. Bioorganic & medicinal chemistry letters 21, 5262-5265. 
De Maria, C.M., RFA (2004). Analytical methods for chlorogenic acid. Quim Nova 27, 586-592. 
Decker, E.A. (1997). Phenolics: prooxidants or antioxidants? Nutrition reviews 55, 396-398. 
Desai, H.G., Kalro, R.H., and Choksi, A.P. (1990). Effect of ginger & garlic on DNA content of 
gastric aspirate. Indian J Med Res 92, 139-141. 
Dorai, T., and Aggarwal, B.B. (2004). Role of chemopreventive agents in cancer therapy. Cancer 
Lett 215, 129-140. 
Dragsted, L.O., Strube, M., and Larsen, J.C. (1993). Cancer-protective factors in fruits and 
vegetables: biochemical and biological background. Pharmacol Toxicol 72 Suppl 1, 116-135. 
Dugasani, S., Pichika, M.R., Nadarajah, V.D., Balijepalli, M.K., Tandra, S., and Korlakunta, J.N. 
(2010). Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, 
[10]-gingerol and [6]-shogaol. J Ethnopharmacol 127, 515-520. 
199 
Epriliati, I., Ginjom, I. R. (2012). Bioavailability of Phytochemicals. In Phytochemicals-A 
Global Perspective of Their Role in Nutrition and Health, V. Rao, ed. (Rijeka: InTech). 
Fauzee, N.J., Wang, Y.L., Dong, Z., Li, Q.G., Wang, T., Mandarry, M.T., Lu, X., and Juan, P. 
(2012). Novel hydrophilic taxane analogues inhibit growth of cancer cells. Asian Pacific journal 
of cancer prevention : APJCP 13, 563-567. 
Ferguson, P.J., Kurowska, E., Freeman, D.J., Chambers, A.F., and Koropatnick, D.J. (2004). A 
flavonoid fraction from cranberry extract inhibits proliferation of human tumor cell lines. J Nutr 
134, 1529-1535. 
Fulda, S., and Debatin, K.M. (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer 
chemotherapy. Oncogene 25, 4798-4811. 
Gad, S.C. (2007). The Mouse. In Animal Models in Toxicology, S.C. Gad, ed. (Boca Raton, FL: 
CRC Press, Taylor & Francis group), pp. 19-146. 
Galeone, C., Negri, E., Pelucchi, C., La Vecchia, C., Bosetti, C., and Hu, J. (2007). Dietary 
intake of fruit and vegetable and lung cancer risk: a case-control study in Harbin, northeast 
China. Ann Oncol 18, 388-392. 
German, J.B. (2005). Genetic dietetics: nutrigenomics and the future of dietetics practice. J Am 
Diet Assoc 105, 530-531. 
Gibellini, L., Pinti, M., Nasi, M., Biasi, S. D., Roat, E., Bertoncelli, L., Cossarizza, A (2010). 
Interfering with ROS metabolism in cancer cells: the potential role of Quercetin. Cancers 2, 
1288-1311. 
Govindarajan, V.S. (1982a). Ginger--chemistry, technology, and quality evaluation: part 1. Crit 
Rev Food Sci Nutr 17, 1-96. 
200 
Govindarajan, V.S. (1982b). Ginger-chemistry, technology, and quality evaluation: part 2. Crit 
Rev Food Sci Nutr 17, 189-258. 
Greenberg, E.R., Baron, J.A., Tosteson, T.D., Freeman, D.H., Jr., Beck, G.J., Bond, J.H., 
Colacchio, T.A., Coller, J.A., Frankl, H.D., Haile, R.W., et al. (1994). A clinical trial of 
antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J 
Med 331, 141-147. 
Gregory, P.A., Lewinsky, R.H., Gardner-Stephen, D.A., and Mackenzie, P.I. (2004). Regulation 
of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicology and applied 
pharmacology 199, 354-363. 
Guha, P. (2006). Betel Leaf: The Neglected Green Gold of India. J Hum Ecol 19, 87-93. 
Gundala, S.R., and Aneja, R. (2014). Piper betel leaf: a reservoir of potential xenohormetic 
nutraceuticals with cancer-fighting properties. Cancer Prev Res (Phila) 7, 477-486. 
Gundala, S.R., Mukkavilli, R., Yang, C., Yadav, P., Tandon, V., Vangala, S., Prakash, S., and 
Aneja, R. (2014). Enterohepatic recirculation of bioactive ginger phytochemicals is associated 
with enhanced tumor growth-inhibitory activity of ginger extract. Carcinogenesis 35, 1320-1329. 
Gundala, S.R., Yang, C., Lakshminarayana, N., Asif, G., Gupta, M.V., Shamsi, S., and Aneja, R. 
(2013). Polar biophenolics in sweet potato greens extract synergize to inhibit prostate cancer cell 
proliferation and in vivo tumor growth. Carcinogenesis 34, 2039-2049. 
Gundala, S.R., Yang, C., Mukkavilli, R., Paranjpe, R., Brahmbhatt, M., Pannu, V., Cheng, A., 
Reid, M. D., Aneja, R. (2014). Hydroxychavicol, a betel leaf component, inhibits prostate cancer 
through ROS_driven DNA damage and apoptosis. Toxicology and applied pharmacology. 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
201 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 
646-674. 
HemaIswarya, S., and Doble, M. (2006). Potential synergism of natural products in the treatment 
of cancer. Phytother Res 20, 239-249. 
Hooper, P.L., Hooper, P.L., Tytell, M., and Vigh, L. (2010). Xenohormesis: health benefits from 
an eon of plant stress response evolution. Cell stress & chaperones 15, 761-770. 
Houghton, P.J. (1995). The role of plants in traditional medicine and current therapy. Journal of 
alternative and complementary medicine 1, 131-143. 
Howitz, K.T., and Sinclair, D.A. (2008). Xenohormesis: sensing the chemical cues of other 
species. Cell 133, 387-391. 
Hu, R., Khor, T.O., Shen, G., Jeong, W.S., Hebbar, V., Chen, C., Xu, C., Reddy, B., Chada, K., 
and Kong, A.N. (2006). Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by 
sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis 27, 2038-
2046. 
Huang, Z., Wang, B., Eaves, D.H., Shikany, J.M., and Pace, R.D. (2007). Total phenolics and 
antioxidant capacity of indigenous vegetables in the southeast United States: Alabama 
Collaboration for Cardiovascular Equality Project. International journal of food sciences and 
nutrition, 1-9. 
Islam, M.S., Yoshimoto, M., Terahara, N., and Yamakawa, O. (2002a). Anthocyanin 
compositions in sweetpotato (Ipomoea batatas L.) leaves. Biosci Biotechnol Biochem 66, 2483-
2486. 
202 
Islam, M.S., Yoshimoto, M., Yahara, S., Okuno, S., Ishiguro, K., and Yamakawa, O. (2002b). 
Identification and characterization of foliar polyphenolic composition in sweetpotato (Ipomoea 
batatas L.) genotypes. J Agric Food Chem 50, 3718-3722. 
Islam, S. (2006). Sweetpotato (Ipomoea batatas L.) Leaf: Its Potential Effect on Human Health 
and Nutrition. Journal of Food Science 71, R13-R121. 
Ito, H., Gonthier, M.P., Manach, C., Morand, C., Mennen, L., Remesy, C., and Scalbert, A. 
(2005). Polyphenol levels in human urine after intake of six different polyphenol-rich beverages. 
The British journal of nutrition 94, 500-509. 
Jacobs, D.R., Jr., Gross, M.D., and Tapsell, L.C. (2009). Food synergy: an operational concept 
for understanding nutrition. Am J Clin Nutr 89, 1543S-1548S. 
Jacobs, D.R., Jr., and Tapsell, L.C. (2007). Food, not nutrients, is the fundamental unit in 
nutrition. Nutr Rev 65, 439-450. 
James A. Duke, M.J.B.-G., Andrea R. Ottesen (2008). Duke's Handbook of Medicinal Plants of 
Latin America (CRC Press). 
Jana, S., and Mandlekar, S. (2009). Role of phase II drug metabolizing enzymes in cancer 
chemoprevention. Current drug metabolism 10, 595-616. 
Jeong, C.H., Bode, A.M., Pugliese, A., Cho, Y.Y., Kim, H.G., Shim, J.H., Jeon, Y.J., Li, H., 
Jiang, H., and Dong, Z. (2009). [6]-Gingerol suppresses colon cancer growth by targeting 
leukotriene A4 hydrolase. Cancer Res 69, 5584-5591. 
Ji, H.F., Li, X.J., and Zhang, H.Y. (2009). Natural products and drug discovery. Can thousands 
of years of ancient medical knowledge lead us to new and powerful drug combinations in the 
fight against cancer and dementia? EMBO reports 10, 194-200. 
203 
Jin, Y.R., Lee, M.S., Lee, J.H., Hsu, H.K., Lu, J.Y., Chao, S.S., Chen, K.T., Liou, S.H., and Ger, 
L.P. (2007). Intake of vitamin A-rich foods and lung cancer risk in Taiwan: with special 
reference to garland chrysanthemum and sweet potato leaf consumption. Asia Pacific journal of 
clinical nutrition 16, 477-488. 
Johnson, J.J., Bailey, H.H., and Mukhtar, H. (2010). Green tea polyphenols for prostate cancer 
chemoprevention: a translational perspective. Phytomedicine : international journal of 
phytotherapy and phytopharmacology 17, 3-13. 
Kandil, F.E., Smith, M.A., Rogers, R.B., Pepin, M.F., Song, L.L., Pezzuto, J.M., and Seigler, 
D.S. (2002). Composition of a chemopreventive proanthocyanidin-rich fraction from cranberry 
fruits responsible for the inhibition of 12-O-tetradecanoyl phorbol-13-acetate (TPA)-induced 
ornithine decarboxylase (ODC) activity. J Agric Food Chem 50, 1063-1069. 
Karna, P., Chagani, S., Gundala, S.R., Rida, P.C., Asif, G., Sharma, V., Gupta, M.V., and Aneja, 
R. (2011a). Benefits of whole ginger extract in prostate cancer. Br J Nutr, 1-12. 
Karna, P., Gundala, S.R., Gupta, M.V., Shamsi, S.A., Pace, R.D., Yates, C., Narayan, S., and 
Aneja, R. (2011b). Polyphenol-rich sweet potato greens extract inhibits proliferation and induces 
apoptosis in prostate cancer cells in vitro and in vivo. Carcinogenesis 32, 1872-1880. 
Karna, P., Zughaier, S., Pannu, V., Simmons, R., Narayan, S., and Aneja, R. (2010). Induction of 
reactive oxygen species-mediated autophagy by a novel microtubule-modulating agent. The 
Journal of biological chemistry 285, 18737-18748. 
Kaur, M., Agarwal, C., and Agarwal, R. (2009). Anticancer and cancer chemopreventive 
potential of grape seed extract and other grape-based products. J Nutr 139, 1806S-1812S. 
Kelloff, G.J., Sigman, C.C., and Greenwald, P. (1999). Cancer chemoprevention: progress and 
promise. Eur J Cancer 35, 2031-2038. 
204 
Khan, N., Afaq, F., and Mukhtar, H. (2008). Cancer chemoprevention through dietary 
antioxidants: progress and promise. Antioxidants & redox signaling 10, 475-510. 
Kim, S.O., Kundu, J.K., Shin, Y.K., Park, J.H., Cho, M.H., Kim, T.Y., and Surh, Y.J. (2005). 
[6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-
kappaB in phorbol ester-stimulated mouse skin. Oncogene 24, 2558-2567. 
Kinjo, J., Nagao, T., Tanaka, T., Nonaka, G., Okawa, M., Nohara, T., and Okabe, H. (2002). 
Activity-guided fractionation of green tea extract with antiproliferative activity against human 
stomach cancer cells. Biol Pharm Bull 25, 1238-1240. 
Kolonel, L.N., Altshuler, D., and Henderson, B.E. (2004). The multiethnic cohort study: 
exploring genes, lifestyle and cancer risk. Nat Rev Cancer 4, 519-527. 
Kondo, Y., and Kondo, S. (2006). Autophagy and cancer therapy. Autophagy 2, 85-90. 
Kumar, N., Misra, P., Dube, A., Bhattacharya, S., Dikshit, M. and Ranade, S. (2010). Piper betle 
Linn. a maligned Pan-Asiatic plant with an array of pharmacological activities and prospects for 
drug discovery Current Science 99, 922-932. 
Kundu, J.K., Na, H.K., and Surh, Y.J. (2009). Ginger-derived phenolic substances with cancer 
preventive and therapeutic potential. Forum Nutr 61, 182-192. 
Kunnumakkara, A.B., Anand, P., and Aggarwal, B.B. (2008). Curcumin inhibits proliferation, 
invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell 
signaling proteins. Cancer Lett 269, 199-225. 
Kurata, R., Adachi, M., Yamakawa, O., and Yoshimoto, M. (2007). Growth suppression of 
human cancer cells by polyphenolics from sweetpotato (Ipomoea batatas L.) leaves. J Agric 
Food Chem 55, 185-190. 
205 
Lafay, S., Morand, C., Manach, C., Besson, C., and Scalbert, A. (2006). Absorption and 
metabolism of caffeic acid and chlorogenic acid in the small intestine of rats. The British journal 
of nutrition 96, 39-46. 
Lamming, D.W., Wood, J.G., and Sinclair, D.A. (2004). Small molecules that regulate lifespan: 
evidence for xenohormesis. Molecular microbiology 53, 1003-1009. 
Lansky, E.P., Jiang, W., Mo, H., Bravo, L., Froom, P., Yu, W., Harris, N.M., Neeman, I., and 
Campbell, M.J. (2005). Possible synergistic prostate cancer suppression by anatomically discrete 
pomegranate fractions. Invest New Drugs 23, 11-20. 
Lee, H.S., Seo, E.Y., Kang, N.E., and Kim, W.K. (2008). [6]-Gingerol inhibits metastasis of 
MDA-MB-231 human breast cancer cells. The Journal of nutritional biochemistry 19, 313-319. 
Lee, S.B., Bae, I.H., Bae, Y.S., and Um, H.D. (2006). Link between mitochondria and NADPH 
oxidase 1 isozyme for the sustained production of reactive oxygen species and cell death. The 
Journal of biological chemistry 281, 36228-36235. 
Lee-Chen, S.F., Chen, C.L., Ho, L.Y., Hsu, P.C., Chang, J.T., Sun, C.M., Chi, C.W., and Liu, 
T.Y. (1996). Role of oxidative DNA damage in hydroxychavicol-induced genotoxicity. 
Mutagenesis 11, 519-523. 
Lee-Hilz, Y.Y., Boerboom, A.M., Westphal, A.H., Berkel, W.J., Aarts, J.M., and Rietjens, I.M. 
(2006). Pro-oxidant activity of flavonoids induces EpRE-mediated gene expression. Chemical 
research in toxicology 19, 1499-1505. 
Li, L., Adams, L.S., Chen, S., Killian, C., Ahmed, A., and Seeram, N.P. (2009). Eugenia 
jambolana Lam. berry extract inhibits growth and induces apoptosis of human breast cancer but 
not non-tumorigenic breast cells. J Agric Food Chem 57, 826-831. 
206 
Liu, R.H. (2003). Health benefits of fruit and vegetables are from additive and synergistic 
combinations of phytochemicals. Am J Clin Nutr 78, 517S-520S. 
Liu, R.H. (2004). Potential synergy of phytochemicals in cancer prevention: mechanism of 
action. J Nutr 134, 3479S-3485S. 
Liu, Z., and Hu, M. (2007). Natural polyphenol disposition via coupled metabolic pathways. 
Expert opinion on drug metabolism & toxicology 3, 389-406. 
Liu, Z., Schwimer, J., Liu, D., Greenway, F.L., Anthony, C.T., and Woltering, E.A. (2005). 
Black raspberry extract and fractions contain angiogenesis inhibitors. J Agric Food Chem 53, 
3909-3915. 
Lumb, A.B. (1994). Effect of dried ginger on human platelet function. Thromb Haemost 71, 110-
111. 
Ma, G.C., Wu, P.F., Tseng, H.C., Chyau, C.C., Lu, H.C., and Chou, F.P. (2013). Inhibitory effect 
of Piper betel leaf extracts on copper-mediated LDL oxidation and oxLDL-induced lipid 
accumulation via inducing reverse cholesterol transport in macrophages. Food chemistry 141, 
3703-3713. 
Manach, C., Scalbert, A., Morand, C., Remesy, C., and Jimenez, L. (2004). Polyphenols: food 
sources and bioavailability. Am J Clin Nutr 79, 727-747. 
Manach, C., Williamson, G., Morand, C., Scalbert, A., and Remesy, C. (2005). Bioavailability 
and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin 
Nutr 81, 230S-242S. 
Mann, J.R., Backlund, M.G., and DuBois, R.N. (2005). Mechanisms of disease: Inflammatory 
mediators and cancer prevention. Nature clinical practice Oncology 2, 202-210. 
207 
Martin, K.R., and Barrett, J.C. (2002). Reactive oxygen species as double-edged swords in 
cellular processes: low-dose cell signaling versus high-dose toxicity. Human & experimental 
toxicology 21, 71-75. 
Martinou, J.C., Desagher, S., and Antonsson, B. (2000). Cytochrome c release from 
mitochondria: all or nothing. Nature cell biology 2, E41-43. 
McCarver, D.G., and Hines, R.N. (2002). The ontogeny of human drug-metabolizing enzymes: 
phase II conjugation enzymes and regulatory mechanisms. The Journal of pharmacology and 
experimental therapeutics 300, 361-366. 
Mertens-Talcott, S.U., Talcott, S.T., and Percival, S.S. (2003). Low concentrations of quercetin 
and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 
human leukemia cells. J Nutr 133, 2669-2674. 
Millot, C., Millot, J.M., Morjani, H., Desplaces, A., and Manfait, M. (1997). Characterization of 
acidic vesicles in multidrug-resistant and sensitive cancer cells by acridine orange staining and 
confocal microspectrofluorometry. The journal of histochemistry and cytochemistry : official 
journal of the Histochemistry Society 45, 1255-1264. 
Mira, L., Fernandez, M.T., Santos, M., Rocha, R., Florencio, M.H., and Jennings, K.R. (2002). 
Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity. 
Free radical research 36, 1199-1208. 
Miura, T., Chiba, M., Kasai, K., Nozaka, H., Nakamura, T., Shoji, T., Kanda, T., Ohtake, Y., and 
Sato, T. (2008). Apple procyanidins induce tumor cell apoptosis through mitochondrial pathway 
activation of caspase-3. Carcinogenesis 29, 585-593. 
208 
Mosha, T.C., and Gaga, H.E. (1999). Nutritive value and effect of blanching on the trypsin and 
chymotrypsin inhibitor activities of selected leafy vegetables. Plant Foods Hum Nutr 54, 271-
283. 
Nagabhushan, M., Amonkar, A.J., Nair, U.J., D'Souza, A.V., and Bhide, S.V. (1989). 
Hydroxychavicol: a new anti-nitrosating phenolic compound from betel leaf. Mutagenesis 4, 
200-204. 
Nelson, W.G., De Marzo, A.M., and Isaacs, W.B. (2003). Prostate cancer. N Engl J Med 349, 
366-381. 
Noble, R.L. (1990). The discovery of the vinca alkaloids--chemotherapeutic agents against 
cancer. Biochemistry and cell biology = Biochimie et biologie cellulaire 68, 1344-1351. 
Olson, J.A., Moon, R.C., Anders, M.W., Fenselau, C., and Shane, B. (1992). Enhancement of 
biological activity by conjugation reactions. J Nutr 122, 615-624. 
Omenn, G.S., Goodman, G.E., Thornquist, M.D., Balmes, J., Cullen, M.R., Glass, A., Keogh, 
J.P., Meyskens, F.L., Valanis, B., Williams, J.H., et al. (1996). Effects of a combination of beta 
carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334, 1150-
1155. 
Pannu, V., Karna, P., Sajja, H.K., Shukla, D., and Aneja, R. (2011). Synergistic antimicrotubule 
therapy for prostate cancer. Biochem Pharmacol 81, 478-487. 
Paranjpe, R., Gundala, S.R., Lakshminarayana, N., Sagwal, A., Asif, G., Pandey, A., and Aneja, 
R. (2013). Piper betel leaf extract: anticancer benefits and bio-guided fractionation to identify 
active principles for prostate cancer management. Carcinogenesis 34, 1558-1566. 
Park, K.K., Chun, K.S., Lee, J.M., Lee, S.S., and Surh, Y.J. (1998). Inhibitory effects of [6]-
gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal 
209 
ornithine decarboxylase activity and skin tumor promotion in ICR mice. Cancer Lett 129, 139-
144. 
Park, Y.J., Wen, J., Bang, S., Park, S.W., and Song, S.Y. (2006). [6]-Gingerol induces cell cycle 
arrest and cell death of mutant p53-expressing pancreatic cancer cells. Yonsei medical journal 
47, 688-697. 
Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA 
Cancer J Clin 55, 74-108. 
Pero, R.W., Lund, H., and Leanderson, T. (2009). Antioxidant metabolism induced by quinic 
acid. Increased urinary excretion of tryptophan and nicotinamide. Phytotherapy research : PTR 
23, 335-346. 
Potter, J.D. (2014). The failure of cancer chemoprevention. Carcinogenesis 35, 974-982. 
Quideau, S., Deffieux, D., Douat-Casassus, C., and Pouysegu, L. (2011). Plant Polyphenols: 
Chemical Properties, Biological Activities, and Synthesis. Angewandte Chemie. 
Raina, K., Blouin, M.J., Singh, R.P., Majeed, N., Deep, G., Varghese, L., Glode, L.M., 
Greenberg, N.M., Hwang, D., Cohen, P., et al. (2007a). Dietary feeding of silibinin inhibits 
prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate 
model. Cancer Res 67, 11083-11091. 
Raina, K., Singh, R.P., Agarwal, R., and Agarwal, C. (2007b). Oral grape seed extract inhibits 
prostate tumor growth and progression in TRAMP mice. Cancer Res 67, 5976-5982. 
Ranaivoson, F.M., Gigant, B., Berritt, S., Joullie, M., and Knossow, M. (2012). Structural 
plasticity of tubulin assembly probed by vinca-domain ligands. Acta crystallographica Section D, 
Biological crystallography 68, 927-934. 
210 
Raskin, I., Ribnicky, D.M., Komarnytsky, S., Ilic, N., Poulev, A., Borisjuk, N., Brinker, A., 
Moreno, D.A., Ripoll, C., Yakoby, N., et al. (2002). Plants and human health in the twenty-first 
century. Trends in biotechnology 20, 522-531. 
Rathee, J.S., Patro, B.S., Mula, S., Gamre, S., and Chattopadhyay, S. (2006). Antioxidant activity 
of piper betel leaf extract and its constituents. J Agric Food Chem 54, 9046-9054. 
Ray, R.B., Raychoudhuri, A., Steele, R., and Nerurkar, P. (2010). Bitter melon (Momordica 
charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory 
genes and promotes apoptosis. Cancer Res 70, 1925-1931. 
Raza, H., and John, A. (2005). Green tea polyphenol epigallocatechin-3-gallate differentially 
modulates oxidative stress in PC12 cell compartments. Toxicology and applied pharmacology 
207, 212-220. 
Reagan-Shaw, S., Nihal, M., and Ahmad, N. (2008). Dose translation from animal to human 
studies revisited. FASEB journal : official publication of the Federation of American Societies 
for Experimental Biology 22, 659-661. 
Reers, M., Smith, T.W., and Chen, L.B. (1991). J-aggregate formation of a carbocyanine as a 
quantitative fluorescent indicator of membrane potential. Biochemistry 30, 4480-4486. 
Ritter, J.K. (2000). Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic 
bioactivation reactions. Chemico-biological interactions 129, 171-193. 
Roberts, M.S., Magnusson, B.M., Burczynski, F.J., and Weiss, M. (2002). Enterohepatic 
circulation: physiological, pharmacokinetic and clinical implications. Clinical pharmacokinetics 
41, 751-790. 
211 
Sakihama, Y., Cohen, M.F., Grace, S.C., and Yamasaki, H. (2002). Plant phenolic antioxidant 
and prooxidant activities: phenolics-induced oxidative damage mediated by metals in plants. 
Toxicology 177, 67-80. 
Sasidharan, S., Chen, Y., Saravanan, D., Sundram, K.M., and Yoga Latha, L. (2011). Extraction, 
isolation and characterization of bioactive compounds from plants' extracts. African journal of 
traditional, complementary, and alternative medicines : AJTCAM / African Networks on 
Ethnomedicines 8, 1-10. 
Sauer, H., Wartenberg, M., and Hescheler, J. (2001). Reactive oxygen species as intracellular 
messengers during cell growth and differentiation. Cellular physiology and biochemistry : 
international journal of experimental cellular physiology, biochemistry, and pharmacology 11, 
173-186. 
Scalbert, A., Morand, C., Manach, C., and Remesy, C. (2002). Absorption and metabolism of 
polyphenols in the gut and impact on health. Biomed Pharmacother 56, 276-282. 
Schumacker, P.T. (2006). Reactive oxygen species in cancer cells: live by the sword, die by the 
sword. Cancer Cell 10, 175-176. 
Seelinger, M., Popescu, R., Giessrigl, B., Jarukamjorn, K., Unger, C., Wallnofer, B., Fritzer-
Szekeres, M., Szekeres, T., Diaz, R., Jager, W., et al. (2012). Methanol extract of the 
ethnopharmaceutical remedy Smilax spinosa exhibits anti-neoplastic activity. International 
journal of oncology 41, 1164-1172. 
Seeram, N.P., Adams, L.S., Hardy, M.L., and Heber, D. (2004). Total cranberry extract versus its 
phytochemical constituents: antiproliferative and synergistic effects against human tumor cell 
lines. J Agric Food Chem 52, 2512-2517. 
212 
Seeram, N.P., Adams, L.S., Henning, S.M., Niu, Y., Zhang, Y., Nair, M.G., and Heber, D. 
(2005). In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid 
and a total pomegranate tannin extract are enhanced in combination with other polyphenols as 
found in pomegranate juice. The Journal of nutritional biochemistry 16, 360-367. 
Sharma, G., Tyagi, A.K., Singh, R.P., Chan, D.C., and Agarwal, R. (2004). Synergistic anti-
cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human 
breast carcinoma cells. Breast cancer research and treatment 85, 1-12. 
Sharma, O.P. (1976). Antioxidant activity of curcumin and related compounds. Biochem 
Pharmacol 25, 1811-1812. 
Shukla, S., and Gupta, S. (2005). Dietary agents in the chemoprevention of prostate cancer. Nutr 
Cancer 53, 18-32. 
Shukla, Y., and Singh, M. (2007). Cancer preventive properties of ginger: a brief review. Food 
Chem Toxicol 45, 683-690. 
Silberberg, M., Morand, C., Mathevon, T., Besson, C., Manach, C., Scalbert, A., and Remesy, C. 
(2006). The bioavailability of polyphenols is highly governed by the capacity of the intestine and 
of the liver to secrete conjugated metabolites. European journal of nutrition 45, 88-96. 
Simonetti, P., Gardana, C., and Pietta, P. (2001). Caffeic acid as biomarker of red wine intake. 
Methods Enzymol 335, 122-130. 
Singletary, K., and MacDonald, C. (2000). Inhibition of benzo[a]pyrene- and 1,6-dinitropyrene-
DNA adduct formation in human mammary epithelial cells bydibenzoylmethane and 
sulforaphane. Cancer Lett 155, 47-54. 
Sporn, M.B. (1976). Approaches to prevention of epithelial cancer during the preneoplastic 
period. Cancer Res 36, 2699-2702. 
213 
Sporn, M.B., and Suh, N. (2000). Chemoprevention of cancer. Carcinogenesis 21, 525-530. 
Steinkellner, H., Rabot, S., Freywald, C., Nobis, E., Scharf, G., Chabicovsky, M., Knasmuller, 
S., and Kassie, F. (2001). Effects of cruciferous vegetables and their constituents on drug 
metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens. Mutat 
Res 480-481, 285-297. 
Sung, B., Prasad, S., Yadav, V.R., and Aggarwal, B.B. (2012). Cancer cell signaling pathways 
targeted by spice-derived nutraceuticals. Nutr Cancer 64, 173-197. 
Surh, Y.J. (2003). Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3, 768-
780. 
Surh, Y.J. (2011). Xenohormesis mechanisms underlying chemopreventive effects of some 
dietary phytochemicals. Annals of the New York Academy of Sciences 1229, 1-6. 
Syed, D.N., Khan, N., Afaq, F., and Mukhtar, H. (2007). Chemoprevention of prostate cancer 
through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 16, 2193-
2203. 
Szatrowski, T.P., and Nathan, C.F. (1991). Production of large amounts of hydrogen peroxide by 
human tumor cells. Cancer Res 51, 794-798. 
Tait, S.W., and Green, D.R. (2010). Mitochondria and cell death: outer membrane 
permeabilization and beyond. Nature reviews Molecular cell biology 11, 621-632. 
Tao, Y., Li, W., Liang, W., and Van Breemen, R.B. (2009). Identification and quantification of 
gingerols and related compounds in ginger dietary supplements using high-performance liquid 
chromatography-tandem mass spectrometry. J Agric Food Chem 57, 10014-10021. 
214 
Toi, M., Bando, H., Ramachandran, C., Melnick, S.J., Imai, A., Fife, R.S., Carr, R.E., Oikawa, 
T., and Lansky, E.P. (2003). Preliminary studies on the anti-angiogenic potential of pomegranate 
fractions in vitro and in vivo. Angiogenesis 6, 121-128. 
Trachootham, D., Alexandre, J., and Huang, P. (2009). Targeting cancer cells by ROS-mediated 
mechanisms: a radical therapeutic approach? Nature reviews Drug discovery 8, 579-591. 
Traka, M., Gasper, A.V., Melchini, A., Bacon, J.R., Needs, P.W., Frost, V., Chantry, A., Jones, 
A.M., Ortori, C.A., Barrett, D.A., et al. (2008). Broccoli consumption interacts with GSTM1 to 
perturb oncogenic signalling pathways in the prostate. PloS one 3, e2568. 
Treutter, D. (2005). Significance of flavonoids in plant resistance and enhancement of their 
biosynthesis. Plant biology 7, 581-591. 
Truong, V.D., McFeeters, R.F., Thompson, R.T., Dean, L.L., and Shofran, B. (2007). Phenolic 
acid content and composition in leaves and roots of common commercial sweetpotato (Ipomea 
batatas L.) cultivars in the United States. J Food Sci 72, C343-349. 
Tsao, A.S., Kim, E.S., and Hong, W.K. (2004). Chemoprevention of cancer. CA Cancer J Clin 
54, 150-180. 
Ulbricht, C.E., and Chao, W. (2010). Phytochemicals in the oncology setting. Curr Treat Options 
Oncol 11, 95-106. 
Ulrich, C.M., Bigler, J., and Potter, J.D. (2006). Non-steroidal anti-inflammatory drugs for 
cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6, 130-140. 
van Breda, S.G., van Agen, E., van Sanden, S., Burzykowski, T., Kleinjans, J.C., and Delft, J.H. 
(2005). Vegetables affect the expression of genes involved in carcinogenic and anticarcinogenic 
processes in the lungs of female C57BL/6 mice. J Nutr 135, 2546-2552. 
215 
Vasala, P.A. (2004). Ginger. In Handbook of Herbs and Spices, K.V. Peter., ed. (Cambridge: 
Woodhead ). 
Veluri, R., Singh, R.P., Liu, Z., Thompson, J.A., Agarwal, R., and Agarwal, C. (2006). 
Fractionation of grape seed extract and identification of gallic acid as one of the major active 
constituents causing growth inhibition and apoptotic death of DU145 human prostate carcinoma 
cells. Carcinogenesis 27, 1445-1453. 
Verma, S., Gupta, M.L., Dutta, A., Sankhwar, S., Shukla, S.K., and Flora, S.J. (2010). 
Modulation of ionizing radiation induced oxidative imbalance by semi-fractionated extract of 
Piper betle: an in vitro and in vivo assessment. Oxidative medicine and cellular longevity 3, 44-
52. 
Wagner, H. (2011). Synergy research: approaching a new generation of phytopharmaceuticals. 
Fitoterapia 82, 34-37. 
Waladkhani, A.R., and Clemens, M.R. (1998). Effect of dietary phytochemicals on cancer 
development (review). Int J Mol Med 1, 747-753. 
Wang, C.C., Chen, L.G., Lee, L.T., and Yang, L.L. (2003). Effects of 6-gingerol, an antioxidant 
from ginger, on inducing apoptosis in human leukemic HL-60 cells. In Vivo 17, 641-645. 
Wang, W., Li, C.Y., Wen, X.D., Li, P., and Qi, L.W. (2009). Plasma pharmacokinetics, tissue 
distribution and excretion study of 6-gingerol in rat by liquid chromatography-electrospray 
ionization time-of-flight mass spectrometry. Journal of pharmaceutical and biomedical analysis 
49, 1070-1074. 
Wells, P.G., Mackenzie, P.I., Chowdhury, J.R., Guillemette, C., Gregory, P.A., Ishii, Y., Hansen, 
A.J., Kessler, F.K., Kim, P.M., Chowdhury, N.R., et al. (2004). Glucuronidation and the UDP-
216 
glucuronosyltransferases in health and disease. Drug metabolism and disposition: the biological 
fate of chemicals 32, 281-290. 
Williams, C. (1995). Healthy eating: clarifying advice about fruit and vegetables. Bmj 310, 
1453-1455. 
Williamson, G., and Manach, C. (2005). Bioavailability and bioefficacy of polyphenols in 
humans. II. Review of 93 intervention studies. Am J Clin Nutr 81, 243S-255S. 
Wilson, C.D., Pace, R.D., Bromfield, E., Jones, G., and Lu, J.Y. (1998). Sweet potato in a 
vegetarian menu plan for NASA's Advanced Life Support Program. Life support & biosphere 
science : international journal of earth space 5, 347-351. 
Wolfe, K., Wu, X., and Liu, R.H. (2003). Antioxidant activity of apple peels. J Agric Food Chem 
51, 609-614. 
Xiao, H., and Yang, C.S. (2008). Combination regimen with statins and NSAIDs: a promising 
strategy for cancer chemoprevention. International journal of cancer Journal international du 
cancer 123, 983-990. 
Xie, J.T., Wang, C.Z., Zhang, B., Mehendale, S.R., Li, X.L., Sun, S., Han, A.H., Du, W., He, 
T.C., and Yuan, C.S. (2009). In vitro and in vivo anticancer effects of American ginseng berry: 
exploring representative compounds. Biol Pharm Bull 32, 1552-1558. 
Yang, C.S., Landau, J.M., Huang, M.T., and Newmark, H.L. (2001). Inhibition of carcinogenesis 
by dietary polyphenolic compounds. Annu Rev Nutr 21, 381-406. 
Yang, J., and Liu, R.H. (2009). Synergistic effect of apple extracts and quercetin 3-beta-d-
glucoside combination on antiproliferative activity in MCF-7 human breast cancer cells in vitro. 
J Agric Food Chem 57, 8581-8586. 
217 
Yang, Y., Zhang, Z., Li, S., Ye, X., Li, X., and He, K. (2014). Synergy effects of herb extracts: 
pharmacokinetics and pharmacodynamic basis. Fitoterapia 92, 133-147. 
Yoshikawa, M., Hatakeyama, S., Chatani, N., Nishino, Y., and Yamahara, J. (1993). [Qualitative 
and quantitative analysis of bioactive principles in Zingiberis Rhizoma by means of high 
performance liquid chromatography and gas liquid chromatography. On the evaluation of 
Zingiberis Rhizoma and chemical change of constituents during Zingiberis Rhizoma processing]. 
Yakugaku Zasshi 113, 307-315. 
Yoshimi, N., Wang, A., Morishita, Y., Tanaka, T., Sugie, S., Kawai, K., Yamahara, J., and Mori, 
H. (1992). Modifying effects of fungal and herb metabolites on azoxymethane-induced intestinal 
carcinogenesis in rats. Japanese journal of cancer research : Gann 83, 1273-1278. 
Yoshimoto, M., Yahara, S., Okuno, S., Islam, M.S., Ishiguro, K., and Yamakawa, O. (2002). 
Antimutagenicity of mono-, di-, and tricaffeoylquinic acid derivatives isolated from sweetpotato 
(Ipomoea batatas L.) leaf. Biosci Biotechnol Biochem 66, 2336-2341. 
Zessner, H., Pan, L., Will, F., Klimo, K., Knauft, J., Niewohner, R., Hummer, W., Owen, R., 
Richling, E., Frank, N., et al. (2008). Fractionation of polyphenol-enriched apple juice extracts to 
identify constituents with cancer chemopreventive potential. Mol Nutr Food Res 52 Suppl 1, 
S28-44. 
Zhao, J., Wang, J., Chen, Y., and Agarwal, R. (1999). Anti-tumor-promoting activity of a 
polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion 
protocol and identification of procyanidin B5-3'-gallate as the most effective antioxidant 
constituent. Carcinogenesis 20, 1737-1745. 
Zick, S.M., Djuric, Z., Ruffin, M.T., Litzinger, A.J., Normolle, D.P., Alrawi, S., Feng, M.R., and 
Brenner, D.E. (2008). Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol 
218 
and conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17, 
1930-1936. 
Zick, S.M., Ruffin, M.T., Djuric, Z., Normolle, D., and Brenner, D.E. (2010). Quantitation of 6-, 
8- and 10-Gingerols and 6-Shogaol in Human Plasma by High-Performance Liquid 
Chromatography with Electrochemical Detection. International journal of biomedical science : 
IJBS 6, 233-240. 
 
